(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
13 February 2020 (13.02.2020)

WIPO | PCT

(10) International Publication Number
WO 2020/033520 A1

(51) International Patent Classification:
A61P 35/00 (2006.01) *C07D 413/14* (2006.01)
A61K 31/437 (2006.01) *C07D 417/14* (2006.01)
C07D 403/14 (2006.01) *C07D 471/04* (2006.01)
C07D 407/14 (2006.01) *C07D 471/08* (2006.01)

(21) International Application Number:
PCT/US2019/045466

(22) International Filing Date:
07 August 2019 (07.08.2019)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
62/715,850 08 August 2018 (08.08.2018) US

(71) Applicant: **BRISTOL-MYERS SQUIBB COMPANY** [US/US]; Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(72) Inventors: **SRIVASTAVA, Anurag S.**; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **CHERNEY, Robert J.**; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US). **NGU, Khehyong**; c/o Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).

(74) Agent: **LIU, Hong** et al.; Bristol-Myers Squibb Company, Route 206 and Province Line Road, Princeton, New Jersey 08543 (US).


(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:
— *as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))*
— *as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))*
— *of inventorship (Rule 4.17(iv))*

Published:
— *with international search report (Art. 21(3))*

(54) Title: INDOLE AND AZAINDOLE INHIBITORS OF PAD ENZYMES



(I)

(57) Abstract: The present invention provides compounds of Formula (I) useful as inhibitors of PAD4, compositions thereof, and methods of treating PAD4-related disorders, wherein each of Ring A, L, Q, R1, R2, R3, R4, R7, and R8 along with other variables are as defined herein.

WO 2020/033520 A1

INDOLE AND AZAINDOLE INHIBITORS OF PAD ENZYMES

CROSS REFERENCE

This application claims the benefit of U.S. Provisional Application Serial No. 62/715,850 filed August 8, 2018, which is incorporated herein in its entirety

BACKGROUND OF THE INVENTION

[0001] PAD4 is a member of the peptidylarginine deiminase (PAD) family of enzymes capable of catalysing the citrullination of arginine into citrulline within peptide sequences. PAD4 is responsible for the deimination or citrullination of a variety of proteins *in vitro* and *in vivo*, with consequences of diverse functional responses in a variety of diseases (*Jones J.E. et al, Curr. Opin. Drug Discov. Devel., 12(5), (2009),616-627*). Examples of exemplar diseases include rheumatoid arthritis, diseases with neutrophilic contributions to pathogenesis (for example vasculitis, systemic lupus erythematosus, ulcerative colitis) in addition to oncology indications. PAD4 inhibitors also have wider applicability as tools and therapeutics for human disease through epigenetic mechanisms.

[0002] Inhibitors of PAD4 have utility against Rheumatoid Arthritis (RA). RA is an auto-immune disease affecting approximately 1% of the population *(Wegner N. et al, Immunol. Rev., 233(1) (2010), 34-54)*. It is characterised by inflammation of articular joints leading to debilitating destruction of bone and cartilage. A weak genetic association between PAD4 polymorphisms and susceptibility to RA has been suggested, albeit inconsistently, in a number of population studies (*Kochi Y. et al, Ann. Rheum. Dis., 70, (2011),512-515*). PAD4 (along with family member PAD2) has been detected in synovial tissue where it is responsible for the deimination of a variety of joint proteins. This process is presumed to lead to a break of tolerance to, and initiation of immune responses to, citrullinated substrates such as fibrinogen, vimentin and collagen in RA joints. These anti-citrullinated protein antibodies (ACPA) contribute to disease pathogenesis and may also be used as a diagnostic test for RA (e.g. the commercially available CCP2 or cyclic citrullinated protein 2 test). In addition, increased citrullination may also offer additional direct contributions to disease pathogenesis through its ability to affect directly the function of several joint and inflammatory mediators (e.g. fibrinogen,

anti-thrombin, multiple chemokines). In a smaller subset of RA patients, anti-PAD4 antibodies can be measured and may correlate with a more erosive form of the disease.

[0003] PAD4 inhibitors are also useful for the reduction of pathological neutrophil activity in a variety of diseases. Studies suggest that the process of Neutrophil Extracellular Trap (NET) formation, an innate defence mechanism by which neutrophils are able to immobilise and kill pathogens, is associated with histone citrullination and is deficient in PAD4 knockout mice (*Neeli I. et al, J. Immunol., 180, (2008), 1895-1902* and *Li P. et al, J. Exp. Med., 207(9), (2010), 1853-1862*). PAD4 inhibitors may therefore have applicability for diseases where NET formation in tissues contributes to local injury and disease pathology. Such diseases include, but are not limited to, small vessel vasculitis (*Kessenbrock K. et al, Nat. Med., 15(6), (2009), 623-625)*, systemic lupus erythematosus (*Hakkim A. et al, Proc. Natl. Acad. Sci. USA, 107(21), (2010), 9813-9818* and *Villanueva E. et al, J. Immunol., 187(1), (2011), 538-52)*, ulcerative colitis *(Savchenko A. et al, Pathol. Int., 61(5), (2011), 290-7)*, cystic fibrosis, asthma *(Dworski R. et al, J. Allergy Clin. Immunol., 127(5), (2011), 1260-6)*, deep vein thrombosis *(Fuchs T. et al, Proc. Natl. Acad. Sci. USA, 107(36), (2010), 15880-5)*, periodontitis *(Vitkov L. et al, Ultrastructural Pathol., 34(1), (2010), 25-30)*, sepsis *(Clark S.R. et al, Nat. Med., 13(4), (2007), 463-9)*, appendicitis *(Brinkmann V. et al, Science, 303, (2004), 1532-5)*, and stroke. In addition, there is evidence that NETs may contribute to pathology in diseases affecting the skin, e.g., in cutaneous lupus erythematosus (*Villanueva E. et al, J. Immunol., 187(1), (2011), 538-52)* and psoriasis (*Lin A.M. et al., J. Immunol., 187(1), (2011), 490-500*), so a PAD4 inhibitor may show benefit to tackle NET skin diseases, when administered by a systemic or cutaneous route. PAD4 inhibitors may affect additional functions within neutrophils and have wider applicability to neutrophilic diseases.

[0004] Studies have demonstrated efficacy of tool PAD inhibitors (for example chloro-amidine) in a number of animal models of disease, including collagen-induced arthritis (*Willis V.C. et al, J. Immunol., 186(7), (2011), 4396-4404*), dextran sulfate sodium (DSS)-induced experimental colitis (*Chumanevich A.A. et al, Am. J. Physiol. Gastrointest. Liver Physiol., 300(6), (2011), G929–G938*), spinal cord repair *(Lange S. et al, Dev. Biol., 355(2), (2011), 205-14)*, and experimental autoimmune encephalomyelitis (EAE). The DSS colitis report also demonstrates that chloro-amidine drives apoptosis of


inflammatory cells both *in vitro* and *in vivo*, suggesting that PAD4 inhibitors may be effective more generally in widespread inflammatory diseases.

[0005] PAD4 inhibitors are also useful in the treatment of cancers (*Slack.J.L. et al, Cell. Mol. Life Sci., 68(4), (2011), 709-720*). Over-expression of PAD4 has been demonstrated in numerous cancers (*Chang X. et al, BMC Cancer, 9, (2009), 40*). An anti-proliferative role has been suggested for PAD4 inhibitors from the observation that PAD4 citrullinates arginine residues in histones at the promoters of p53-target genes such as p21, which are involved in cell cycle arrest and induction of apoptosis (*Li P. et al, Mol. Cell Biol., 28(15), (2008), 4745-4758*).

[0006] The aforementioned role of PAD4 in deiminating arginine residues in histones may be indicative of a role for PAD4 in epigenetic regulation of gene expression. PAD4 is the primary PAD family member observed to be resident in the nucleus as well as the cytoplasm. Early evidence that PAD4 may act as a histone demethyliminase as well as a deiminase is inconsistent and unproven. However, it may reduce histone arginine methylation (and hence epigenetic regulation associated with this mark) indirectly *via* depletion of available arginine residues by conversion to citrulline. PAD4 inhibitors are useful as epigenetic tools or therapeutics for affecting expression of varied target genes in additional disease settings. Through such mechanisms, PAD4 inhibitors may also be effective in controlling citrullination levels in stem cells and may therefore therapeutically affect the pluripotency status and differentiation potential of diverse stem cells including, but not limited to, embryonic stem cells, neural stem cells, haematopoietic stem cells and cancer stem cells. Accordingly, there remains an unmet need to identify and develop PAD4 inhibitors for the treatment of PAD4-mediated disorders.

SUMMARY OF THE INVENTION

[0007] It has now been found that compounds of Formula (I) are useful as inhibitors of PAD4:



(I)


or a pharmaceutically acceptable salt thereof, wherein each of Ring A, L, Q, R_1, R_2, R_3, R_4, R_7, and R_8 along with other variables are as defined herein.

[0008] In some embodiments, a provided compound demonstrates selectivity for PAD4 with respect to PAD2. The present invention also provides pharmaceutically acceptable compositions comprising a provided compound. Provided compounds are useful in treatment of various disorders associated with PAD4. Such disorders are described in detail, herein, and include, for example rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, and psoriasis.

DETAILED DESCRIPTION OF THE INVENTION

1. General Description of Certain Aspects of the Invention

[0009] In some embodiments, such compounds include those of the formulae described herein, or a pharmaceutically acceptable salt thereof, wherein each variable is as defined herein and described in embodiments. Such compounds have the structure of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

Q is selected from N and CH;

Ring A is 4- to 15-membered heterocyclyl substituted with 1-4 R_7;

R_1 is selected from CH_3 and CD_3;

R_2 is selected from H, C_{1-3} alkyl substituted with 0-2 C_{3-6} cycloalkyl substituted with 0-4 F, Cl, and C_{1-3} alkyl;

R_3 is selected from H, F, Cl, Br, $-OR_b$, and C_{1-3} alkyl substituted with 0-5 R_c;

L is absent or selected from $-NR_d-$, -O-, $-C(=O)NR_d-$, and $-S(O)_p-$;

R_4 is selected from C_{1-6} alkyl substituted with 1-4 F, OH, and C_{3-6} cycloalkyl, $-(CH_2)_r$-aryl substituted with 1-7 R_5, $-(CH_2)_r-C_{3-12}$ cycloalkyl substituted with

1-7 R_5, -$(CH_2)_r$-heterocyclyl comprising carbon atoms and 1-3 heteroatoms selected from N, NR_6, O, and S and substituted with 1-7 R_5;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, =O, nitro, C_{1-4}alkyl substituted with 0-5 R_e, C_{2-4}alkenyl substituted with 0-5 R_e, C_{2-4}alkynyl substituted with 0-5 R_e, -$(CHR_d)_rOR_b$, -$(CHR_d)_rS(O)_pR_c$, -$(CHR_d)_rS(O)_pNR_aR_a$, -$(CHR_d)_rNR_aS(O)_pR_c$, -$(CHR_d)_rNR_aR_a$, -$(CHR_d)_rNR_aC(=O)R_b$, -$(CHR_d)_rNR_aC(=O)OR_b$, -$(CHR_d)_rNR_aC(=O)NR_aR_a$, -$(CHR_d)_rC(=O)R_b$, -$(CHR_d)_rC(=O)OR_b$, -$(CHR_d)_rC(=O)NR_aR_a$, -$(CHR_d)_rOC(=O)R_b$, -$(CHR_d)_rOC(=O)OR_b$, -$(CHR_d)_rO(CH_2)_rC(=O)NR_aR_a$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_6 is selected from H, C_{1-3}alkyl substituted with 0-4 R_e, -$S(O)_pR_c$, -$(CH_2)_rC(=O)R_b$, -$(CH_2)_r$ $C(=O)OR_b$, -$(CH_2)_rC(=O)(CH_2)_rNR_aR_a$, -$C(=O)(CH_2)_rNR_aC(=O)R_b$, -$S(O)_pNR_aR_a$, -$(CH_2)_r$-$C_{3-6}$cycloalkyl substituted with 0-4 R_e, -$(CH_2)_r$-aryl substituted with 0-4 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-4 R_e;

R_7 is selected from H, F, Cl, CN, C_{1-3} alkyl, =N-OR_b, -$(CH_2)_rOR_b$, -$(CH_2)_rNR_aR_a$, -$NR_aC(=NH)C_{1-3}$alkyl, -$NR_aC(=O)OR_b$, carbocyclyle, and heterocyclyle; alternatively, two R_7 groups are taken together to form carbocyclyl or heterocyclyl;

R_8, at each occurrence, is independently selected from H, F, Cl, Br, and C_{1-4}alkyl substituted with 0-5 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r$-C_{3-6} carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_d, at each occurrence, is independently selected from H,C_{1-6} alkyl substituted with 0-5 R_e, and OH,




R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, $-(CH_2)_r$-C_{3-6} cycloalkyl, $-(CH_2)_r$-aryl, $-(CH_2)_r$-heterocyclyl, $Si(C_{1-4}alkyl)_3$, F, Cl, Br, CN, NO_2, =O, CO_2H, $-(CH_2)_rOR_f$, $S(O)_pR_f$, $C(=O)NR_fR_f$, $S(O)_pNR_fR_f$, and $-(CH_2)_rNR_fR_f$;


R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{2-5} alkenyl, C_{2-5} alkynyl, C_{3-6} cycloalkyl, and phenyl, or R_f and R_f together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with C_{1-4}alkyl;

p, at each occurrence, is independently selected from zero, 1, and 2;

r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4;

provided:

(1) when L is absent, R_4 is not  ,  , and  ;

(2) when L is $-NR_d-$, R_4 is not  , and  ; and

(3) when L is –O-, R_4 is not C_{3-6} cycloalkyl.

2. *Definitions*

[0010] Throughout the specification and the appended claims, a given chemical formula or name shall encompass all stereo and optical isomers and racemates thereof where such isomers exist. Unless otherwise indicated, all chiral (enantiomeric and diastereomeric) and racemic forms are within the scope of the invention. Many geometric isomers of C=C double bonds, C=N double bonds, ring systems, and the like can also be present in the compounds, and all such stable isomers are contemplated in the present invention. Cis- and trans- (or *E*- and *Z*-) geometric isomers of the compounds of the

present invention are described and may be isolated as a mixture of isomers or as separated isomeric forms. The present compounds can be isolated in optically active or racemic forms. Optically active forms may be prepared by resolution of racemic forms or by synthesis from optically active starting materials. All processes used to prepare compounds of the present invention and intermediates made therein are considered to be part of the present invention. When enantiomeric or diastereomeric products are prepared, they may be separated by conventional methods, for example, by chromatography or fractional crystallization. Depending on the process conditions the end products of the present invention are obtained either in free (neutral) or salt form. Both the free form and the salts of these end products are within the scope of the invention. If so desired, one form of a compound may be converted into another form. A free base or acid may be converted into a salt; a salt may be converted into the free compound or another salt; a mixture of isomeric compounds of the present invention may be separated into the individual isomers. Compounds of the present invention, free form and salts thereof, may exist in multiple tautomeric forms, in which hydrogen atoms are transposed to other parts of the molecules and the chemical bonds between the atoms of the molecules are consequently rearranged. It should be understood that all tautomeric forms, insofar as they may exist, are included within the invention.

[0011] As used herein, the term "alkyl" or "alkylene" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms. For examples, "C_1 to C_{12} alkyl" or "C_{1-12} alkyl" (or alkylene), is intended to include C_1, C_2, C_3, C_4, C_5, C_6, C_7, C_8, C_9, C_{10}, C_{11} and C_{12} alkyl groups; "C_4 to C_{18} alkyl" or "C_{4-18} alkyl" (or alkylene), is intended to include C_4, C_5, C_6, C_7, C_8, C_9, C_{10}, C_{11}, C_{12}, C_{13}, C_{14}, C_{15}, C_{16}, C_{17}, and C_{18} alkyl groups. Additionally, for example, "C_1 to C_6 alkyl" or "C_{1-6} alkyl" denotes alkyl having 1 to 6 carbon atoms. Alkyl group can be unsubstituted or substituted with at least one hydrogen being replaced by another chemical group. Example alkyl groups include, but are not limited to, methyl (Me), ethyl (Et), propyl (*e.g.*, n-propyl and isopropyl), butyl (*e.g.*, n-butyl, isobutyl, *t*-butyl), and pentyl (*e.g.*, n-pentyl, isopentyl, neopentyl). When "C_0 alkyl" or "C_0 alkylene" is used, it is intended to denote a direct bond.

[0012] "Alkenyl" or "alkenylene" is intended to include hydrocarbon chains of either straight or branched configuration having the specified number of carbon atoms and one

or more, preferably one to two, carbon-carbon double bonds that may occur in any stable point along the chain. For example, "C_2 to C_6 alkenyl" or "C_{2-6} alkenyl" (or alkenylene), is intended to include C_2, C_3, C_4, C_5, and C_6 alkenyl groups. Examples of alkenyl include, but are not limited to, ethenyl, 1-propenyl, 2-propenyl, 2-butenyl, 3-butenyl, 2-pentenyl, 3, pentenyl, 4-pentenyl, 2-hexenyl, 3-hexenyl, 4-hexenyl, 5-hexenyl, 2-methyl-2-propenyl, and 4-methyl-3-pentenyl.

[0013] "Alkynyl" or "alkynylene" is intended to include hydrocarbon chains of either straight or branched configuration having one or more, preferably one to three, carbon-carbon triple bonds that may occur in any stable point along the chain. For example, "C_2 to C_6 alkynyl" or "C_{2-6} alkynyl" (or alkynylene), is intended to include C_2, C_3, C_4, C_5, and C_6 alkynyl groups; such as ethynyl, propynyl, butynyl, pentynyl, and hexynyl.

[0014] The term "alkoxy" or "alkyloxy" refers to an -O-alkyl group. For example, "C_1 to C_6 alkoxy" or "C_{1-6} alkoxy" (or alkyloxy), is intended to include C_1, C_2, C_3, C_4, C_5, and C_6 alkoxy groups. Example alkoxy groups include, but are not limited to, methoxy, ethoxy, propoxy (*e.g.*, n-propoxy and isopropoxy), and *t*-butoxy. Similarly, "alkylthio" or "thioalkoxy" represents an alkyl group as defined above with the indicated number of carbon atoms attached through a sulphur bridge; for example methyl-S- and ethyl-S-.

[0015] "Halo" or "halogen" includes fluoro, chloro, bromo, and iodo. "Haloalkyl" is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more halogens. Examples of haloalkyl include, but are not limited to, fluoromethyl, difluoromethyl, trifluoromethyl, trichloromethyl, pentafluoroethyl, pentachloroethyl, 2,2,2-trifluoroethyl, heptafluoropropyl, and heptachloropropyl. Examples of haloalkyl also include "fluoroalkyl" that is intended to include both branched and straight-chain saturated aliphatic hydrocarbon groups having the specified number of carbon atoms, substituted with 1 or more fluorine atoms.

[0016] The term "cycloalkyl" refers to cyclized alkyl groups, including mono-, bi- or poly-cyclic ring systems. For example, "C_3 to C_6 cycloalkyl" or "C_{3-6} cycloalkyl" is intended to include C_3, C_4, C_5, and C_6 cycloalkyl groups. Example cycloalkyl groups include, but are not limited to, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, and norbornyl. Branched cycloalkyl groups such as 1-methylcyclopropyl and

2-methylcyclopropyl are included in the definition of "cycloalkyl". The term "cycloalkenyl" refers to cyclized alkenyl groups. C_{4-6} cycloalkenyl is intended to include C_4, C_5, and C_6 cycloalkenyl groups. Example cycloalkenyl groups include, but are not limited to, cyclobutenyl, cyclopentenyl, and cyclohexenyl.

[0017] As used herein, "carbocycle", "carbocyclyl", or "carbocyclic residue" is intended to mean any stable 3-, 4-, 5-, 6-, 7-, or 8-membered monocyclic or bicyclic or 7-, 8-, 9-, 10-, 11-, 12-, or 13-membered bicyclic or tricyclic hydrocarbon ring, any of which may be saturated, partially unsaturated, unsaturated or aromatic. Examples of such carbocycles include, but are not limited to, cyclopropyl, cyclobutyl, cyclobutenyl, cyclopentyl, cyclopentenyl, cyclohexyl, cycloheptenyl, cycloheptyl, cycloheptenyl, adamantyl, cyclooctyl, cyclooctenyl, cyclooctadienyl, [3.3.0]bicyclooctane, [4.3.0]bicyclononane, [4.4.0]bicyclodecane (decalin), [2.2.2]bicyclooctane, fluorenyl, phenyl, naphthyl, indanyl, adamantyl, anthracenyl, and tetrahydronaphthyl (tetralin). As shown above, bridged rings are also included in the definition of carbocycle (*e.g.*, [2.2.2]bicyclooctane). Preferred carbocycles, unless otherwise specified, are cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, phenyl, indanyl, and tetrahydronaphthyl. When the term "carbocycle" is used, it is intended to include "aryl." A bridged ring occurs when one or more, preferably one to three, carbon atoms link two non-adjacent carbon atoms. Preferred bridges are one or two carbon atoms. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge.

[0018] As used herein, the term "bicyclic carbocycle" or "bicyclic carbocyclic group" is intended to mean a stable 9- or 10-membered carbocyclic ring system that contains two fused rings and consists of carbon atoms. Of the two fused rings, one ring is a benzo ring fused to a second ring; and the second ring is a 5- or 6-membered carbon ring which is saturated, partially unsaturated, or unsaturated. The bicyclic carbocyclic group may be attached to its pendant group at any carbon atom which results in a stable structure. The bicyclic carbocyclic group described herein may be substituted on any carbon if the resulting compound is stable. Examples of a bicyclic carbocyclic group are, but not limited to, naphthyl, 1,2-dihydronaphthyl, 1,2,3,4-tetrahydronaphthyl, and indanyl.

[0019] "Aryl" groups refer to monocyclic or bicyclic aromatic hydrocarbons, including, for example, phenyl, and naphthyl. Aryl moieties are well known and

described, for example, in Lewis, R.J., ed., *Hawley's Condensed Chemical Dictionary*, 15th Edition, John Wiley & Sons, Inc., New York (2007). "C_{6-10} aryl" refers to phenyl and naphthyl.

[0020] As used herein, the term "heterocycle", "heterocyclyl", or "heterocyclic group" is intended to mean a stable 3-, 4-, 5-, 6-, or 7-membered monocyclic or bicyclic or 7-, 8-, 9-, 10-, 11-, 12-, 13-, or 14-membered polycyclic heterocyclic ring that is saturated, partially unsaturated, or fully unsaturated, and that contains carbon atoms and 1, 2, 3 or 4 heteroatoms independently selected from the group consisting of N, O and S; and including any polycyclic group in which any of the above-defined heterocyclic rings is fused to a benzene ring. The nitrogen and sulfur heteroatoms may optionally be oxidized (*i.e.*, N→O and $S(O)_p$, wherein p is 0, 1 or 2). The nitrogen atom may be substituted or unsubstituted (*i.e.*, N or NR wherein R is H or another substituent, if defined). The heterocyclic ring may be attached to its pendant group at any heteroatom or carbon atom that results in a stable structure. The heterocyclic rings described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. A nitrogen in the heterocycle may optionally be quaternized. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1. When the term "heterocycle" is used, it is intended to include heteroaryl.

[0021] Examples of heterocycles include, but are not limited to, acridinyl, azetidinyl, azocinyl, benzimidazolyl, benzofuranyl, benzothiofuranyl, benzothiophenyl, benzoxazolyl, benzoxazolinyl, benzthiazolyl, benztriazolyl, benztetrazolyl, benzisoxazolyl, benzisothiazolyl, benzimidazolinyl, carbazolyl, 4a*H*-carbazolyl, carbolinyl, chromanyl, chromenyl, cinnolinyl, decahydroquinolinyl, 2*H*,6*H*-1,5,2-dithiazinyl, dihydrofuro[2,3-*b*]tetrahydrofuran, furanyl, furazanyl, imidazolidinyl, imidazolinyl, imidazolyl, 1*H*-indazolyl, imidazolopyridinyl, indolenyl, indolinyl, indolizinyl, indolyl, 3*H*-indolyl, isatinoyl, isobenzofuranyl, isochromanyl, isoindazolyl, isoindolinyl, isoindolyl, isoquinolinyl, isothiazolyl, isothiazolopyridinyl, isoxazolyl, isoxazolopyridinyl, methylenedioxyphenyl, morpholinyl, naphthyridinyl, octahydroisoquinolinyl, oxadiazolyl, 1,2,3-oxadiazolyl, 1,2,4-oxadiazolyl, 1,2,5-oxadiazolyl, 1,3,4-oxadiazolyl, oxazolidinyl, oxazolyl, oxazolopyridinyl,

oxazolidinylperimidinyl, oxindolyl, pyrimidinyl, phenanthridinyl, phenanthrolinyl, phenazinyl, phenothiazinyl, phenoxathiinyl, phenoxazinyl, phthalazinyl, piperazinyl, piperidinyl, piperidonyl, 4-piperidonyl, piperonyl, pteridinyl, purinyl, pyranyl, pyrazinyl, pyrazolidinyl, pyrazolinyl, pyrazolopyridinyl, pyrazolyl, pyridazinyl, pyridooxazolyl, pyridoimidazolyl, pyridothiazolyl, pyridinyl, pyrimidinyl, pyrrolidinyl, pyrrolinyl, 2-pyrrolidonyl, 2*H*-pyrrolyl, pyrrolyl, quinazolinyl, quinolinyl, 4*H*-quinolizinyl, quinoxalinyl, quinuclidinyl, tetrazolyl, tetrahydrofuranyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, 6*H*-1,2,5-thiadiazinyl, 1,2,3-thiadiazolyl, 1,2,4-thiadiazolyl, 1,2,5-thiadiazolyl, 1,3,4-thiadiazolyl, thianthrenyl, thiazolyl, thienyl, thiazolopyridinyl, thienothiazolyl, thienooxazolyl, thienoimidazolyl, thiophenyl, triazinyl, 1,2,3-triazolyl, 1,2,4-triazolyl, 1,2,5-triazolyl, 1,3,4-triazolyl, and xanthenyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

[0022] Examples of 5- to 10-membered heterocycles include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, piperazinyl, piperidinyl, imidazolyl, imidazolidinyl, indolyl, tetrazolyl, isoxazolyl, morpholinyl, oxazolyl, oxadiazolyl, oxazolidinyl, tetrahydrofuranyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, triazolyl, benzimidazolyl, 1*H*-indazolyl, benzofuranyl, benzothiofuranyl, benztetrazolyl, benzotriazolyl, benzisoxazolyl, benzoxazolyl, oxindolyl, benzoxazolinyl, benzthiazolyl, benzisothiazolyl, isatinoyl, isoquinolinyl, octahydroisoquinolinyl, tetrahydroisoquinolinyl, tetrahydroquinolinyl, isoxazolopyridinyl, quinazolinyl, quinolinyl, isothiazolopyridinyl, thiazolopyridinyl, oxazolopyridinyl, imidazolopyridinyl, and pyrazolopyridinyl. Also included are fused ring and spiro compounds containing, for example, the above heterocycles.

[0023] Bridged rings are also included in the definition of heterocycle. A bridged ring occurs when one or more, preferably one to three, atoms (*i.e.*, C, O, N, or S) link two non-adjacent carbon or nitrogen atoms. Examples of bridged rings include, but are not limited to, one carbon atom, two carbon atoms, one nitrogen atom, two nitrogen atoms, and a carbon-nitrogen group. It is noted that a bridge always converts a monocyclic ring into a tricyclic ring. When a ring is bridged, the substituents recited for the ring may also be present on the bridge.

[0024] As used herein, the term "bicyclic heterocycle" or "bicyclic heterocyclic group" is intended to mean a stable 9- or 10-membered heterocyclic ring system which

contains two fused rings and consists of carbon atoms and 1, 2, 3, or 4 heteroatoms independently selected from the group consisting of N, O and S. Of the two fused rings, one ring is a 5- or 6-membered monocyclic aromatic ring comprising a 5-membered heteroaryl ring, a 6-membered heteroaryl ring or a benzo ring, each fused to a second ring. The second ring is a 5- or 6-membered monocyclic ring which is saturated, partially unsaturated, or unsaturated, and comprises a 5-membered heterocycle, a 6-membered heterocycle or a carbocycle (provided the first ring is not benzo when the second ring is a carbocycle).

[0025] The bicyclic heterocyclic group may be attached to its pendant group at any heteroatom or carbon atom which results in a stable structure. The bicyclic heterocyclic group described herein may be substituted on carbon or on a nitrogen atom if the resulting compound is stable. It is preferred that when the total number of S and O atoms in the heterocycle exceeds 1, then these heteroatoms are not adjacent to one another. It is preferred that the total number of S and O atoms in the heterocycle is not more than 1.

[0026] Examples of a bicyclic heterocyclic group are, but not limited to, quinolinyl, isoquinolinyl, phthalazinyl, quinazolinyl, indolyl, isoindolyl, indolinyl, 1*H*-indazolyl, benzimidazolyl, 1,2,3,4-tetrahydroquinolinyl, 1,2,3,4-tetrahydroisoquinolinyl, 5,6,7,8-tetrahydro-quinolinyl, 2,3-dihydro-benzofuranyl, chromanyl, 1,2,3,4-tetrahydro-quinoxalinyl, and 1,2,3,4-tetrahydro-quinazolinyl.

[0027] As used herein, the term "aromatic heterocyclic group" or "heteroaryl" is intended to mean stable monocyclic and polycyclic aromatic hydrocarbons that include at least one heteroatom ring member such as sulfur, oxygen, or nitrogen. Heteroaryl groups include, without limitation, pyridyl, pyrimidinyl, pyrazinyl, pyridazinyl, triazinyl, furyl, quinolyl, isoquinolyl, thienyl, imidazolyl, thiazolyl, indolyl, pyrroyl, oxazolyl, benzofuryl, benzothienyl, benzthiazolyl, isoxazolyl, pyrazolyl, triazolyl, tetrazolyl, indazolyl, 1,2,4-thiadiazolyl, isothiazolyl, purinyl, carbazolyl, benzimidazolyl, indolinyl, benzodioxolanyl, and benzodioxane. Heteroaryl groups are substituted or unsubstituted. The nitrogen atom is substituted or unsubstituted (*i.e.*, N or NR wherein R is H or another substituent, if defined). The nitrogen and sulfur heteroatoms may optionally be oxidized (*i.e.*, N→O and $S(O)_p$, wherein p is 0, 1 or 2).

[0028] Examples of 5- to 6-membered heteroaryls include, but are not limited to, pyridinyl, furanyl, thienyl, pyrrolyl, pyrazolyl, pyrazinyl, imidazolyl, imidazolidinyl,

tetrazolyl, isoxazolyl, oxazolyl, oxadiazolyl, oxazolidinyl, thiadiazinyl, thiadiazolyl, thiazolyl, triazinyl, and triazolyl.

[0029] The term "counter ion" is used to represent a negatively charged species such as chloride, bromide, hydroxide, acetate, and sulfate or a positively charged species such as sodium (Na^+), potassium (K^+), ammonium (R_nNH_m+ where n=0-4 and m=0-4) and the like.

[0030] When a dotted ring is used within a ring structure, this indicates that the ring structure may be saturated, partially saturated or unsaturated.

[0031] As used herein, the term "amine protecting group" means any group known in the art of organic synthesis for the protection of amine groups which is stable to an ester reducing agent, a disubstituted hydrazine, R4-M and R7-M, a nucleophile, a hydrazine reducing agent, an activator, a strong base, a hindered amine base and a cyclizing agent. Such amine protecting groups fitting these criteria include those listed in Wuts, P.G.M. et al., *Protecting Groups in Organic Synthesis*, 4th Edition, Wiley (2007) and *The Peptides: Analysis, Synthesis, Biology*, Vol. 3, Academic Press, New York (1981), the disclosure of which is hereby incorporated by reference. Examples of amine protecting groups include, but are not limited to, the following: (1) acyl types such as formyl, trifluoroacetyl, phthalyl, and p-toluenesulfonyl; (2) aromatic carbamate types such as benzyloxycarbonyl (Cbz) and substituted benzyloxycarbonyls, 1-(p-biphenyl)-1-methylethoxycarbonyl, and 9-fluorenylmethyloxycarbonyl (Fmoc); (3) aliphatic carbamate types such as *tert*-butyloxycarbonyl (Boc), ethoxycarbonyl, diisopropylmethoxycarbonyl, and allyloxycarbonyl; (4) cyclic alkyl carbamate types such as cyclopentyloxycarbonyl and adamantyloxycarbonyl; (5) alkyl types such as triphenylmethyl and benzyl; (6) trialkylsilane such as trimethylsilane; (7) thiol containing types such as phenylthiocarbonyl and dithiasuccinoyl; and (8) alkyl types such as triphenylmethyl, methyl, and benzyl; and substituted alkyl types such as 2,2,2-trichloroethyl, 2-phenylethyl, and *t*-butyl; and trialkylsilane types such as trimethylsilane.

[0032] As referred to herein, the term "substituted" means that at least one hydrogen atom is replaced with a non-hydrogen group, provided that normal valencies are maintained and that the substitution results in a stable compound. Ring double bonds, as used herein, are double bonds that are formed between two adjacent ring atoms (*e.g.*, C=C, C=N, or N=N).

[0033] In cases wherein there are nitrogen atoms (*e.g.*, amines) on compounds of the present invention, these may be converted to N-oxides by treatment with an oxidizing agent (*e.g.*, mCPBA and/or hydrogen peroxides) to afford other compounds of this invention. Thus, shown and claimed nitrogen atoms are considered to cover both the shown nitrogen and its N-oxide (N→O) derivative.

[0034] When any variable occurs more than one time in any constituent or formula for a compound, its definition at each occurrence is independent of its definition at every other occurrence. Thus, for example, if a group is shown to be substituted with 0-3 R, then said group may optionally be substituted with up to three R groups, and at each occurrence R is selected independently from the definition of R.

[0035] When a bond to a substituent is shown to cross a bond connecting two atoms in a ring, then such substituent may be bonded to any atom on the ring. When a substituent is listed without indicating the atom in which such substituent is bonded to the rest of the compound of a given formula, then such substituent may be bonded via any atom in such substituent.

[0036] Combinations of substituents and/or variables are permissible only if such combinations result in stable compounds.

[0037] The phrase "pharmaceutically acceptable" is employed herein to refer to those compounds, materials, compositions, and/or dosage forms that are, within the scope of sound medical judgment, suitable for use in contact with the tissues of human beings and animals without excessive toxicity, irritation, allergic response, and/or other problem or complication, commensurate with a reasonable benefit/risk ratio.

[0038] As used herein, "pharmaceutically acceptable salts" refer to derivatives of the disclosed compounds wherein the parent compound is modified by making acid or base salts thereof. Examples of pharmaceutically acceptable salts include, but are not limited to, mineral or organic acid salts of basic groups such as amines; and alkali or organic salts of acidic groups such as carboxylic acids. The pharmaceutically acceptable salts include the conventional non-toxic salts or the quaternary ammonium salts of the parent compound formed, for example, from non-toxic inorganic or organic acids. Examples of pharmaceutically acceptable, nontoxic acid addition salts are salts of an amino group formed with inorganic acids such as hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid and perchloric acid or with organic acids such as acetic acid, oxalic

acid, maleic acid, tartaric acid, citric acid, succinic acid or malonic acid or by using other methods used in the art such as ion exchange. Other pharmaceutically acceptable salts include adipate, alginate, ascorbate, aspartate, benzenesulfonate, benzoate, bisulfate, borate, butyrate, camphorate, camphorsulfonate, citrate, cyclopentanepropionate, digluconate, dodecylsulfate, ethanesulfonate, formate, fumarate, glucoheptonate, glycerophosphate, gluconate, hemisulfate, heptanoate, hexanoate, hydroiodide, 2–hydroxy–ethanesulfonate, lactobionate, lactate, laurate, lauryl sulfate, malate, maleate, malonate, methanesulfonate, 2–naphthalenesulfonate, nicotinate, nitrate, oleate, oxalate, palmitate, pamoate, pectinate, persulfate, 3–phenylpropionate, phosphate, pivalate, propionate, stearate, succinate, sulfate, tartrate, thiocyanate, p–toluenesulfonate, undecanoate, valerate salts, and the like.

[0039] Salts derived from appropriate bases include alkali metal, alkaline earth metal, ammonium and $N^+(C_{1-4}alkyl)_4$ salts. Representative alkali or alkaline earth metal salts include sodium, lithium, potassium, calcium, magnesium, and the like. Further pharmaceutically acceptable salts include, when appropriate, nontoxic ammonium, quaternary ammonium, and amine cations formed using counterions such as halide, hydroxide, carboxylate, sulfate, phosphate, nitrate, loweralkyl sulfonate and aryl sulfonate.

[0040] The pharmaceutically acceptable salts of the present invention can be synthesized from the parent compound that contains a basic or acidic moiety by conventional chemical methods. Generally, such salts can be prepared by reacting the free acid or base forms of these compounds with a stoichiometric amount of the appropriate base or acid in water or in an organic solvent, or in a mixture of the two; generally, nonaqueous media like ether, ethyl acetate, ethanol, isopropanol, or acetonitrile are preferred. Lists of suitable salts are found in Allen, Jr., L.V., ed., *Remington: The Science and Practice of Pharmacy*, 22nd Edition, Pharmaceutical Press, London, UK (2012), the disclosure of which is hereby incorporated by reference.

[0041] In addition, compounds of formula I may have prodrug forms. Any compound that will be converted *in vivo* to provide the bioactive agent (*i.e.*, a compound of formula I) is a prodrug within the scope and spirit of the invention. Various forms of prodrugs are well known in the art. For examples of such prodrug derivatives, see:

a) Bundgaard, H., ed., *Design of Prodrugs*, Elsevier (1985), and Widder, K. et al., eds., *Methods in Enzymology*, 112:309-396, Academic Press (1985);

b) Bundgaard, H., Chapter 5, "Design and Application of Prodrugs", Krosgaard-Larsen, P. et al., eds., *A Textbook of Drug Design and Development*, pp. 113-191, Harwood Academic Publishers (1991);

c) Bundgaard, H., *Adv. Drug Deliv. Rev.*, 8:1-38 (1992);

d) Bundgaard, H. et al., *J. Pharm. Sci.*, 77:285 (1988);

e) Kakeya, N. et al., *Chem. Pharm. Bull.*, 32:692 (1984); and

f) Rautio, J., ed., *Prodrugs and Targeted Delivery (Methods and Principles in Medicinal Chemistry)*, Vol. 47, Wiley-VCH (2011).

[0042] Compounds containing a carboxy group can form physiologically hydrolyzable esters that serve as prodrugs by being hydrolyzed in the body to yield formula I compounds *per se*. Such prodrugs are preferably administered orally since hydrolysis in many instances occurs principally under the influence of the digestive enzymes. Parenteral administration may be used where the ester *per se* is active, or in those instances where hydrolysis occurs in the blood. Examples of physiologically hydrolyzable esters of compounds of formula I include C_{1-6}alkyl, C_{1-6}alkylbenzyl, 4-methoxybenzyl, indanyl, phthalyl, methoxymethyl, C_{1-6} alkanoyloxy-C_{1-6}alkyl (*e.g.*, acetoxymethyl, pivaloyloxymethyl or propionyloxymethyl), C_{1-6}alkoxycarbonyloxy-C_{1-6}alkyl (*e.g.*, methoxycarbonyl-oxymethyl or ethoxycarbonyloxymethyl, glycyloxymethyl, phenylglycyloxymethyl, (5-methyl-2-oxo-1,3-dioxolen-4-yl)-methyl), and other well known physiologically hydrolyzable esters used, for example, in the penicillin and cephalosporin arts. Such esters may be prepared by conventional techniques known in the art.

[0043] Preparation of prodrugs is well known in the art and described in, for example, King, F.D., ed., *Medicinal Chemistry: Principles and Practice*, The Royal Society of Chemistry, Cambridge, UK (2nd Edition, reproduced (2006)); Testa, B. et al., *Hydrolysis in Drug and Prodrug Metabolism. Chemistry, Biochemistry and Enzymology*, VCHA and Wiley-VCH, Zurich, Switzerland (2003); Wermuth, C.G., ed., *The Practice of Medicinal Chemistry*, 3rd Edition, Academic Press, San Diego, CA (2008).

[0044] The present invention is intended to include all isotopes of atoms occurring in the present compounds. Isotopes include those atoms having the same atomic number but

different mass numbers. By way of general example and without limitation, isotopes of hydrogen include deuterium (symbol D or 2H) and tritium (symbol T or 3H). For example, a methyl group may be represented by CH_3 or CD_3. Isotopes of carbon include ^{13}C and ^{14}C. Isotopically-labeled compounds of the invention can generally be prepared by conventional techniques known to those skilled in the art or by processes analogous to those described herein, using an appropriate isotopically-labeled reagent in place of the non-labeled reagent otherwise employed.

[0045] The term "solvate" means a physical association of a compound of this invention with one or more solvent molecules, whether organic or inorganic. This physical association includes hydrogen bonding. In certain instances the solvate will be capable of isolation, for example when one or more solvent molecules are incorporated in the crystal lattice of the crystalline solid. The solvent molecules in the solvate may be present in a regular arrangement and/or a non-ordered arrangement. The solvate may comprise either a stoichiometric or nonstoichiometric amount of the solvent molecules. "Solvate" encompasses both solution-phase and isolable solvates. Exemplary solvates include, but are not limited to, hydrates, ethanolates, methanolates, and isopropanolates. Methods of solvation are generally known in the art.

[0046] The terms “measurable affinity” and “measurably inhibit,” as used herein, means a measurable change in PAD4 activity between a sample comprising a compound of the present invention, or composition thereof, and PAD4, and an equivalent sample comprising PAD4 in the absence of said compound, or composition thereof.

[0047] Abbreviations as used herein, are defined as follows: "1 x" for once, "2 x" for twice, "3 x" for thrice, "°C" for degrees Celsius, "eq" for equivalent or equivalents, "g" for gram or grams, "mg" for milligram or milligrams, "L" for liter or liters, "mL" for milliliter or milliliters, "µL" for microliter or microliters, "N" for normal, "M" for molar, "mmol" for millimole or millimoles, "min" for minute or min, "h" for hour or h, "rt" for room temperature, "RT" for retention time, "atm" for atmosphere, "psi" for pounds per square inch, "conc." for concentrate, "aq" for "aqueous", "sat" or "sat'd " for saturated, "MW" for molecular weight, "mp" for melting point, "MS" or "Mass Spec" for mass spectrometry, "ESI" for electrospray ionization mass spectroscopy, "HR" for high resolution, "HRMS" for high resolution mass spectrometry, "LCMS" for liquid chromatography mass spectrometry, "HPLC" for high pressure liquid chromatography, "RP HPLC" for reverse

phase HPLC, "TLC" or "tlc" for thin layer chromatography, "NMR" for nuclear magnetic resonance spectroscopy, "nOe" for nuclear Overhauser effect spectroscopy, "^{1}H" for proton, "δ" for delta, "s" for singlet, "d" for doublet, "t" for triplet, "q" for quartet, "m" for multiplet, "br" for broad, "Hz" for hertz, and "α", "β", "R", "S", "E", "Z" and "ee" are stereochemical designations familiar to one skilled in the art. As used herein, the term "pharmaceutically acceptable salt" refers to those salts which are, within the scope of sound medical judgment, suitable for use in contact with the tissues of humans and lower animals without undue toxicity, irritation, allergic response and the like, and are commensurate with a reasonable benefit/risk ratio.


AcOH or HOAc	acetic acid
ACN	acetonitrile
Alk	Alkyl
$AlMe_3$	Trimethylaluminum
BBr_3	boron tribromide
Bn	benzyl
Boc	*tert*-butyloxycarbonyl
BOP reagent	benzotriazol-1-yloxytris(dimethylamino)phosphonium hexafluorophosphate
Bu	butyl
i-Bu	isobutyl
t-Bu	*tert*-butyl
t-BuOH	*tert*-butanol
Cbz	carbobenzyloxy
$CDCl_3$	deutero-chloroform
CD_3OD	deutero-methanol
CH_2Cl_2	dichloromethane
CH_3CN	acetonitrile
$CHCl_3$	chloroform
DCM	dichloromethane

DIEA, DIPEA or Hunig's base	diisopropylethylamine
DMF	dimethyl formamide
DMSO	dimethyl sulfoxide
Et	ethyl
Et_3N or TEA	triethylamine
Et_2O	diethyl ether
EtOAc	ethyl acetate
EtOH	ethanol
HCl	hydrochloric acid
HPLC	high-performance liquid chromatography
K_2CO_3	potassium carbonate
K_2HPO_4	potassium hydrogenphosphate
LCMS	liquid chromatography mass spectrometry
LiHMDS	lithium bis(trimethylsilyl)amide
LG	leaving group
Me	methyl
MeOH	methanol
$MgSO_4$	magnesium sulfate
MsOH or MSA	methylsulfonic acid
NaCl	sodium chloride
Na_2CO_3	sodium carbonate
$NaHCO_3$	sodium bicarbonate
NaOH	sodium hydroxide
Na_2SO_4	sodium sulfate
NH_3	ammonia
NH_4Cl	ammonium chloride
NH_4OAc	ammonium acetate
$Pd(OAc)_2$	palladium(II) acetate
$Pd(dppf)Cl_2$	[1,1'-Bis(diphenylphosphino)ferrocene]*palladium*(II) dichloride

$Pd(PPh_3)_4$	tetrakis(triphenylphosphine)palladium(0)
PG	protecting group
Ph	phenyl
Pr	propyl
i-Pr	isopropyl
i-PrOH or IPA	isopropanol
Rt	retention time
SiO_2	silica oxide
SFC	supercritical fluid chromatography
TBAI	Tetrabutylammonium iodide
TEA	triethylamine
TFA	trifluoroacetic acid
TFAA	Trifluoroacetic anhydride
THF	tetrahydrofuran
$TiCl_4$	titanium tetrachloride
T3P	1-propanephosphonic acid cyclic anhydride

3. *Description of Exemplary Compounds*

[0048] In a first aspect, the present invention provides a compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

Q is selected from N and CH;

Ring A is 4- to 15-membered heterocyclyl substituted with 1-4 R_7;

R_1 is selected from CH_3 and CD_3;

R_2 is selected from H, C_{1-3} alkyl substituted with 0-5 R_e, and C_{3-6} cycloalkyl substituted with 0-5 R_e;

R_3 is selected from H, F, Cl, Br, $-OR_b$, and C_{1-3} alkyl substituted with 0-5 R_e;

L is absent or selected from $-NR_d-$, -O-, $-C(=O)NR_d-$, and $-S(O)_p-$;

R_4 is selected from -$(CH_2)_r$-aryl substituted with 1-5 R_5, -$(CH_2)_r$-C_{3-12} cycloalkyl substituted with 1-5 R_5, -$(CH_2)_r$-heterocyclyl comprising carbon atoms and 1-3 heteroatoms selected from N, NR_6, O, and S and substituted with 1-5 R_5;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, nitro, C_{1-4}alkyl substituted with 0-5 R_e, C_{2-4}alkenyl substituted with 0-5 R_e, C_{2-4}alkynyl substituted with 0-5 R_e, -$(CHR_d)_rOR_b$, -$(CHR_d)_rS(O)_pR_c$, -$(CHR_d)_rS(O)_pNR_aR_a$, -$(CHR_d)_rNR_aS(O)_pR_c$, -$(CHR_d)_rNR_aR_a$, -$(CHR_d)_rNR_aC(=O)R_b$, -$(CHR_d)_rNR_aC(=O)OR_b$, -$(CHR_d)_rNR_aC(=O)NR_aR_a$, -$(CHR_d)_rC(=O)R_b$, -$(CHR_d)_rC(=O)OR_b$, -$(CHR_d)_rC(=O)NR_aR_a$, -$(CHR_d)_rOC(=O)R_b$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_6 is selected from H, C_{1-3}alkyl substituted with 0-4 R_e, -$S(O)_pR_c$, -$C(=O)R_b$, -$C(=O)OR_b$, -$C(=O)(CH_2)_rNR_aR_a$, -$S(O)_pNR_aR_a$, -$(CH_2)_r$-C_{3-6}cycloalkyl substituted with 0-4 R_e, -$(CH_2)_r$-aryl substituted with 0-4 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-4 R_e;

R_7 is selected from H, F, Cl, CN, C_{1-3} alkyl, =N-OR_b, -$(CH_2)_rOR_b$, -$(CH_2)_rNR_aR_a$, -$NR_aC(=NH)C_{1-3}$alkyl, -$NR_aC(=O)OR_b$, a carbocyle, and a heterocycle; alternatively, two R_7 groups are taken together to form a carbocycle or heterocyle;

R_8, at each occurrence, is independently selected from H, F, Cl, Br, and C_{1-4}alkyl substituted with 0-5 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-

C_{3-6} carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_d, at each occurrence, is independently selected from H andC_{1-6} alkyl substituted with 0-5 R_e,




R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, -$(CH_2)_r$-C_{3-6} cycloalkyl, -$(CH_2)_r$-aryl, $Si(C_{1-4}alkyl)_3$, F, Cl, Br, CN, NO_2, =O, CO_2H, -$(CH_2)_rOR_f$, $S(O)_pR_f$, $C(=O)NR_fR_f$, $S(O)_pNR_fR_f$, and -$(CH_2)_rNR_fR_f$;


R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{2-5} alkenyl, C_{2-5} alkynyl, C_{3-6} cycloalkyl, and phenyl, or R_f and R_f together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with C_{1-4}alkyl;

p, at each occurrence, is independently selected from zero, 1, and 2;

r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4; and






provided:

(1) when L is absent, R_4 is not  ,  , and  ;

(2) when L is –NR_d-, R_4 is not  , and  ; and

(3) when L is –O-, R_4 is not C_{3-6} cycloalkyl.

[0049] In a second aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof, within the scope of the first aspect, wherein:




















Ring A is selected from  ,  ,  ,  , and  ;


R_1 is selected from CH_3 and CD_3;


R_2 is selected from methyl, ethyl, and -CH_2-cyclopropyl substituted with 0-3 R_e;


R_3 is selected from H, F, Cl, Br, and –OC_{1-4} alkyl;

L is absent or selected from -NR_d-, -O-, -C(=O)NH-, -S-, and -$S(O)_2$-;

R_4 is selected from  , , , ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , ,  , , .







R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, C_{1-4}alkyl substituted with 0-5 R_e, C_{2-4}alkenyl, C_{2-4}alkynyl, $-(CHR_d)_rOR_b$, $-(CH_2)_rS(O)_pR_c$, $-(CH_2)_rS(O)_pNR_aR_a$, $-(CH_2)_rNR_aS(O)_pR_c$, $-(CH_2)_rNR_aR_a$, $-(CH_2)_rNR_aC(=O)R_b$, $-(CH_2)_rNR_aC(=O)OR_b$, $-(CH_2)_rNR_aC(=O)NR_aR_a$, $-(CH_2)_rC(=O)R_b$, $-(CH_2)_rC(=O)OR_b$, $-(CH_2)_rOC(=O)R_b$, $-(CH_2)_rC(=O)NR_aR_a$, $-(CH_2)_rOC(=O)R_b$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_6, at each occurrence, is independently selected from H, C_{1-3}alkyl substituted with 0-4 R_e, $-S(O)_pR_c$, $-C(=O)R_b$, $-C(=O)(CH_2)_rNR_aR_a$, $-C(=O)OR_b$, $-S(O)_pNR_aR_a$, $-(CH_2)_r$-aryl substituted with 0-4 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-4 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl

substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-6} carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_d, at each occurrence, is independently selected from H and C_{1-6} alkyl substituted with 0-5 R_e;


R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, -$(CH_2)_r$-C_{3-6} cycloalkyl, -$(CH_2)_r$-aryl, F, Cl, Br, CN, NO_2, =O, -NH_2, -NHC_{1-4}alkyl, -$N(C_{1-4}alkyl)_2$, -C(=O)OH, -C(=O)OC_{1-4}alkyl, -$(CH_2)_r$OH, and -$(CH_2)_r$$OC_{1-4}$alkyl;

R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;

p, at each occurrence, is independently selected from zero, 1, and 2; and



r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

[0050] In a third aspect, the present invention provides a compound of formula (II):







(II)


or a pharmaceutically acceptable salt thereof, wherein:

Ring A is selected from  ,  , and ;

R_2 is selected from methyl and -CH_2-cyclopropyl;

R_3 is selected from H, F, and –OC_{1-4} alkyl;

R_4 is selected from  ,  ,  ,  .



and ;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, C_{1-4}alkyl substituted with 0-4 R_e, $-(CHR_d)_rOR_b$, $-S(O)_pR_c$, $-S(O)_pNR_aR_a$, $-(CH_2)_rNR_aS(O)_pR_c$, $-(CH_2)_rNR_aR_a$, $-(CH_2)_rNR_aC(=O)R_b$, $-NR_aC(=O)OR_b$, $-NR_aC(=O)NR_aR_a$, $-(CH_2)_rC(=O)R_b$, -

$(CH_2)_rC(=O)OR_b$, $-(CH_2)_rC(=O)NR_aR_a$, $-(CH_2)_rOC(=O)R_b$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_6, at each occurrence, is independently selected from H, C_{1-3}alkyl substituted with 0-4 R_e, $-S(O)_pR_c$, $-C(=O)R_b$, $-(CH_2)_r-C(=O)NR_aR_a$, $-C(=O)(CH_2)_rNR_aC(=O)R_b$, $-C(=O)OR_b$, $-S(O)_pNR_aR_a$, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, $-(CH_2)_r-C_{2-6}$ alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-6}$ carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_d, at each occurrence, is independently selected from H and C_{1-6} alkyl substituted with 0-5 R_e;


R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, $-(CH_2)_r-C_{3-6}$ cycloalkyl, $-(CH_2)_r$-aryl, F, Cl, Br, CN, NO_2, =O, $-NH_2$, $-NHC_{1-4}$alkyl, $-N(C_{1-4}alkyl)_2$, $-C(=O)OH$, $-C(=O)OC_{1-4}$alkyl, $-(CH_2)_rOH$, and $-(CH_2)_rOC_{1-4}$alkyl;

R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;

p, at each occurrence, is independently selected from zero, 1, and 2; and


r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

[0051] In a fourth aspect, the present invention provides a compound of formula (III):



(III)

or a pharmaceutically acceptable salt thereof, wherein:

Ring A is  ,

R_2 is -CH_2-cyclopropyl;

R_3 is –OC_{1-4} alkyl;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, C_{1-4}alkyl substituted with 0-4 R_e, -$(CHR_d)_tOR_b$, - $S(O)_pR_c$ - $(CH_2)_tNR_aR_a$, -$(CH_2)_tNHC(=O)R_b$, -$NHC(=O)OR_b$, -$(CH_2)_rNHS(O)_pR_c$, - $(CH_2)_tC(=O)NR_aR_a$, -$(CH_2)_tC(=O)OR_b$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_t$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_t$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, -$(CH_2)_t$-C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_t$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_t$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_t$-C_{3-6} carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_t$-heterocyclyl substituted with 0-5 R_e;

R_d, at each occurrence, is independently selected from H and C_{1-6} alkyl;

R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, -$(CH_2)_t$-C_{3-6} cycloalkyl, -$(CH_2)_t$-aryl, F, Cl, Br, CN,

NO_2, =O, $-NH_2$, $-NHC_{1-4}$alkyl, $-N(C_{1-4}alkyl)_2$, $-C(=O)OH$, $-C(=O)OC_{1-4}$alkyl, $-(CH_2)_rOH$, $-(CH_2)_rOC_{1-4}$alkyl, and SO_2C_{1-4}alkyl;

R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;

p, at each occurrence, is independently selected from zero, 1, and 2; and


r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

[0052] In a fifth aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof, within the scope of the fourth aspect, wherein:

R_3 is $-OCH_3$; and



R_5, at each occurrence, is independently selected from H, F, Cl, Br, C_{1-4}alkyl, -OH, $-OC_{1-3}$alkyl, and $-NHS(O)_2C_{2-4}$alkenyl.

[0053] In a sixth aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof, within the scope of the third aspect, wherein:

Ring A is  ;

R_2 is $-CH_2$-cyclopropyl;

R_3 is $-OC_{1-4}$ alkyl;

R_4 is selected from  and  ;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, C_{1-4}alkyl substituted with 0-4 R_e, $-(CH_2)_rOR_b$, $-S(O)_pR_c$, $-S(O)_pNR_aR_a$, $-(CH_2)_rNR_aS(O)_pR_c$, $-(CH_2)_rNR_aR_a$, $-(CH_2)_rNR_aC(=O)R_b$, $-NR_aC(=O)OR_b$, $-NR_aC(=O)NR_aR_a$, $-(CH_2)_rC(=O)R_b$, $-(CH_2)_rC(=O)OR_b$, $-(CH_2)_rC(=O)NR_aR_a$, $-(CH_2)_rOC(=O)R_b$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, $-(CH_2)_r-C_{2-6}$ alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-6}$ carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, $-(CH_2)_r-C_{3-6}$ cycloalkyl, $-(CH_2)_r$-aryl, F, Cl, Br, CN, NO_2, =O, $-NH_2$, $-NHC_{1-4}$alkyl, $-N(C_{1-4}alkyl)_2$, -C(=O)OH, $-C(=O)OC_{1-4}$alkyl, $-(CH_2)_rOH$, and $-(CH_2)_rOC_{1-4}$alkyl;

R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;

p, at each occurrence, is independently selected from zero, 1, and 2; and


r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

[0054] In a seventh aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof, within the scope of the sixth asepct, wherein:

R_3 is $-OCH_3$; and



















R_5, at each occurrence, is independently selected from H, F, Cl, Br, C_{1-4}alkyl, -OH, $-OC_{1-3}$alkyl, and $-NHS(O)_2C_{2-4}$alkenyl.

[0055] In an eighth aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof, within the scope of the third aspect, wherein:

Ring A is  ;

R_2 is $-CH_2$-cyclopropyl;

R_3 is $-OC_{1-4}$ alkyl;

R_4 is selected from  , , ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , and

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN C_{1-4}alkyl, $-OR_b$, $-S(O)_pR_c$ $-(CH_2)_rNR_aR_a$, $-(CH_2)_rNR_aC(=O)R_b$, $-NR_aC(=O)OR_b$, $-(CH_2)_rNR_aS(O)_pR_c$, $-C(=O)NR_aR_a$, $-C(=O)OR_b$, C_{3-6}cycloalkyl

substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_6, at each occurrence, is independently selected from H, C_{1-3}alkyl substituted with 0-4 R_e, $-S(O)_pR_c$, $-C(=O)R_b$, $-(CH_2)_r-C(=O)NR_aR_a$, $-C(=O)(CH_2)_rNR_aC(=O)R_b$, $-C(=O)OR_b$, $-S(O)_pNR_aR_a$, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, $-(CH_2)_r-C_{2-6}$ alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-6}$ carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;










R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, $-(CH_2)_r-C_{3-6}$ cycloalkyl, $-(CH_2)_r$-aryl, F, Cl, Br, CN, NO_2, =O, $-NH_2$, $-NHC_{1-4}$alkyl, $-N(C_{1-4}alkyl)_2$, $-C(=O)OH$, $-C(=O)OC_{1-4}$alkyl, $-(CH_2)_rOH$, and $-(CH_2)_rOC_{1-4}$alkyl;

R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;

p, at each occurrence, is independently selected from zero, 1, and 2; and


r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

[0056] In a ninth aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof, within the scope of the eighth aspect, wherein:

R_4 is selected from  ,  ,  ,  ,  ,  ,  ,  , and  ;


R_5, at each occurrence, is independently selected from H, F, Cl, Br, C_{1-4}alkyl, and OH.

[0057] In a tenth aspect, the present invention provides a compound of formula (IV):




(IV)

or a pharmaceutically acceptable salt thereof, within the scope of the ninth aspect, wherein:

Ring A is  ;

R_2 is selected from methyl and -CH_2-cyclopropyl;

R_3 is selected from H, F, and –OC_{1-4} alkyl;

R_4 is selected from  , and ;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, C_{1-4}alkyl, $-(CH_2)_rOR_b$, $-NR_aR_a$, $-NR_aC(=O)R_b$, $-NR_aC(=O)OR_b$, $-C(=O)OR_b$, $NR_aS(O)_pR_c$, $-C(=O)NR_aR_a$, $-NR_aC(=O)NR_aR_a$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_6, at each occurrence, is independently selected from H and C_{1-3}alkyl;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-6}$ carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_d, at each occurrence, is independently selected from H and C_{1-3} alkyl;

R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, $-(CH_2)_r-C_{3-6}$ cycloalkyl, $-(CH_2)_r$-aryl, F, Cl, Br, CN, NO_2, =O, $N(C_{1-4}alkyl)_2$, $-C(=O)OH$, $-C(=O)OC_{1-4}$alkyl, $-(CH_2)_rOH$, and $-(CH_2)_rOC_{1-4}$alkyl;

R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;


p, at each occurrence, is independently selected from zero, 1, and 2; and

r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

[0058] In an eleventh aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof, within the scope of the tenth aspect, wherein:

R_2 is CH_2-cyclopropyl;

R_3 is $-OCH_3$;

R_4 is  ;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, C_{1-4}alkyl, and $-(CH_2)_{0-1}OH$; and




R_d is H.

[0059] In a twelfth aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof, within the scope of the second aspect, wherein:

L is -C(=O)NH-;

R_2 is $-CH_2$-cyclopropyl;

R_3 is $-OC_{1-4}$ alkyl;

R_4 is selected from  ,  , and  ;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, C_{1-4}alkyl, -OH, and -CN; and


R_6, at each occurrence, is independently selected from H and C_{1-3}alkyl.

[0060] In a thirteenth aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof, within the scope of the second aspect, wherein:

L is -O-;

R_2 is -CH_2-cyclopropyl;


R_3 is –OC_{1-4} alkyl;

R_4 is selected from  , and ;

and

R_5, at each occurrence, is independently selected from H, F, Cl, Br, C_{1-4}alkyl, -OH, and –CN.

[0061] In a fourteenth aspect, the present invention provides a compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

Q is selected from N and CH;

Ring A is 4- to 15-membered heterocyclyl substituted with 1-4 R_7;

R_1 is selected from CH_3, CD_3, and –CH_2-5 membered heterocyclyl compring carbon atoms and 1-3 heteroatoms selected from N, NC_{1-4}alkyl, O, and S;

R_2 is selected from H, C_{1-3} alkyl substituted with 0-5 R_e, and -$(CH_2)_r$-C_{3-6} cycloalkyl substituted with 0-5 R_e;

R_3 is selected from H, F, Cl, Br, –OR_b, and C_{1-3} alkyl substituted with 0-5 R_e;

L is absent or selected from -NR_d-, -O-, -C(=O)NR_d-, and -$S(O)_p$-;

R_4 is selected from -$(CH_2)_r$-aryl substituted with 1-7 R_5, -$(CH_2)_r$-C_{3-12} cycloalkyl (substituted with 1-2 OR_b, C(=O)OR_b, -C(=O)NR_aR_a, -

$NR_aC(=O)R_b$), -$(CH_2)_r$-heterocyclyl comprising carbon atoms and 1-3 heteroatoms selected from N, NR_6, O, and S and substituted with 1-7 R_5;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, =O, nitro, C_{1-4}alkyl substituted with 0-5 R_e, C_{2-4}alkenyl substituted with 0-5 R_e, C_{2-4}alkynyl substituted with 0-5 R_e, -$(CHR_d)_rOR_b$, -$(CHR_d)_rS(O)_pR_c$, -$(CHR_d)_rS(O)_pNR_aR_a$, -$(CHR_d)_rNR_aS(O)_pR_c$, -$(CHR_d)_rNR_aR_a$, -$(CHR_d)_rNR_aC(=O)R_b$, -$(CHR_d)_rNR_aC(=O)OR_b$, -$(CHR_d)_rNR_aC(=O)NR_aR_a$, -$(CHR_d)_rC(=O)R_b$, -$(CHR_d)_rC(=O)OR_b$, -$(CHR_d)_rC(=O)NR_aR_a$, -$(CHR_d)_rOC(=O)R_b$, -$(CHR_d)_rOC(=O)OR_b$, -$(CHR_d)_rO(CH_2)_rC(=O)NR_aR_a$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_6 is selected from H, C_{1-3}alkyl substituted with 0-4 R_e, -$S(O)_pR_c$, -$(CH_2)_rC(=O)R_b$, -$(CH_2)_r$ $C(=O)OR_b$, -$(CH_2)_rC(=O)(CH_2)_rNR_aR_a$, -$C(=O)(CH_2)_rNR_aC(=O)R_b$, -$S(O)_pNR_aR_a$, -$(CH_2)_r$-$C_{3-6}$cycloalkyl substituted with 0-4 R_e, -$(CH_2)_r$-aryl substituted with 0-4 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-4 R_e;

R_7 is selected from H, F, Cl, CN, C_{1-3} alkyl, =N-OR_b, -$(CH_2)_rOR_b$, -$(CH_2)_rNR_aR_a$, -$NR_aC(=NH)C_{1-3}$alkyl, -$NR_aC(=O)OR_b$, carbocyclyl, and heterocyclyl; alternatively, two R_7 groups are taken together to form carbocyclyl or heterocyclyl;

R_8, at each occurrence, is independently selected from H, F, Cl, Br, and C_{1-4}alkyl substituted with 0-5 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r$-C_{3-6} carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_d, at each occurrence, is independently selected from H,C_{1-6} alkyl substituted with 0-5 R_e, and OH,




R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, $-(CH_2)_r$-C_{3-6} cycloalkyl, $-(CH_2)_r$-aryl, $-(CH_2)_r$-heterocyclyl, $Si(C_{1-4}alkyl)_3$, F, Cl, Br, CN, NO_2, =O, CO_2H, $-(CH_2)_rOR_f$, $S(O)_pR_f$, $C(=O)NR_fR_f$, $S(O)_pNR_fR_f$, and $-(CH_2)_rNR_fR_f$;



R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{2-5} alkenyl, C_{2-5} alkynyl, C_{3-6} cycloalkyl, and phenyl, or R_f and R_f together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with C_{1-4}alkyl;

p, at each occurrence, is independently selected from zero, 1, and 2;

r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4;


provided:






(1) when L is absent, R_4 is not  ,  , and  ;

(2) when L is $-NR_d-$, R_4 is not  , and  ; and

(3) when L is –O-, R_4 is not C_{3-6} cycloalkyl.

[0062] In a fifteenth aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof, within the scope of the fourteenth aspect, wherein:



is selected from  ,  ,  ,  , and  ;





R_1 is selected from CH_3 and CD_3;





R_2 is selected from methyl, ethyl and $-CH_2$-cyclopropyl substituted with 0-3 R_e;





R_3 is selected from H, F, Cl, Br, and $-OC_{1-4}$ alkyl;






L is absent or selected from $-NR_d-$, -O-, -C(=O)NH-, -S-, and $-S(O)_2-$;


R_4 is selected from


 ,  ,  ,  ,  ,


 ,  ,  ,  ,


 ,  ,  ,  ,

 ,  ,  ,  ,  .









, and ;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, =O, C_{1-4}alkyl substituted with 0-5 R_e, C_{2-4}alkenyl, C_{2-4}alkynyl, -$(CHR_d)_rOR_b$, -$(CH_2)_rS(O)_pR_c$, -$(CH_2)_rS(O)_pNR_aR_a$, -$(CH_2)_rNR_aS(O)_pR_c$, -$(CH_2)_rNR_aR_a$, -$(CH_2)_rNR_aC(=O)R_b$, -$(CH_2)_rNR_aC(=O)OR_b$, -$(CH_2)_rNR_aC(=O)NR_aR_a$, -$(CH_2)_rC(=O)R_b$, -$(CH_2)_rC(=O)OR_b$, -$(CHR_d)_rC(=O)NR_aR_a$, -$(CH_2)_rOC(=O)R_b$, -$(CH_2)_rOC(=O)OR_b$, -$(CH_2)_r$ $O(CH_2)_rC(=O)NR_aR_a$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_6, at each occurrence, is independently selected from H, C_{1-3}alkyl substituted with 0-4 R_e, -$S(O)_pR_c$, -$C(=O)R_b$, -$(CH_2)_rC(=O)OR_b$, -$(CH_2)_rC(=O)(CH_2)_rNR_aR_a$, -$C(=O)(CH_2)_rNR_aC(=O)R_b$, -$S(O)_pNR_aR_a$, -$(CH_2)_r$-aryl substituted with 0-4 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-4 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r$-C_{3-6} carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_d, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, and OH;


R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, $-(CH_2)_r$-C_{3-6} cycloalkyl, $-(CH_2)_r$-aryl, $-(CH_2)_r$-heterocyclyl, F, Cl, Br, CN, NO_2, =O, $-NH_2$, $-NHC_{1-4}$alkyl, $-N(C_{1-4}$alkyl$)_2$, -C(=O)OH, $-C(=O)OC_{1-4}$alkyl, $-(CH_2)_rOH$, and $-(CH_2)_rOC_{1-4}$alkyl;

R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;

p, at each occurrence, is independently selected from zero, 1, and 2; and


r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

[0063] In a sixteenth aspect, the present invention provides a compound of Formula (II):




(II)


or a pharmaceutically acceptable salt thereof, within the scope of the fifteenth aspect, wherein:




is selected from




,




,



,




, and




;


R_2 is selected from CH_3, CH_2CH_3 and $-CH_2$-cyclopropyl substituted with 0-2 F, Cl, and CH_3;


R_3 is selected from H, F, and $-OC_{1-4}$ alkyl;



R_4 is selected from







, and ;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, =O, C_{1-4}alkyl substituted with 0-4 R_e, $-(CHR_d)_rOR_b$, $-(CH_2)_r S(O)_pR_c$, $-S(O)_pNR_aR_a$, $-(CH_2)_rNR_aS(O)_pR_c$, $-(CH_2)_rNR_aR_a$, $-(CH_2)_rNR_aC(=O)R_b$, $-NR_aC(=O)OR_b$, $-NR_aC(=O)NR_aR_a$, $-(CH_2)_rC(=O)R_b$, $-(CH_2)_rC(=O)OR_b$, $-(CHR_d)_rC(=O)NR_aR_a$, $-(CH_2)_rOC(=O)R_b$, $-(CH_2)_rOC(=O)OR_b$, $-(CH_2)_r O(CH_2)_rC(=O)NR_aR_a$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_6, at each occurrence, is independently selected from H, C_{1-3}alkyl substituted with 0-4 R_e, $-S(O)_pR_c$, $-C(=O)R_b$, $-(CH_2)_rC(=O)OR_b$, $-(CH_2)_rC(=O)NR_aR_a$, $-C(=O)(CH_2)_rNR_aC(=O)R_b$, $-S(O)_pNR_aR_a$, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, $-(CH_2)_r-C_{2-6}$ alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r$-C_{3-6} carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_d, at each occurrence, is independently selected from H and C_{1-6} alkyl substituted with 0-5 R_e;


R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, $-(CH_2)_r$-C_{3-6} cycloalkyl, $-(CH_2)_r$-aryl, $-(CH_2)_r$-heterocyclyl, F, Cl, Br, CN, NO_2, =O, $-NH_2$, $-NHC_{1-4}$alkyl, $-N(C_{1-4}$alkyl$)_2$, -C(=O)OH, $-C(=O)OC_{1-4}$alkyl, $-(CH_2)_rOH$, and $-(CH_2)_rOC_{1-4}$alkyl;

R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;

p, at each occurrence, is independently selected from zero, 1, and 2; and




r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

[0064] In a seventeenth aspect, the present invention provides a compound of Formula (III):



(III)

or a pharmaceutically acceptable salt thereof, within the scope of the sixteenth aspect, wherein:

 is selected from  and  ,

R_2 is $-CH_2$-cyclopropyl;

R_3 is $-OC_{1-4}$ alkyl;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, C_{1-4}alkyl substituted with 0-4 R_e, $-(CHR_d)_rOR_b$, $-(CH_2)_rS(O)_pR_c$, $-S(O)_pNR_aR_a$, $-(CH_2)_rNHS(O)_pR_c$, $-(CH_2)_rNR_aR_a$, $-(CH_2)_rNHC(=O)R_b$, $-NHC(=O)OR_b$, $-(CHR_d)_rC(=O)NR_aR_a$, $-(CH_2)_rC(=O)OR_b$, $-OC(=O)OR_b$, $-O(CH_2)_{0-1}C(=O)NR_aR_a$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, $-(CH_2)_r$-C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r$-C_{3-6} carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_d, at each occurrence, is independently selected from H, C_{1-4} alkyl, and OH;

R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, $-(CH_2)_r$-C_{3-6} cycloalkyl, $-(CH_2)_r$-aryl, $-(CH_2)_r$-heterocyclyl, F, Cl, Br, CN, NO_2, =O, $-NH_2$, $-NHC_{1-4}$alkyl, $-N(C_{1-4}alkyl)_2$, -C(=O)OH, $-C(=O)OC_{1-4}$alkyl, $-(CH_2)_rOH$, $-(CH_2)_rOC_{1-4}$alkyl, and SO_2C_{1-4}alkyl;






R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;

p, at each occurrence, is independently selected from zero, 1, and 2; and

r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

[0065] In an eighteenth aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof, within the scope of the seventeenth aspect, wherein:




R_3 is $-OCH_3$;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, C_{1-4}alkyl, -$(CH_2)_{0-1}OR_b$, -$S(O)_2NH_2$, -$NHS(O)_2C_{1-3}$ alkyl,-$NHS(O)_2C_{2-4}$alkenyl, -$NHC(=O)R_b$, -$C(=O)NH_2$ and heterocyclyl selected from  ,  ,  ,  , and  ;

R_b, at each occurrence, is independently selected from H and C_{1-6} alkyl substituted with 0-5 R_e,





R_e, at each occurrence, is independently selected from C_{1-6} alkyl, F, Cl, Br, CN, NO_2, =O, $-NH_2$, $-NHC_{1-4}$alkyl, $-N(C_{1-4}$alkyl$)_2$, -C(=O)OH, $-C(=O)OC_{1-4}$alkyl, $-(CH_2)_rOH$, $-(CH_2)_rOC_{1-4}$alkyl, and SO_2C_{1-4}alkyl;

[0066] In a nineteenth aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof, within the scope of the sixteenth aspect, wherein:

 is selected from  and  ;

R_2 is -CH_2-cyclopropyl;

R_3 is $-OC_{1-4}$ alkyl;

R_4 is selected from  ,  ,  , and  ;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, C_{1-4}alkyl substituted with 0-4 R_e, $-(CH_2)_rOR_b$, $-S(O)_pR_c$, $-S(O)_pNR_aR_a$, $-(CH_2)_rNR_aS(O)_pR_c$, $-(CH_2)_rNR_aR_a$, $-(CH_2)_rNR_aC(=O)R_b$, $-NR_aC(=O)OR_b$, $-NR_aC(=O)NR_aR_a$, $-(CH_2)_rC(=O)R_b$, $-(CH_2)_rC(=O)OR_b$, $-(CH_2)_rC(=O)NR_aR_a$, $-(CH_2)_rOC(=O)R_b$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, $-(CH_2)_r$-C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r$-C_{3-6} carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, $-(CH_2)_r$-C_{3-6} cycloalkyl, $-(CH_2)_r$-aryl, F, Cl, Br, CN, NO_2, =O, $-NH_2$, $-NHC_{1-4}$alkyl, $-N(C_{1-4}alkyl)_2$, $-C(=O)OH$, $-C(=O)OC_{1-4}$alkyl, $-(CH_2)_rOH$, and $-(CH_2)_rOC_{1-4}$alkyl;



R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;

p, at each occurrence, is independently selected from zero, 1, and 2; and

r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.




[0067] In a twentieth aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof, within the scope of the nineteenth aspect, wherein:

R_3 is $-OCH_3$;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, C_{1-4}alkyl, -OH, -OC_{1-3}alkyl, -$NHS(O)_2C_{2-4}$alkenyl, $NHC(=O)OC_{1-4}$ alkyl, $C(=O)NH_2$, $C(=O)NHC_{1-4}$alkyl, and heterocyclyl selected from  and  ; and


R_e, at each occurrence, is independently selected from C_{1-6} alkyl, F, Cl, Br, CN, NO_2, =O, $-NH_2$, -NHC_{1-4}alkyl, -$N(C_{1-4}$alkyl$)_2$, $-C(=O)OH$, -$C(=O)OC_{1-4}$alkyl, -$(CH_2)_rOH$, -$(CH_2)_rOC_{1-4}$alkyl, and SO_2C_{1-4}alkyl;


[0068] In a twenty first aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof, within the scope of the sixteenth aspect, wherein:


 is selected from  and  ;


R_2 is -CH_2-cyclopropyl;


R_3 is $-OC_{1-4}$ alkyl;


R_4 is selected from 














:

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN C_{1-4}alkyl, $-OR_b$, $-S(O)_pR_c$ $-(CH_2)_rNR_aS(O)_pR_c$, $-(CH_2)_rNR_aR_a$, $-(CH_2)_rNR_aC(=O)R_b$, $-NR_aC(=O)OR_b$, $-C(=O)OR_b$, $C(=O)NR_aR_a$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_6, at each occurrence, is independently selected from H, C_{1-3}alkyl substituted with 0-4 R_e, $-S(O)_pR_c$, $-C(=O)R_b$, $-C(=O)OR_b$, $-(CH_2)_r-C(=O)NR_aR_a$, $-C(=O)(CH_2)_rNR_aC(=O)R_b$, $-S(O)_pNR_aR_a$, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, $-(CH_2)_r-C_{2-6}$ alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-6}$ carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;




R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, $-(CH_2)_r-C_{3-6}$ cycloalkyl, $-(CH_2)_r$-aryl, F, Cl, Br, CN, NO_2, =O, $-NH_2$, $-NHC_{1-4}$alkyl, $-N(C_{1-4}alkyl)_2$, $-C(=O)OH$, $-C(=O)OC_{1-4}$alkyl, $-(CH_2)_rOH$, and $-(CH_2)_rOC_{1-4}$alkyl;

R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;

p, at each occurrence, is independently selected from zero, 1, and 2; and


r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

[0069] In a twenty second aspect, the present invention provides a compound or a pharmaceutically acceptable salt thereof, within the scope of the twenty first aspect, wherein:

R_4 is selected from  ,  ,  , and ; and





R_5, at each occurrence, is independently selected from H, F, Cl, Br, C_{1-4}alkyl, OH, and –C(=O)OH.

[0070] In a twenty third aspect, the present invention provides a compound of Fomrula (V):






(V)

or a pharmaceutically acceptable salt thereof, wherein:


 is selected from  ,  , and  ;

R_2 is -CH_2-cyclopropyl;

R_3 is –OCH_3; and




R_4 is selected from  ,  , and  .

[0071] In a twenty fourth aspect, the present invention provides a compound of Formula (VI):




(VI)

or a pharmaceutically acceptable salt thereof, wherein:


 is selected from  ,  , and  ;

R_2 is -CH_2-cyclopropyl;

R_4 is selected from  ; and




R_5 is selected from H, OH, CH_2OH, and $-C(CH_3)_2OH$.

[0072] In a twenty fifth aspect, the present invention provides a compound of Formula (VII):




(VII)

or a pharmaceutically acceptable salt thereof, wherein:

 is selected from  and  ;

R_2 is -CH_2-cyclopropyl;

R_4 is selected from  ;

R_5, at each occurrence, is independently selected from F, Cl, C_{1-4}alkyl, $-(CH_2)_rOR_b$, $-S(O)_2NR_aR_a$, $-NR_aS(O)_2R_c$, and $-C(=O)NR_aR_a$;

R_6, at each occurrence, is independently selected from H and C_{1-3}alkyl;

R_a, at each occurrence, is independently selected from H and C_{1-4} alkyl substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H and C_{1-4} alkyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently C_{1-4} alkyl substituted with 0-5 R_e;

R_e, at each occurrence, is independently selected from F, Cl, Br, -OH, and -OC_{1-4}alkyl;

and

r, at each occurrence, is independently selected from zero, 1, and 2.

[0073] In one embodiment, the present invention provides compounds with IC_{50} values ≤ 4.000 μM, using the RFMS PAD4 functional assay disclosed herein, preferably, IC_{50} values ≤ 1.000 μM, preferably, IC_{50} values ≤ 0.500 μM, preferably, IC_{50} values ≤ 0.100 μM, more preferably, IC_{50} values ≤ 0.050 μM, more preferably, IC_{50} values ≤ 0.03 μM, more preferably, IC_{50} values ≤ 0.02 μM, even more preferably, IC_{50} values ≤ 0.01 μM.


[0074] As defined above and described herein, R_1 is selected from CH_3 and CD_3. In some embodiments, R_1 is CH_3. In some embodiments, R_1 is CD_3.


[0075] As defined above and described herein, R_2 is hydrogen, C_{1-3} alkyl substituted with 0-5 R_e, or C_{3-6} cycloalkyl substituted with 0-5 R_e. In some embodiments, R_2 is hydrogen. In some embodiments, R_2 is C_{1-2} alkyl substituted with C_{3-6} cycloalkyl. In some embodiments, R_2 is C_{3-6} cycloalkyl. In some embodiments, R_2 is methyl. In some embodiments, R_2 is ethyl. In some embodiments, R_2 is cyclopropyl. In some embodiments, R_2 is cyclobutyl. In some embodiments, R_2 is cyclopentyl. In some embodiments, R_2 is cyclohexyl. In some embodiments, R_2 is cyclopropylmethyl. In some embodiments, R_2 is cyclobutylmethyl. In some embodiments, R_2 is cyclopentylmethyl. In some embodiments, R_2 is cyclohexylmethyl. In some embodiments, R_2 is cyclopropylethyl. In some embodiments, R_2 is cyclobutylethyl. In some embodiments, R_2 is cyclopentylethyl. In some embodiments, R_2 is cyclohexylethyl. In some embodiments, R_2 is –CH_2-cyclopropyl or –CH_2-cyclobutyl. In some embodiments, R_2 is –CH_2-cyclobutyl optionally substituted with methyl and –OH. In certain embodiments, R_2 is selected from those functional groups depicted in the examples below.


[0076] As defined above and described herein, Q is N or CH. In some embodiments, Q is N. In some embodiments, Q is CH. In certain embodiments, Q is selected from those functional groups depicted in the examples below.





[0077] As defined above and described herein, R_3 is selected from H, F, Cl, Br, $-OR_b$, and C_{1-3} alkyl substituted with 0-5 R_e. In some embodiments, R_3 is H. In some embodiments, R_3 is F, Cl, Br. In some embodiments, R_3 is F, In some embodiments, R^3 is C_{1-3} alkyl. In some embodiments, R_3 is methyl. In some embodiments, R_3 is ethyl. In some embodiments, R_3 is propyl. In some embodiments, R_3 is OR_b. In some embodiments, R_3 is $-OCH_3$. In some embodiments, R_3 is $-OCH_2CH_3$. In some embodiments, R_3 is $-OCH_2CH_2CH_3$. In certain embodiments, R_3 is $-OCH(F)_2$. In certain embodiments, R_3 is selected from those functional groups depicted in the examples below.


[0078] As defined above and described herein, L is absent, $-NR_d-$, $-O-$, $-C(=O)NR_d-$, or $-S(O)_p-$; in some embodiments, L is absent. In some embodiments, L is $-NR_d-$, R_d is H or C_{1-3}alkyl. In some embodiments, L is $-O-$. In some embodiments, L is $-C(=O)NH-$. In some embodiments, L is $-S(O)_2-$. In some embodiments, L is $-S-$. In certain embodiments, L is selected from those functional groups depicted in the examples below.




[0079] As defined above and described herein, each R_4 is  ,



















[0080] In some embodiments, R_4 is  . In some embodiments, R_4 is  . In some embodiments, R_4 is  . In some embodiments, R_4 is  .


[0081] In some embodiments, R_4 is  .


[0082] In some embodiments, R_4 is  . In some embodiments, R_4 is  . In some embodiments, R_4 is  .



[0083] In some embodiments, R_4 is  ,  ,  ,  ,  ,  ,  ,  ,  .

[0084] In certain embodiments, R_4 is  ,  .



[0085] In certain embodiments, R_4 is  ,  , and  .

[0086] In certain embodiments, R_4 is  and .

[0087] In certain embodiments, R_4 is  , and .

[0088] In certain embodiments, R_4 is  and  .

[0089] In certain embodiments, R_4 is C_{1-5} alkyl substituted with 1-4 F, Cl, Br, OH, and C_{3-6} cycloalkyl.







In certain embodiments, R_4 is R_4 is selected from  ,  , and .





[0090]

[0091] As defined above and described herein, R_5 is H, F, Cl, Br, CN, C_{1-4}alkyl substituted with 0-5 R_e, C_{2-4}alkenyl, C_{2-4}alkynyl, nitro, $-S(O)_pR_c$, $-S(O)_pNR_aR_a$, $-NR_aS(O)_pR_c$, $-(CH_2)_tOR_b$, $-(CH_2)_tNR_aR_a$, $-NR_aC(=O)R_b$, $NR_aC(=O)OR_b$ $-NR_aC(=O)NR_aR_a$, $-C(=O)R_b$, $-C(=O)OR_b$, $C(=O)NR_aR_a$, $-OC(=O)R_b$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e

[0092] In some embodiments, R_5 is H, F, Cl, CN, C_{1-4}alkyl, C_{1-4}alkyl (substituted with OH, NH_2, and COOH), SC_{1-4}alkyl, $S(O)_2C_{1-4}$alkyl, $S(O)_2$NH-cyclopropyl, $-(CH_2)_{0-1}NHS(O)_2C_{1-4}$alkyl, $N(R_d)S(O)_2C_{2-4}$alkenyl, $-(CH_2)_{0-1}OH$, OC_{1-4}alkyl, $-(CH_2)_{0-1}NH_2$, $-(CH_2)_{0-1}NHC(=O)C_{1-4}$alkyl, $-NR_dC(=O)C_{2-4}$alkenyl, $-NHC(=O)C_{2-4}$alkynyl, $-(CH_2)_{0-1}C(=O)OH$, $-C(=O)OC_{1-4}$alkyl, $-NHC(=O)OC_{1-4}$alkyl, $-NHC(=O)O(CH_2)_2OC_{1-4}$alkyl, $-NHC(=O)OCH_2$-cyclopropyl, $-NHC(=O)NH_2$, $C(=O)NHC_{1-4}$alkyl, $CONH(CH_2)_1$.

$_2$C(=O)OH, -$(CH_2)_{0-1}$C(=O)NH_2, -$(CH_2)_{0-1}$C(=O)NHC_{1-4}alkyl, C(=O)NH-pyridine, -C(=O)NH$(CH_2)_2$N(C_{1-4}alkyl)$_2$, -C(=O)NH$(CH_2)_2$OH, -C(=O)NH$(CH_2)_2$S(O)$_2C_{1-4}$alkyl, and -OC(=O)C_{1-4}alkyl.

[0093] In some embodiments, R_5 is  ,  ,  ,  ,  , or  .

In some embodiments, R_5 is  ,  ,  , and  ;









[0094] In some embodiments, R_5 is F. In some embodiments, R_5 is C_{1-4}alkyl. In some embodiments, R_5 is –OH or -OC_{1-3}alkyl. In some embodiments, R_5 is -NHS(O)$_2C_{2-4}$alkenyl. In certain embodiments, R_5 is selected from those functional groups depicted in the examples below.


















[0095] As defined above and described herein, R_6 is H, C_{1-3}alkyl substituted with 0-4 R_e, -S(O)$_pR_c$, -C(=O)R_b, -$(CH_2)_r$-C(=O)NR_aR_a, -C(=O)$(CH_2)_rNR_aC$(=O)R_b, -C(=O)OR_b, -S(O)$_pNR_aR_a$, aryl substituted with 0-4 R_e, or heterocyclyl substituted with 0-4 R_e.







[0096] In some embodiments, R_6 is H. In some embodiments, R_6 is methyl or isopropyl. In some embodiments, R_6 is -$(CH_2)_2$C(=O)NH_2. In some embodiments, R_6 is -$(CH_2)_2$OH. . In some embodiments, R_6 is C(=O)C_{1-4}alkyl. In certain embodiments, R_6 is selected from those functional groups depicted in the examples below.









[0097] As defined above and described herein, R_7 is H, F, Cl, C_{1-3}alkyl, -NR_aR_a, or -NR_aC(=O)OR_b. In some embodiments, R_7 is NH_2. In some embodiments, R_7 is F.






[0098] As defined above and described herein, R_8 is H, F, Cl, Br, or C_{1-4}alkyl substituted with 0-5 R_e. In some embodiments, R_8 is H. In some embodiments, R_8 is C_{1-3}alkyl.





[0099] As defined above, Ring A is  ,  ,  ,  ,  ,  ,  ,  , or  .





[00100] In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  ,  ,  ,  ,  ,  ,  ,  , or  . In some embodiments, Ring A is  ,  ,  ,  ,  ,  ,  ,  ,  .










, or  . In some embodiments, Ring A is












or  . In some embodiments, Ring A is 




















































, or  . In some embodiments, Ring A is  ,  ,  ,

some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  .


[00102] In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  .


[00103] In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is . In some embodiments, Ring A is  . In some embodiments, Ring A is  .

[00104] In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is  . In some embodiments, Ring A is . In some embodiments, Ring A is . In some




embodiments, Ring A is . In some embodiments, Ring A is




. In some embodiments, Ring A is  . In some


embodiments, Ring A is  . In some embodiments, Ring A is




.





5 **[00105]** In some embodiments, Ring A is . In some







embodiments, Ring A is . In some embodiments, Ring A is










. In some embodiments, Ring A is  . In some






embodiments, Ring A is . In some embodiments, Ring A is








. In some embodiments, Ring A is 
. In some embodiments, Ring A is 
. In some embodiments, Ring A is 
.







[00106] In some embodiments, Ring A is
. In some embodiments, Ring A is 
. In some embodiments, Ring A is 
. In some embodiments, Ring A is 
. In some embodiments, Ring A is 
. In some embodiments, Ring A is 
. In some embodiments, Ring A is 
. In certain embodiments, R_4 is selected from those functional groups depicted in the examples below.

[00107] As defined above and described herein, r is 0-4. In some embodiments, r is 0. In some embodiments, r is 1. In some embodiments, r is 2. In some embodiments, r is 3. In some embodiments, r is 4.







In some embodiments, Ring A is  or  , R_1 is CH_3, R_2 is  cyclopropylmethyl, Q is N or CH, R_3 is H, F, or $-OCH_3$, R_4 is , and R_5 is H, F, Cl, CN, C_{1-4}alkyl, C_{1-4}alkyl substituted with OH, NH_2, and COOH, SC_{1-4}alkyl, $S(O)_2C_{1-4}$alkyl, $S(O)_2$NH-cyclopropyl, $-(CH_2)_{0-1}NHS(O)_2C_{1-4}$alkyl, $N(R_d)S(O)_2C_{2-4}$alkenyl, $-(CH_2)_{0-1}OH$, OC_{1-4}alkyl, $-(CH_2)_{0-1}NH_2$, $-(CH_2)_{0-1}NHC(=O)C_{1-4}$alkyl, $-NR_dC(=O)C_{2-4}$alkenyl, $-NHC(=O)C_{2-4}$alkynyl, $-(CH_2)_{0-1}C(=O)OH$, $-C(=O)OC_{1-4}$alkyl, $-NHC(=O)OC_{1-4}$alkyl, $-NHC(=O)O(CH_2)_2OC_{1-4}$alkyl, $-NHC(=O)OCH_2$-cyclopropyl, $-NHC(=O)NH_2$, $C(=O)NHC_{1-4}$alkyl, $CONH(CH_2)_{1-2}C(=O)OH$, $-(CH_2)_{0-1}C(=O)NH_2$, $-(CH_2)_{0-1}C(=O)NHC_{1-4}$alkyl, C(=O)NH-pyridine, $-C(=O)NH(CH_2)_2N(C_{1-4}alkyl)_2$, $-C(=O)NH(CH_2)_2OH$, $-C(=O)NH(CH_2)_2S(O)_2C_{1-4}$alkyl, and $-OC(=O)C_{1-4}$alkyl,



 ,  ,  ,  ,  , or  .


[00108] In some embodiments, Ring A is  or  , R_1 is CH_3, R_2 is cyclopropylmethyl, Q is N or CH, R_3 is H, F, or $-OCH_3$, R_5 is



 or  , and R_5 is H, F, Cl, CN, C_{1-4}alkyl, C_{1-4}alkyl substituted with OH, NH_2, and COOH, SC_{1-4}alkyl, $S(O)_2C_{1-4}$alkyl, $S(O)_2$NH-cyclopropyl, $-(CH_2)_{0-1}NHS(O)_2C_{1-4}$alkyl, $N(R_d)S(O)_2C_{2-4}$alkenyl, $-(CH_2)_{0-1}OH$, OC_{1-}


$_4$alkyl, -$(CH_2)_{0-1}NH_2$, -$(CH_2)_{0-1}NHC(=O)C_{1-4}$alkyl, -$NR_dC(=O)C_{2-4}$alkenyl, -$NHC(=O)C_{2-4}$alkynyl, -$(CH_2)_{0-1}C(=O)OH$, -$C(=O)OC_{1-4}$alkyl, -$NHC(=O)OC_{1-4}$alkyl, -$NHC(=O)O(CH_2)_2OC_{1-4}$alkyl, -$NHC(=O)OCH_2$-cyclopropyl, -$NHC(=O)NH_2$, $C(=O)NHC_{1-4}$alkyl, $CONH(CH_2)_{1-2}C(=O)OH$, -$(CH_2)_{0-1}C(=O)NH_2$, -$(CH_2)_{0-1}C(=O)NHC_{1-4}$alkyl, C(=O)NH-pyridine, -$C(=O)NH(CH_2)_2N(C_{1-4}alkyl)_2$, -$C(=O)NH(CH_2)_2OH$, -$C(=O)NH(CH_2)_2S(O)_2C_{1-4}$alkyl, and -$OC(=O)C_{1-4}$alkyl,








, or  .


[00109] In some embodiments, Ring A is  or  , R_1 is CH_3, R2 is cyclopropylmethyl, Q is N or CH, R3 is H, F, or –OCH3, R4 is



 .


[00110] In some embodiments, Ring A is or   , R_1 is CH_3, R_2 is cyclopropylmethyl, Q is N or CH, R_3 is H, F, or –OCH_3, R_4 is

 .




[00111] In some embodiments, Ring A is  or  , R_1 is CH_3, R_2 is cyclopropylmethyl, Q is N or CH, R_3 is H, F, or –OCH_3, R_4 is




 .




[00112] In some embodiments, Ring A is  or  , R_1 is CH_3, R_2 is cyclopropylmethyl, Q is N or CH, R_3 is H, F, or $-OCH_3$, R_4 is


















.

[00113] In some embodiments, Ring A is or   , R_1 is CH_3, R_2 is cyclopropylmethyl, Q is N or CH, R_3 is H, F, or $-OCH_3$, R_4 is  ,




 ,  , and  .





[00114] In some embodiments, Ring A is  or  , R_1 is CH_3, R_2 is cyclopropylmethyl, Q is N or CH, R_3 is H, F, or $-OCH_3$, R_4 is 

 ,  ,  ,  .

, and .

[00115] In some embodiments, Ring A is  or  , R_1 is CH_3, R_2 is cyclopropylmethyl, Q is N or CH, R_3 is H, F, or $-OCH_3$, R_4 is 

, and R_5 is H, F, C_{1-4}alkyl, $-OH$, $-OC_{1-3}$alkyl and $-NHS(O)_2C_{2-4}$alkenyl.

[00116] In some embodiments, the compound of formula (I) is selected from examples depicted below. In certain embodiments, the present invention provides any compound

described above and herein, or a pharmaceutically acceptable salt thereof or a composition for use in therapy. In some embodiments, the present invention provides any compound described above and herein in isolated form. In some embodiments, the present invention provides the compounds according to any one of claims 1 to 16

[00117]

4. Uses, Formulation and Administration

Pharmaceutically acceptable compositions

[00118] According to another embodiment, the invention provides a composition comprising a compound of this invention or a pharmaceutically acceptable derivative thereof and a pharmaceutically acceptable carrier, adjuvant, or vehicle. The amount of compound in compositions of this invention is such that is effective to measurably inhibit PAD4, in a biological sample or in a patient. In certain embodiments, the amount of compound in compositions of this invention is such that is effective to measurably inhibit PAD4, in a biological sample or in a patient. In certain embodiments, a composition of this invention is formulated for administration to a patient in need of such composition. In some embodiments, a composition of this invention is formulated for oral administration to a patient.

[00119] The term "subject," as used herein, is used interchangeably with the term "patient" and means an animal, preferably a mammal. In some embodiments, a subject or patient is a human. In other embodiments, a subject (or patient) is a veterinary subject (or patient). In some embodiments, a veterinary subject (or patient) is a canine, a feline, or an equine subject.

[00120] The term "pharmaceutically acceptable carrier, adjuvant, or vehicle" refers to a non-toxic carrier, adjuvant, or vehicle that does not destroy the pharmacological activity of the compound with which it is formulated. Pharmaceutically acceptable carriers, adjuvants or vehicles that may be used in the compositions of this invention include, but are not limited to, ion exchangers, alumina, aluminum stearate, lecithin, serum proteins, such as human serum albumin, buffer substances such as phosphates, glycine, sorbic acid, potassium sorbate, partial glyceride mixtures of saturated vegetable fatty acids, water, salts or electrolytes, such as protamine sulfate, disodium hydrogen phosphate, potassium hydrogen phosphate, sodium chloride, zinc salts, colloidal silica, magnesium trisilicate,

polyvinyl pyrrolidone, cellulose-based substances, polyethylene glycol, sodium carboxymethylcellulose, polyacrylates, waxes, polyethylene-polyoxypropylene-block polymers, polyethylene glycol and wool fat.

[00121] Compositions of the present invention may be administered orally, parenterally, by inhalation spray, topically, rectally, nasally, buccally, vaginally or via an implanted reservoir. The term "parenteral" as used herein includes subcutaneous, intravenous, intramuscular, intra-articular, intra-synovial, intrasternal, intrathecal, intrahepatic, intralesional and intracranial injection or infusion techniques. Preferably, the compositions are administered orally, intraperitoneally or intravenously. Sterile injectable forms of the compositions of this invention may be aqueous or oleaginous suspension. These suspensions may be formulated according to techniques known in the art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution or suspension in a non-toxic parenterally acceptable diluent or solvent, for example as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium.

[00122] For this purpose, any bland fixed oil may be employed including synthetic mono- or di-glycerides. Fatty acids, such as oleic acid and its glyceride derivatives are useful in the preparation of injectables, as are natural pharmaceutically-acceptable oils, such as olive oil or castor oil, especially in their polyoxyethylated versions. These oil solutions or suspensions may also contain a long-chain alcohol diluent or dispersant, such as carboxymethyl cellulose or similar dispersing agents that are commonly used in the formulation of pharmaceutically acceptable dosage forms including emulsions and suspensions. Other commonly used surfactants, such as Tweens, Spans and other emulsifying agents or bioavailability enhancers which are commonly used in the manufacture of pharmaceutically acceptable solid, liquid, or other dosage forms may also be used for the purposes of formulation.

[00123] Pharmaceutically acceptable compositions of this invention may be orally administered in any orally acceptable dosage form including, but not limited to, capsules, tablets, aqueous suspensions or solutions. In the case of tablets for oral use, carriers commonly used include lactose and corn starch. Lubricating agents, such as magnesium

stearate, are also typically added. For oral administration in a capsule form, useful diluents include lactose and dried cornstarch. When aqueous suspensions are required for oral use, the active ingredient is combined with emulsifying and suspending agents. If desired, certain sweetening, flavoring or coloring agents may also be added.

[00124] Alternatively, pharmaceutically acceptable compositions of this invention may be administered in the form of suppositories for rectal administration. These can be prepared by mixing the agent with a suitable non-irritating excipient that is solid at room temperature but liquid at rectal temperature and therefore will melt in the rectum to release the drug. Such materials include cocoa butter, beeswax and polyethylene glycols.

[00125] Pharmaceutically acceptable compositions of this invention may also be administered topically, especially when the target of treatment includes areas or organs readily accessible by topical application, including diseases of the eye, the skin, or the lower intestinal tract. Suitable topical formulations are readily prepared for each of these areas or organs.

[00126] Topical application for the lower intestinal tract can be effected in a rectal suppository formulation (see above) or in a suitable enema formulation. Topically-transdermal patches may also be used.

[00127] For topical applications, provided pharmaceutically acceptable compositions may be formulated in a suitable ointment containing the active component suspended or dissolved in one or more carriers. Carriers for topical administration of compounds of this invention include, but are not limited to, mineral oil, liquid petrolatum, white petrolatum, propylene glycol, polyoxyethylene, polyoxypropylene compound, emulsifying wax and water. Alternatively, provided pharmaceutically acceptable compositions can be formulated in a suitable lotion or cream containing the active components suspended or dissolved in one or more pharmaceutically acceptable carriers. Suitable carriers include, but are not limited to, mineral oil, sorbitan monostearate, polysorbate 60, cetyl esters wax, cetearyl alcohol, 2-octyldodecanol, benzyl alcohol and water.

[00128] For ophthalmic use, provided pharmaceutically acceptable compositions may be formulated as micronized suspensions in isotonic, pH adjusted sterile saline, or, preferably, as solutions in isotonic, pH adjusted sterile saline, either with or without a preservative such as benzylalkonium chloride. Alternatively, for ophthalmic uses, the

pharmaceutically acceptable compositions may be formulated in an ointment such as petrolatum.

[00129] Pharmaceutically acceptable compositions of this invention may also be administered by nasal aerosol or inhalation. Such compositions are prepared according to techniques well-known in the art of pharmaceutical formulation and may be prepared as solutions in saline, employing benzyl alcohol or other suitable preservatives, absorption promoters to enhance bioavailability, fluorocarbons, and/or other conventional solubilizing or dispersing agents.

[00130] Most preferably, pharmaceutically acceptable compositions of this invention are formulated for oral administration. Such formulations may be administered with or without food. In some embodiments, pharmaceutically acceptable compositions of this invention are administered without food. In other embodiments, pharmaceutically acceptable compositions of this invention are administered with food.

[00131] Pharmaceutically acceptable compositions of this invention can be administered to humans and other animals orally, rectally, parenterally, intracisternally, intravaginally, intraperitoneally, topically (as by powders, ointments, or drops), bucally, as an oral or nasal spray, or the like, depending on the severity of the infection being treated. In certain embodiments, the compounds of the invention may be administered orally or parenterally at dosage levels of about 0.01 mg/kg to about 50 mg/kg and preferably from about 1 mg/kg to about 25 mg/kg, of subject body weight per day, one or more times a day, to obtain the desired therapeutic effect.

[00132] Liquid dosage forms for oral administration include, but are not limited to, pharmaceutically acceptable emulsions, microemulsions, solutions, suspensions, syrups and elixirs. In addition to the active compounds, the liquid dosage forms may contain inert diluents commonly used in the art such as, for example, water or other solvents, solubilizing agents and emulsifiers such as ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propylene glycol, 1,3-butylene glycol, dimethylformamide, oils (in particular, cottonseed, groundnut, corn, germ, olive, castor, and sesame oils), glycerol, tetrahydrofurfuryl alcohol, polyethylene glycols and fatty acid esters of sorbitan, and mixtures thereof. Besides inert diluents, the oral compositions can also include adjuvants such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.

[00133] Injectable preparations, for example, sterile injectable aqueous or oleaginous suspensions may be formulated according to the known art using suitable dispersing or wetting agents and suspending agents. The sterile injectable preparation may also be a sterile injectable solution, suspension or emulsion in a nontoxic parenterally acceptable diluent or solvent, for example, as a solution in 1,3-butanediol. Among the acceptable vehicles and solvents that may be employed are water, Ringer's solution, U.S.P. and isotonic sodium chloride solution. In addition, sterile, fixed oils are conventionally employed as a solvent or suspending medium. For this purpose any bland fixed oil can be employed including synthetic mono- or diglycerides. In addition, fatty acids such as oleic acid are used in the preparation of injectables.

[00134] Injectable formulations can be sterilized, for example, by filtration through a bacterial-retaining filter, or by incorporating sterilizing agents in the form of sterile solid compositions which can be dissolved or dispersed in sterile water or other sterile injectable medium prior to use.

[00135] In order to prolong the effect of a compound of the present invention, it is often desirable to slow the absorption of the compound from subcutaneous or intramuscular injection. This may be accomplished by the use of a liquid suspension of crystalline or amorphous material with poor water solubility. The rate of absorption of the compound then depends upon its rate of dissolution that, in turn, may depend upon crystal size and crystalline form. Alternatively, delayed absorption of a parenterally administered compound form is accomplished by dissolving or suspending the compound in an oil vehicle. Injectable depot forms are made by forming microencapsule matrices of the compound in biodegradable polymers such as polylactide-polyglycolide. Depending upon the ratio of compound to polymer and the nature of the particular polymer employed, the rate of compound release can be controlled. Examples of other biodegradable polymers include poly(orthoesters) and poly(anhydrides). Depot injectable formulations are also prepared by entrapping the compound in liposomes or microemulsions that are compatible with body tissues.

[00136] Compositions for rectal or vaginal administration are preferably suppositories which can be prepared by mixing the compounds of this invention with suitable non-irritating excipients or carriers such as cocoa butter, polyethylene glycol or a suppository

wax which are solid at ambient temperature but liquid at body temperature and therefore melt in the rectum or vaginal cavity and release the active compound.

[00137] Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules. In such solid dosage forms, the active compound is mixed with at least one inert, pharmaceutically acceptable excipient or carrier such as sodium citrate or dicalcium phosphate and/or a) fillers or extenders such as starches, lactose, sucrose, glucose, mannitol, and silicic acid, b) binders such as, for example, carboxymethylcellulose, alginates, gelatin, polyvinylpyrrolidinone, sucrose, and acacia, c) humectants such as glycerol, d) disintegrating agents such as agar--agar, calcium carbonate, potato or tapioca starch, alginic acid, certain silicates, and sodium carbonate, e) solution retarding agents such as paraffin, f) absorption accelerators such as quaternary ammonium compounds, g) wetting agents such as, for example, cetyl alcohol and glycerol monostearate, h) absorbents such as kaolin and bentonite clay, and i) lubricants such as talc, calcium stearate, magnesium stearate, solid polyethylene glycols, sodium lauryl sulfate, and mixtures thereof. In the case of capsules, tablets and pills, the dosage form may also comprise buffering agents.

[00138] Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polyethylene glycols and the like. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings and other coatings well known in the pharmaceutical formulating art. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes. Solid compositions of a similar type may also be employed as fillers in soft and hard-filled gelatin capsules using such excipients as lactose or milk sugar as well as high molecular weight polethylene glycols and the like.

[00139] The active compounds can also be in micro-encapsulated form with one or more excipients as noted above. The solid dosage forms of tablets, dragees, capsules, pills, and granules can be prepared with coatings and shells such as enteric coatings, release controlling coatings and other coatings well known in the pharmaceutical

formulating art. In such solid dosage forms the active compound may be admixed with at least one inert diluent such as sucrose, lactose or starch. Such dosage forms may also comprise, as is normal practice, additional substances other than inert diluents, e.g., tableting lubricants and other tableting aids such a magnesium stearate and microcrystalline cellulose. In the case of capsules, tablets and pills, the dosage forms may also comprise buffering agents. They may optionally contain opacifying agents and can also be of a composition that they release the active ingredient(s) only, or preferentially, in a certain part of the intestinal tract, optionally, in a delayed manner. Examples of embedding compositions that can be used include polymeric substances and waxes.

[00140] Dosage forms for topical or transdermal administration of a compound of this invention include ointments, pastes, creams, lotions, gels, powders, solutions, sprays, inhalants or patches. The active component is admixed under sterile conditions with a pharmaceutically acceptable carrier and any needed preservatives or buffers as may be required. Ophthalmic formulation, ear drops, and eye drops are also contemplated as being within the scope of this invention. Additionally, the present invention contemplates the use of transdermal patches, which have the added advantage of providing controlled delivery of a compound to the body. Such dosage forms can be made by dissolving or dispensing the compound in the proper medium. Absorption enhancers can also be used to increase the flux of the compound across the skin. The rate can be controlled by either providing a rate controlling membrane or by dispersing the compound in a polymer matrix or gel.

[00141] The amount of compounds of the present invention that may be combined with the carrier materials to produce a composition in a single dosage form will vary depending upon the host treated, the particular mode of administration. Preferably, provided compositions should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of the inhibitor can be administered to a patient receiving these compositions.

[00142] A compound of the current invention can be administered alone or in combination with one or more other therapeutic compounds, possible combination therapy taking the form of fixed combinations or the administration of a compound of the invention and one or more other therapeutic compounds being staggered or given

independently of one another, or the combined administration of fixed combinations and one or more other therapeutic compounds. Exemplary of such other therapeutic agents include corticosteroids, rolipram, calphostin, cytokine-suppressive anti-inflammatory drugs (CSAIDs), Interleukin-10, glucocorticoids, salicylates, nitric oxide, and other immunosuppressants; nuclear translocation inhibitors, such as deoxyspergualin (DSG); non-steroidal antiinflammatory drugs (NSAIDs) such as ibuprofen, celecoxib and rofecoxib; steroids such as prednisone or dexamethasone; antiviral agents such as abacavir; antiproliferative agents such as methotrexate, leflunomide, FK506 (tacrolimus, Prograf); cytotoxic drugs such as azathiprine and cyclophosphamide; TNF-α inhibitors such as tenidap, anti-TNF antibodies or soluble TNF receptor, and rapamycin (sirolimus or Rapamune) or derivatives thereof. A compound of the current invention can besides or in addition be administered especially for tumor therapy in combination with chemotherapy, radiotherapy, immunotherapy, phototherapy, surgical intervention, or a combination of these. Long-term therapy is equally possible as is adjuvant therapy in the context of other treatment strategies, as described above. Other possible treatments are therapy to maintain the patient's status after tumor regression, or even chemopreventive therapy, for example in patients at risk.

[00143] Those additional agents may be administered separately from an inventive compound-containing composition, as part of a multiple dosage regimen. Alternatively, those agents may be part of a single dosage form, mixed together with a compound of this invention in a single composition. If administered as part of a multiple dosage regime, the two active agents may be submitted simultaneously, sequentially or within a period of time from one another normally within five hours from one another.

[00144] As used herein, the term "combination," "combined," and related terms refers to the simultaneous or sequential administration of therapeutic agents in accordance with this invention. For example, a compound of the present invention may be administered with another therapeutic agent simultaneously or sequentially in separate unit dosage forms or together in a single unit dosage form. Accordingly, the present invention provides a single unit dosage form comprising a compound of the current invention, an additional therapeutic agent, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

[00145] The amount of both an inventive compound and additional therapeutic agent (in those compositions which comprise an additional therapeutic agent as described above) that may be combined with the carrier materials to produce a single dosage form will vary depending upon the host treated and the particular mode of administration. Preferably, compositions of this invention should be formulated so that a dosage of between 0.01 - 100 mg/kg body weight/day of an inventive compound can be administered.

[00146] In those compositions which comprise an additional therapeutic agent, that additional therapeutic agent and the compound of this invention may act synergistically. Therefore, the amount of additional therapeutic agent in such compositions will be less than that required in a monotherapy utilizing only that therapeutic agent.

[00147] The amount of additional therapeutic agent present in the compositions of this invention will be no more than the amount that would normally be administered in a composition comprising that therapeutic agent as the only active agent. Preferably the amount of additional therapeutic agent in the presently disclosed compositions will range from about 50% to 100% of the amount normally present in a composition comprising that agent as the only therapeutically active agent.

[00148] It should also be understood that a specific dosage and treatment regimen for any particular patient will depend upon a variety of factors, including the activity of the specific compound employed, the age, body weight, general health, sex, diet, time of administration, rate of excretion, drug combination, and the judgment of the treating physician and the severity of the particular disease being treated. The amount of a compound of the present invention in the composition will also depend upon the particular compound in the composition.

5. Uses of Compounds and Pharmaceutically Acceptable Compositions

[00149] Compounds and compositions described herein are generally useful for the inhibition of PAD4.

[00150] The activity of a compound utilized in this invention as an inhibitor of PAD4, may be assayed *in vitro*, *in vivo* or in a cell line. *In vitro* assays include assays that determine the inhibition of PAD4. Detailed conditions for assaying a compound utilized

in this invention as an inhibitor of PAD4 are set forth in the Examples below. In some embodiments, a provided compound inhibits PAD4 selectively as compared to PAD2.

[00151] As used herein, the terms "treatment," "treat," and "treating" refer to reversing, alleviating, delaying the onset of, or inhibiting the progress of a disease or disorder, or one or more symptoms thereof, as described herein. In some embodiments, treatment may be administered after one or more symptoms have developed. In other embodiments, treatment may be administered in the absence of symptoms. For example, treatment may be administered to a susceptible individual prior to the onset of symptoms (e.g., in light of a history of symptoms and/or in light of genetic or other susceptibility factors). Treatment may also be continued after symptoms have resolved, for example to prevent or delay their recurrence.

[00152] Provided compounds are inhibitors of PAD4and are therefore useful for treating one or more disorders associated with activity of PAD4. Thus, in certain embodiments, the present invention provides a method for treating a PAD4-mediated disorder comprising the step of administering to a patient in need thereof a compound of the present invention, or pharmaceutically acceptable composition thereof.

[00153] In one embodiment, a PAD4-mediated disorder is a disease, condition, or disorder mediated by inappropriate PAD4 activity. In some embodiments, a PAD4-mediated disorder is selected from the group consisting of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, and psoriasis. In a further embodiment, the disorder mediated by inappropriate PAD4 activity is rheumatoid arthritis. In a further embodiment, the disorder mediated by inappropriate PAD4 activity is systemic lupus. In a further embodiment, the disorder mediated by inappropriate PAD4 activity is vasculitis. In a further embodiment, the disorder mediated by inappropriate PAD4 activity is cutaneous lupus erythematosus. In a further embodiment, the disorder mediated by inappropriate PAD4 activity is psoriasis.

[00154] In one embodiment there is provided a method of treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, or psoriasis, which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound or a pharmaceutically acceptable salt thereof.

[00155] In one embodiment there is provided a method of treatment of rheumatoid arthritis, which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound, or a pharmaceutically acceptable salt thereof. In one embodiment there is provided a method of treatment of systemic lupus, which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound, or a pharmaceutically acceptable salt thereof. In one embodiment there is provided a method of treatment of vasculitis, which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound, or a pharmaceutically acceptable salt thereof. In one embodiment there is provided a method of treatment of cutaneous lupus erythematosus, which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound, or a pharmaceutically acceptable salt thereof. In one embodiment there is provided a method of treatment of psoriasis, which method comprises administering to a human subject in need thereof, a therapeutically effective amount of a provided compound, or a pharmaceutically acceptable salt thereof.

[00156] In some embodiments, a PAD4-mediated disorder is selected from the group consisting of acid-induced lung injury, acne (PAPA), acute lymphocytic leukemia, acute, respiratory distress syndrome, Addison's disease, adrenal hyperplasia, adrenocortical insufficiency, ageing, AIDS, alcoholic hepatitis, alcoholic hepatitis, alcoholic liver disease, allergen induced asthma, allergic bronchopulmonary, aspergillosis, allergic conjunctivitis, alopecia, Alzheimer's disease, amyloidosis, amyotropic lateral sclerosis, and weight loss, angina pectoris, angioedema, anhidrotic ecodermal dysplasia-ID, ankylosing spondylitis, anterior segment, inflammation, antiphospholipid syndrome, aphthous stomatitis, appendicitis, arthritis, asthma, atherosclerosis, atopic dermatitis, autoimmune diseases, autoimmune hepatitis, bee sting-induced inflammation, Bechet's disease, Bechet's syndrome, Bells Palsey, berylliosis, Blau syndrome, bone pain, bronchiolitis, burns, bursitis, cancer, cardiac hypertrophy, carpal tunnel syndrome, catabolic disorders, cataracts, cerebral aneurysm, chemical irritant-induced inflammation, chorioretinitis, chronic heart failure, chronic lung disease of prematurity, chronic lymphocytic leukemia, chronic obstructive pulmonary disease, colitis, complex regional pain syndrome, connective tissue disease, corneal ulcer, crohn's disease, cryopyrin-

associated periodic syndromes, cyrptococcosis, cystic fibrosis, deficiency of the interleukin-1–receptor antagonist (DIRA), dermatitis, dermatitis endotoxemia, dermatomyositis, diffuse intrinsic pontine glioma, endometriosis, endotoxemia, epicondylitis, erythroblastopenia, familial amyloidotic polyneuropathy, familial cold urticarial, familial Mediterranean fever, fetal growth retardation, glaucoma, glomerular disease, glomerular nephritis, gout, gouty arthritis, graft-versus-host disease, gut diseases, head injury, headache, hearing loss, heart disease, hemolytic anemia, Henoch-Scholein purpura, hepatitis, hereditary periodic fever syndrome, herpes zoster and simplex, HIV-1, Hodgkin's disease, Huntington's disease, hyaline membrane disease, hyperammonemia, hypercalcemia, hypercholesterolemia, hyperimmunoglobulinemia D with recurrent fever (HIDS), hypoplastic and other anemias, hypoplastic anemia, idiopathic thrombocytopenic purpura, incontinentia pigmenti, infectious mononucleosis, inflammatory bowel disease, inflammatory lung disease, inflammatory neuropathy, inflammatory pain, insect bite-induced inflammation, iritis, irritant-induced inflammation, ischemia/reperfusion, juvenile rheumatoid arthritis, keratitis, kidney disease, kidney injury caused by parasitic infections, kidney injury caused by parasitic infections, kidney transplant rejection prophylaxis, leptospiriosis, leukemia, Loeffler's syndrome, lung injury, lung injury, lupus, lupus, lupus nephritis, lymphoma, meningitis, mesothelioma, mixed connective tissue disease, Muckle-Wells syndrome (urticaria deafness amyloidosis), multiple sclerosis, muscle wasting, muscular dystrophy, myasthenia gravis, myocarditis, mycosis fungiodes, mycosis fungoides, myelodysplastic syndrome, myositis, nasal sinusitis, necrotizing enterocolitis, neonatal onset multisystem inflammatory disease (NOMID), nephrotic syndrome, neuritis, neuropathological diseases, non-allergen induced asthma, obesity, ocular allergy, optic neuritis, organ transplant, osteoarthritis, otitis media, Paget's disease, pain, pancreatitis, Parkinson's disease, pemphigus, pericarditis, periodic fever, periodontitis, peritoneal endometriosis, pertussis, pharyngitis and adenitis (PFAPA syndrome), plant irritant-induced inflammation, pneumonia, pneumonitis, pneumosysts infection, poison ivy/ urushiol oil-induced inflammation, polyarteritis nodosa, polychondritis, polycystic kidney disease, polymyositis, psoriasis, psoriasis, psoriasis, psoriasis, psychosocial stress diseases, pulmonary disease, pulmonary hypertension, pulmonayr fibrosis, pyoderma gangrenosum, pyogenic sterile arthritis, renal disease, retinal disease, rheumatic carditis, rheumatic disease, rheumatoid arthritis, sarcoidosis,

seborrhea, sepsis, severe pain, sickle cell, sickle cell anemia, silica-induced disease, Sjogren's syndrome, skin diseases, sleep apnea, solid tumors, spinal cord injury, Stevens-Johnson syndrome, stroke, subarachnoid hemorrhage, sunburn, temporal arteritis, tenosynovitis, thrombocytopenia, thyroiditis, tissue transplant, TNF receptor associated periodic syndrome (TRAPS), toxoplasmosis, transplant, traumatic brain injury, tuberculosis, type 1 diabetes, type 2 diabetes, ulcerative colitis, urticarial, uveitis, Wegener's granulomatosis, interstitial lung disease, psoriatic arthritis, juvenile idiopathic arthritis, Sjögren's syndrome, antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis, antiphospholipid antibody syndrome, sepsis, deep vein thrombosis, fibrosis, Alzheimer's, scleroderma and CREST syndrome.

[00157] In one embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in therapy. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of a disorder mediated by inappropriate PAD4 activity. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, or psoriasis. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of rheumatoid arthritis. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of systemic lupus. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of vasculitis. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of cutaneous lupus erythematosus. In another embodiment, the invention provides a provided compound, or a pharmaceutically acceptable salt thereof, for use in the treatment of psoriasis. In another embodiment, the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of a disorder mediated by inappropriate PAD4 activity. In another embodiment, the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in

the treatment of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, or psoriasis. In another embodiment, the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of rheumatoid arthritis. In another embodiment, the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of systemic lupus. In another embodiment, the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of vasculitis. In another embodiment, the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of cutaneous lupus erythematosus. In another embodiment, the invention provides the use of a provided compound, or a pharmaceutically acceptable salt thereof, in the manufacture of a medicament for use in the treatment of psoriasis. In a further embodiment, the invention provides a pharmaceutical composition for the treatment or prophylaxis of a disorder mediated by inappropriate PAD4 activity comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a further embodiment, the invention provides a pharmaceutical composition for the treatment or prophylaxis of rheumatoid arthritis, vasculitis, systemic lupus erythematosus, ulcerative colitis, cancer, cystic fibrosis, asthma, cutaneous lupus erythematosus, or psoriasis, comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a further embodiment, the invention provides a pharmaceutical composition for the treatment or prophylaxis of rheumatoid arthritis comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a further embodiment, the invention provides a pharmaceutical composition for the treatment or prophylaxis of systemic lupus comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a further embodiment, the invention provides a pharmaceutical composition for the treatment or prophylaxis of vasculitis comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a further embodiment, the invention provides a pharmaceutical composition for the treatment or prophylaxis of cutaneous lupus erythematosus comprising a provided compound, or a pharmaceutically acceptable salt thereof. In a further embodiment, the invention provides a pharmaceutical

composition for the treatment or prophylaxis of psoriasis comprising a provided compound, or a pharmaceutically acceptable salt thereof

[00158] All features of each of the aspects of the invention apply to all other aspects mutatis mutandis.


[00159] In order that the invention described herein may be more fully understood, the following examples are set forth. It should be understood that these examples are for illustrative purposes only and are not to be construed as limiting this invention in any manner.

Exemplification

[00160] As depicted in the Examples below, in certain exemplary embodiments, compounds are prepared according to the following general procedures. It will be appreciated that, although the general methods depict the synthesis of certain compounds of the present invention, the following general methods, and other methods known to one of ordinary skill in the art, can be applied to all compounds and subclasses and species of each of these compounds, as described herein.


[00161] Certain compounds of the present invention were prepared according to Schemes described below.

Scheme 1



For compounds that involve heteroatom couplings, see Scheme 2.

Scheme 2




where P_1 is a suitable orthogonal protecting group, such as Cbz or Boc
Where X is a halogen

W = -NHR or -OH or -SH

For the synthesis of sulfones, see Scheme 3.


Scheme 3



where P_1 is a suitable orthogonal protecting group, such as Cbz or Boc
Where X is a halogen


For the synthesis of carboxamides, see Scheme 4.

Scheme 4



For the synthesis of compounds involving photoredox chemistry, see Scheme 5.

Scheme 5



Description of analytical LCMS methods:

Method 1: Column: Waters XBridge C18, 2.1 mm x 50 mm, 1.7 µm particles; Mobile Phase A: 5:95 acetonitrile:water with 10 mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile:water with 10 mM ammonium acetate; Temperature: 50 °C; Gradient: 0 %B to 100 %B over 3 min, then a 0.5 min hold at 100 %B; Flow: 1 mL/min; Detection: MS and UV (220 nm).


Method 2: Column: Waters XBridge C18, 2.1 mm x 50 mm, 1.7 µm particles; Mobile Phase A: 5:95 acetonitrile:water with 0.1 % trifluoroacetic acid; Mobile Phase B:

95:5 acetonitrile:water with 0.1 % trifluoroacetic acid; Temperature: 50 °C; Gradient: 0 %B to 100 %B over 3 min, then a 0.5 min hold at 100 %B; Flow: 1 mL/min; Detection: MS and UV (220 nm).

Method 3: Waters Acquity UPLC BEH C18, 2.1 x 50 mm, 1.7 µm particles; Mobile Phase A: water with 0.05% TFA; Mobile Phase B: ACN with 0.05% TFA; Gradient: 2-98% B over 1 minute, then a 0.5 minute hold at 98% B; Flow: 0.8 mL/min; Detection: UV at 254 nm.

[00162] The structures drawn in the current application generically as A below (Figure 1) are meant as a representation of the fully chiral structure B, with the chiral azabicycloheptane moiety named as ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl).


Figure 1



A B

Intermediate 1

2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid




Intermediate 1

[00163] The methyl 2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate (4 g, 9.41 mmol) [for this starting material see: WO 2017/0100594)] was dissolved in THF (45 mL), MeOH (15 mL) and 2M LiOH aq (9.41 mL). This was stirred at 70 °C for 90 min. To add to this, the reaction was repeated as follows: The methyl 2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate

(2.9 g, 6.83 mmol) was dissolved in THF (24 mL), MeOH (8 mL) and 2M LiOH aq (6.83 ml). The saponification was found to be over as per LCMS. This crude was combined with the earlier reaction crude. The mixture was slowly treated with 2N HCl until the pH reached ~6. At this stage a tan colored solid precipitated out as 2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid (6.9 g): ^{1}H NMR (400 MHz, DMSO-d_6) δ 12.83 (br s, 1H), 8.20 (d, *J*=8.3 Hz, 1H), 7.96 (s, 1H), 7.41 (s, 1H), 7.28 (d, *J*=8.2 Hz, 1H), 7.17 (s, 1H), 4.44 (br d, *J*=6.9 Hz, 2H), 4.15 (s, 3H), 4.02 (s, 3H), 1.18 - 1.04 (m, 1H), 0.36 - 0.27 (m, 2H), 0.13 (q, *J*=4.7 Hz, 2H), LCMS (M+H)+ = 411.3,retention time = 1.01 min (Method 3).

Intermediate 2

tert-butyl ((1R,4R,7R)-2-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate




Intermediate 2

[00164] To a mixture of 5-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid (5.8 g, 14.12 mmol), tert-butyl ((7R)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (3.30 g, 15.53 mmol), and Hunig's Base (7.40 ml, 42.4 mmol) was added DMF (35 mL). The mixture became a solid, and therefore, additional DMF (100 ml) was added (became a slurry). Next, this was treated with HATU (6.44 g, 16.94 mmol) in portions to ensure that the HATU was dissolved before adding the next portion. The reaction eventually went into a yellow colored solution. After 2h of stirring at rt, the reaction was found to be complete. The reaction mixture was diluted with EtOAc and washed with 10% LiCl aq (2X) followed by brine. The combined aq layer was extracted with EtOAc. The combined organic layer was dried (MgSO4), filtered, and concentrated to a dark yellow brown oil. This brown oil was purified by flash chromatography (EtOAc/Hexane), and the product fractions were

combined and concentrated to give tert-butyl ((1R,4R,7R)-2-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (11 g): ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.19 (d, *J*=8.2 Hz, 1H), 7.51 - 7.36 (m, 1H), 7.27 (d, *J*=8.2 Hz, 1H), 7.13 (s, 1H), 7.01 - 6.95 (m, 1H), 4.44 (br d, *J*=7.1 Hz, 2H), 4.12 (s, 3H), 4.00 (s, 3H), 3.74 - 3.45 (m, 2H), 3.32 (s, 1H), 3.11 - 3.03 (m, 1H), 2.48 - 2.37 (m, 1H), 2.00 - 1.89 (m, 1H), 1.80 (br s, 2H), 1.52 - 1.44 (m, 1H), 1.44 - 1.28 (m, 9H), 1.15 - 1.05 (m, *J*=4.6 Hz, 1H), 0.30 (br d, *J*=7.7 Hz, 2H), 0.13 (br d, *J*=4.8 Hz, 2H), LCMS (M+H)+ = 605.3, retention time = 1.05 min (Method 3).

Intermediate 3

tert-butyl ((1R,4R,7R)-2-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate




Intermediate 3

[00165] A portion of the above tert-butyl ((1R,4R,7R)-2-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (9 g) was dissolved in DCM (100 mL) and treated with TFA (25 mL). After 2 h, additional TFA (15 mL) was added. After 1 h, the reaction was concentrated and then it was dissolved in EtOAc. It was made basic with a very slow addition of solid NaHCO3. After the effervescence subsided, it was allowed to stir for 30 min more. The organic layer was separated and washed with brine. Combined aq layer was extracted with EtOAc. Combined organic layer was dried (MgSO4), filtered and concentrated to yield ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-

benzo[d]imidazol-5-yl)methanone (7 g) as a yellow foamy solid: ^{1}H NMR (400 MHz, DMSO-d_6) δ 8.20 (d, *J*=8.2 Hz, 1H), 7.55 - 7.39 (m, 1H), 7.28 (d, *J*=8.2 Hz, 1H), 7.15 (s, 1H), 7.02 - 6.95 (m, 1H), 4.44 (br d, *J*=6.9 Hz, 2H), 4.13 (s, 3H), 4.07 - 4.04 (m, 1H), 4.00 (s, 3H), 3.79 - 3.40 (m, 2H), 3.19 - 3.10 (m, 1H), 2.48 - 2.43 (m, 1H), 1.97 - 1.81 (m, 3H), 1.62 - 1.53 (m, 1H), 1.14 - 1.02 (m, 1H), 0.35 - 0.28 (m, 2H), 0.12 (br s, 2H); LCMS (M+H)+ = 505.3, retention time = 0.86 min (Method 3).

Example 1

6-(2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydroquinolin-2(1H)-one




Example 1

[00166] A 2dr pressure vial was charged with ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-1-methyl-1H-benzo[d]imidazol-5-yl)methanone (25 mg, 0.053 mmol), 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinolin-2(1H)-one (17.25 mg, 0.063 mmol), 3M potassium phosphate tribasic aq (0.053 mL, 0.158 mmol) and 1,1'-Bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (4.30 mg, 5.26 μmol) in THF (1 mL). The vial was capped and the reaction mixture was made anaerobic by a pump / backfill with nitrogen cycle (5X). The reaction was set to stir at 70 °C for 7h. The mixture was concentrated and dried in vacuo. It was dissolved in DMF and purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 15% B, 15-55% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 C. Fraction collection was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation. The purified material was then

diluted with DMF, treated with Si-Pyridine and shaken for a minimum of 2 h. The resulting mixture was filtered and dried via centrifugal evaporation to give 6-(2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydroquinolin-2(1H)-one (12 mg): ^{1}H NMR (500 MHz, DMSO-d_6) δ 10.08 (s, 1H), 8.15 (d, *J*=8.2 Hz, 1H), 8.02 - 7.97 (m, 2H), 7.89 - 7.78 (m, 1H), 7.76 - 7.69 (m, 2H), 7.45 (br d, *J*=8.6 Hz, 1H), 7.10 (s, 1H), 7.01 (d, *J*=8.2 Hz, 1H), 4.64 (br d, *J*=7.0 Hz, 2H), 3.99 (s, 3H), 3.74 (br s, 1H), 3.63 - 3.48 (m, 1H), 3.35 - 3.27 (m, 1H), 3.17 - 3.04 (m, 1H), 3.01 (br t, *J*=7.5 Hz, 2H), 2.56 - 2.52 (m, 3H), 2.23 (br s, 1H), 2.06 - 1.91 (m, 2H), 1.72 (br t, *J*=9.3 Hz, 1H), 1.49 - 1.39 (m, 1H), 1.23 (br d, *J*=8.4 Hz, 1H), 0.32 (br d, *J*=7.8 Hz, 2H), 0.23 (br s, 2H); LC/MS (M+H) = 585.9; Retention Time = 1.43 min (Method 1).

Example 2

((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-((6-fluoropyridin-3-yl)oxy)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone




Example 2

[00167] A 1 dram vial was charged with tert-butyl ((1R,4R,7R)-2-(2-(6-bromo-1-(cyclopropylmethyl)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (0.037 g, 0.040 mmol), 2-fluoro-5-hydroxypyridine (5.42 mg, 0.048 mmol), cesium carbonate (0.020 g, 0.060 mmol) and Rockphos Pd G3 (3.35 mg, 3.99 μmol) in dioxane (1 mL). The vial was capped and the reaction mixture was made anaerobic by a pump / backfill with nitrogen cycle (5X). The reaction was set to stir at 90 °C overnight. After cooling, the mixture was diluted with EtOAc, dried (MgSO4), filtered, and concentrated. The resulting residue was dissolved in dichloromethane (1 mL) and treated with TFA (0.5 ml, 6.49 mmol). Mixture was stirred at rt for 90 min before it was concentrated. The residue was dissolved in DMF, filtered and purified via preparative LC/MS with the following conditions: Column:

XBridge C18, 19 x 200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 26-66% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation. The purified material was then diluted with DMF, treated with Si-Pyridine and shaken for a minimum of 2 h. The resulting mixture was filtered and concentrated via centrifugal evaporation to give ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-((6-fluoropyridin-3-yl)oxy)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone (4.1 mg): ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.03 (br s, 1H), 7.72 (br d, *J*=8.5 Hz, 1H), 7.68 (br t, *J*=6.0 Hz, 1H), 7.44 (br s, 1H), 7.34 (s, 1H), 7.21 (br dd, *J*=8.7, 2.9 Hz, 1H), 7.06 (s, 1H), 6.95 - 6.90 (m, 2H), 4.37 (br d, *J*=6.4 Hz, 2H), 4.10 (s, 3H), 3.98 (s, 3H), 3.75 (br s, 1H), 3.66 - 3.48 (m, 1H), 3.17 (s, 1H), 3.08 - 2.99 (m, 1H), 2.21 (br s, 1H), 2.04 - 1.91 (m, 2H), 1.74 (br t, *J*=9.5 Hz, 1H), 1.48 - 1.40 (m, 1H), 1.23 (s, 2H), 1.04 - 0.94 (m, 1H), 0.26 (br d, *J*=7.9 Hz, 2H), -0.02 (br s, 2H); LC/MS (M+H) = 581.3; Retention Time = 1.75 min (Method 1).

Example 3

((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(pyridin-4-ylthio)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone



Example 3


[00168] A mixture of tert-butyl ((1R,4R,7R)-2-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (47 mg, 0.078 mmol), Pd2(dba)3 (14.22 mg, 0.016 mmol), (2R)-1-[(1R)-1-[bis (1,1-dimethylethyl)phosphino]ethyl]-2-(dicyclohexylphosphino)ferrocene (8.61 mg, 0.016 mmol) in DME (1.5 mL) was treated with potassium tert-butoxide (10.46 mg, 0.093 mmol). The vial was sealed and the

reaction mixture was made anaerobic by a pump / backfill with nitrogen cycle (5X). The reaction was set to stir at rt for 10 min. The vial cap was opened under a nitrogen flush and treated with 4-mercaptopyridine (10.36 mg, 0.093 mmol). The vial was capped and made anaerobic by pump/backfill w/N2 (3X). The reaction mixture was stirred at 110 °C overnight. As per LCMS, desired product was observed along with some starting material. In order to gain more product, the reaction was repeated and the details follow: A mixture of tert-butyl ((1R,4R,7R)-2-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (110 mg, 0.182 mmol) (2R)-1-[(1R)-1-[bis (1,1-dimethylethyl)phosphino]ethyl]-2-(dicyclohexylphosphino)ferrocene (20.16 mg, 0.036 mmol), Pd2(dba)3 (33.3 mg, 0.036 mmol) in dioxane (2 mL) under a nitrogen flush was treated with potassium tert-butoxide (24.48 mg, 0.218 mmol). The vial was sealed and the reaction mixture was made anaerobic by a pump / backfill with nitrogen cycle (5X). The reaction was set to stir at rt for 10 min. The vial cap was opened under a nitrogen flush and treated with 4-mercaptopyridine (24.25 mg, 0.218 mmol). The vial was capped and made anaerobic by pump/backfill w/N2 (3X). The reaction mixture was stirred at 110 ° for 20h. After cooling, the reaction was quenched with satd. NH4Cl aq. It was diluted with EtOAc and then washed with water followed by brine. The combined aq layer was extracted with EtOAc. The combined organic layer was dried (MgSO4). Crude products from the two experiments were combined and purified by flash chromatography (12 g ISCO cartridge was used with EtOAc-Hexanes). The product fractions were combined and concentrated (crude weight = 0.1 g). The resulting residue was dissolved in DCM (1 mL) and treated with TFA (0.5 ml, 6.49 mmol). After 1h, the solution was concentrated and the residue was dissolved the residue in DMF, filtered and purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5-µm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 24% B, 24-64% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 C. Fraction collection was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation. The purified material was then diluted with DMF, treated with Si-Pyridine and shaken for a minimum of 2 h. The resulting mixture was

filtered and dried via centrifugal evaporation to give ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(pyridin-4-ylthio)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone (10.1 mg): ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.49 (br s, 2H), 8.21 (br d, *J*=7.9 Hz, 1H), 7.41 - 7.35 (m, 4H), 7.15 (s, 1H), 6.98 - 6.93 (m, 1H), 4.37 (br d, *J*=6.1 Hz, 2H), 4.14 (s, 3H), 4.00 (br s, 3H), 3.71 (br s, 2H), 3.57 - 3.47 (m, 1H), 3.10 (br d, *J*=11.0 Hz, 1H), 2.91 (s, 1H), 2.75 (s, 1H), 1.92 (br s, 4H), 1.48 (br t, *J*=8.4 Hz, 1H), 1.08 - 1.00 (m, 1H), 0.27 (br d, *J*=7.6 Hz, 2H), 0.00 (br s, 2H); LC/MS (M+H) = 580.4; Retention Time = 1.58 min (Method 1).

Example 4

((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(pyridin-4-ylsulfonyl)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone




Example 4

[00169] A mixture of tert-butyl ((1R,4R,7R)-2-(2-(6-bromo-1-(cyclopropylmethyl)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (120 mg, 0.185 mmol), (2R)-1-[(1R)-1-[bis (1,1-dimethylethyl)phosphino]ethyl]-2-(dicyclohexylphosphino)ferrocene (20.52 mg, 0.037 mmol), Pd2(dba)3 (33.9 mg, 0.037 mmol) in dioxane (2 mL) under a nitrogen flush was treated with potassium tert-butoxide (24.91 mg, 0.222 mmol). The vial was sealed and the reaction mixture was made anaerobic by a pump / backfill with nitrogen cycle (5X). The reaction was stirred at rt for 10 min. The vial cap was opened under a nitrogen flush and treated with 4-mercaptopyridine (30.8 mg, 0.278 mmol). The vial was capped and made anaerobic by pump/backfill w/N2 (3X). The reaction mixture was stirred at 110 °C overnight. The reaction was quenched with satd. NH4Cl aq. It was diluted with EtOAc and then washed with water followed by brine. The combined aq layer was extracted with EtOAc. The combined organic layer was dried (MgSO4), filtered, and concentrated.

The resulting residue was purified by flash chromatographed (EtOAc/Hexane) to yield tert-butyl ((1R,4R,7R)-2-(2-(1-(cyclopropylmethyl)-6-(pyridin-4-ylthio)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (38 mg, 0.056 mmol, 30.3 % yield) as a brownish oil which was dissolved in acetone (1.5 mL) and was treated with water (1.500 ml) followed by oxone (103 mg, 0.168 mmol). This was stirred overnight. The reaction was diluted with EtOAc and then washed with 1.5M K2HPO4 aq followed by brine. The combined aq layer was extracted with EtOAc. The combined organic layer was dried (MgSO4), filtered and concentrated. The resulting residue was dissolved in CH2Cl2 (1 mL) and treated with TFA (0.5 ml, 6.49 mmol). After stirring for 1h, the deprotection was found complete. Concentrated and dried in vacuo briefly. The residue was dissolved in DMF and purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5-µm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: a 0-minute hold at 12% B, 12-52% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 C. Fraction collection was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation. The purified material was then diluted with DMF, treated with Si-Pyridine and shaken for a minimum of 2 h. The resulting mixture was filtered and dried via centrifugal evaporation to give ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(pyridin-4-ylsulfonyl)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone (12.6 mg, 0.020 mmol, 10.8 % yield): ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.80 (br d, *J*=5.5 Hz, 2H), 8.38 (br s, 1H), 7.90 (br d, *J*=5.2 Hz, 2H), 7.87 (br d, *J*=8.5 Hz, 1H), 7.62 (br d, *J*=8.5 Hz, 1H), 7.35 (s, 1H), 7.49 - 7.34 (m, 1H), 7.15 (s, 1H), 6.96 - 6.88 (m, 1H), 4.48 (br d, *J*=7.0 Hz, 2H), 4.02 (s, 3H), 3.93 (br s, 3H), 3.74 - 3.50 (m, 1H), 3.44 - 3.39 (m, 1H), 3.15 - 3.07 (m, 1H), 2.61 (br s, 1H), 1.96 - 1.77 (m, 3H), 1.65 - 1.52 (m, 1H), 1.01 - 0.94 (m, *J*=5.8 Hz, 1H), 0.26 (br d, *J*=7.6 Hz, 2H), 0.00 (br s, 2H); LC/MS (M+H) = 611.37; Retention Time = 1.45 min (Method 1).

Example 5

((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-((4-hydroxyphenyl)amino)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone




Example 5

[00170] A vial was charged with tert-butyl ((1R,4R,7R)-2-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (25 mg, 0.041 mmol), 4-aminophenol (6.76 mg, 0.062 mmol), cesium carbonate (40.4 mg, 0.124 mmol) and 2nd generation X-Phos precatalyst (3.25 mg, 4.13 μmol) in dioxane (1 mL) and tBuOH (0.25 mL). The vial was capped and the reaction mixture was made anaerobic by a pump / backfill with nitrogen cycle (5X). The reaction was stirred at 70 °C overnight. After cooling, the mixture was diluted with EtOAc and dried (MgSO4), filtered and concentrated. The resulting residue was dissolved in CH2Cl2 (1 mL) and treated with TFA (0.5 ml, 6.49 mmol). This mixture was stirred at rt for 2hrs before it was concentrated. The resulting residue was dissolved in DMF and was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: a 0-minute hold at 17% B, 17-57% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 C. Fraction collection was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation. The purified material was then diluted with DMF, treated with Si-Pyridine and shaken for a minimum of 2 h. The resulting mixture was filtered and dried via centrifugal evaporation to give ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-((4-hydroxyphenyl)amino)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone (13.8 mg, 0.024 mmol, 57.8 % yield): ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.83 (s, 1H), 7.75 (d, *J*=8.5 Hz, 1H), 7.56 (br d, *J*=8.9 Hz, 2H), 7.40 - 7.27 (m, 1H), 6.89 -

6.79 (m, 2H), 6.68 (br d, *J*=8.9 Hz, 2H), 6.59 (d, *J*=8.5 Hz, 1H), 4.39 (br d, *J*=6.7 Hz, 2H), 4.08 (s, 3H), 3.93 (s, 3H), 3.73 (br s, 1H), 3.65 - 3.42 (m, 1H), 3.16 - 2.95 (m, 2H), 2.22 - 2.07 (m, 1H), 2.00 - 1.87 (m, 2H), 1.77 - 1.60 (m, 1H), 1.44 - 1.28 (m, 1H), 1.11 (br s, 1H), 0.25 (br d, *J*=7.9 Hz, 2H), 0.13 (br d, *J*=4.0 Hz, 2H); LC/MS (M+H) = 578.26; Retention Time = 1.41 min (Method 1).

Intermediate 4

2-(5-((1R,4R,7R)-7-((tert-butoxycarbonyl)amino)-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-carboxylic acid



Intermediate 4


[00171] To a solution of tert-butyl ((1R,4R,7R)-2-(2-(6-bromo-1-(cyclopropylmethyl)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (0.36 g, 0.555 mmol), DPPF (0.062 g, 0.111 mmol) and TEA (0.232 mL, 1.665 mmol) in DMF (2 mL) and MeOH (0.500 mL) was bubbled CO (g) for 5 min following which the reaction solution was treated with palladium (II) acetate (0.037 g, 0.056 mmol). CO (g) was bubbled for another min. The vial was sealed and a balloon containing carbon monoxide was connected to the vial via a needle. This was then stirred at 90 °C.

[00172] After stirring overnight, the reaction was found to be incomplete. Additional amounts of DPPF (0.062 g, 0.111 mmol), MeOH (0.500 mL) and palladium (II) acetate (0.037 g, 0.056 mmol) were added to the reaction and the solution was saturated with CO (g) by bubbling for 5 min. The vial was sealed and a CO (g) balloon was attached. The mixture was stirred at 90°C for another 18h. After cooling, the mixture was diluted with EtOAc and filtered through Celite. The mixture was then washed with 10% LiCl (aq) (2X) followed by brine. The combined aq. layer was extracted with EtOAc. The combined organic layer was dried (MgSO4), filtered and concentrated. The resulting residue was purified via flash chromatographed (EtOAc/Hexane) to give the methyl ester

as a brown oil, which was then dissolved in THF (2 mL) and MeOH (0.5 mL). This solution was treated with 2M LiOH aq (0.555 mL, 1.110 mmol). The reaction was stirred at 70 °C for 2h. The temperature was then raised to 80 °C. After 1h, the reaction was still not complete and 2M LiOH aq (0.278 mL, 0.555 mmol) was added and stirring was continued at 80 °C. After 7h the saponification was complete. After cooling, the mixture was diluted with EtOAc and 2M HCl was added (pH=5). The organic layer was separated and then washed with brine. It was dried (MgSO4), filtered, and concentrated to give the intermediate 2-(5-((1R,4R,7R)-7-((tert-butoxycarbonyl)amino)-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-carboxylic acid: LC/MS (M+H) = 614.3; Retention Time = 0.87 min (Method 3).

Example 6

2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-N-(pyridin-4-yl)-1H-indole-6-carboxamide




Example 6

[00173] A mixture of 2-(5-((1R,4R,7R)-7-((tert-butoxycarbonyl)amino)-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-indole-6-carboxylic acid (30 mg, 0.049 mmol - from the above procedure), 4-aminopyridine (4.38 µl, 0.059 mmol) and Hunig's Base (0.026 ml, 0.147 mmol) in DMF (1 mL) at rt was treated with HATU (22.30 mg, 0.059 mmol). The reaction was stirred overnight at rt. The reaction mixture was then diluted with EtOAc and washed with 10% LiCl (aq) followed by brine. The combined aq layer was extracted with EtOAc. The combined organic layer was dried (MgSO4), filtered, and concentrated. The resulting residue was dissolved in CH2Cl2 (1 mL) and treated with TFA (0.5 ml, 6.49 mmol). After stirring 1 h, the reaction was evaporated. This residue was dissolved in DMF and purified via preparative LC/MS with the following conditions: Column:

XBridge C18, 19 x 200 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 10-mM ammonium acetate; Mobile Phase B: 95:5 acetonitrile: water with 10-mM ammonium acetate; Gradient: 14-54% B over 20 minutes, then a 4-minute hold at 100% B; Flow: 20 mL/min. Fractions containing the desired product were combined and dried via centrifugal evaporation. The purified material was then diluted with DMF, treated with Si-Pyridine and shaken for a minimum of 2 h. The resulting mixture was filtered and dried via centrifugal evaporation to give 2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-N-(pyridin-4-yl)-1H-indole-6-carboxamide (5.9 mg, 10.01 μmol, 20.47 % yield): ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.45 (br t, *J*=5.4 Hz, 1H), 8.16 - 8.13 (m, 1H), 7.71 - 7.67 (m, 1H), 7.65 - 7.60 (m, 1H), 7.44 - 7.31 (m, 1H), 7.02 (s, 1H), 6.95 - 6.88 (m, 1H), 4.41 (br d, *J*=6.7 Hz, 2H), 4.13 (br d, *J*=8.3 Hz, 1H), 4.06 (s, 3H), 3.95 (s, 3H), 3.78 - 3.66 (m, 3H), 3.61 (q, *J*=7.7 Hz, 1H), 3.49 (br dd, *J*=8.3, 5.4 Hz, 1H), 3.34 - 3.22 (m, 1H), 3.04 (br d, *J*=11.5 Hz, 1H), 2.52 (br s, 2H), 2.24 - 2.12 (m, 1H), 2.02 - 1.88 (m, 3H), 1.78 - 1.68 (m, 1H), 1.62 (dq, *J*=12.9, 6.5 Hz, 1H), 1.42 (br s, 1H), 1.20 (br s, 1H), 1.06 (br s, 1H), 0.28 (br d, *J*=7.8 Hz, 2H), 0.00 (br s, 2H); LC/MS (M+H) = 590.36; Retention Time = 1.25 min (Method 3).

Example 7

6-(2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydroquinolin-2(1H)-one




Example 7

[00174] A 2dr vial was charged with ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone (125 mg, 0.248 mmol),), 6-(4,4,5,5-tetramethyl-1,3,2-dioxaborolan-2-yl)-3,4-dihydroquinolin-2(1H)-one (81 mg, 0.297 mmol), potassium phosphate tribasic, 3M in water (0.248 mL, 0.743 mmol) and 1,1'-

Bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (20.21 mg, 0.025 mmol) in THF (2 mL). The vial was capped and the reaction mixture was made anaerobic by a pump / backfill with nitrogen cycle (5X). The reaction was stirred at 70 °C for overnight. After cooling, the mixture was concentrated and dried in vacuo. It was dissolved in DMF and purified via prep HPLC. Prep HPLC conditions: Start % B = 20, Final % B = 70, Gradient Time = 15 min, Flow Rate = 30 ml/min, Wavelength = 254, Solvent Pair = MeCN - H20 - TFA; Solvent A = 0.1% TFA in water ; Solvent B = 0.1% TFA in MeCN; Column 2 = 1: Luna 5u C18 30 x 100 mm AXIA Product eluted at 7.92 min. The desired fractions were combined and it was diluted with EtOAc and then washed with 1.5M K2HPO4 (aq) followed by brine. The combined aq layer was extracted with EtOAc. The combined organic layer was dried (MgSO4), filtered and concentrated. The residue was dissolved in DCM-MeOH and treated with 25 mgs of Py-resin. This was shaken for over 2h before it was filtered and concentrated. The residue was dissolved into a mixture of water-acetonitrile, frozen and lyophilized to give 6-(2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydroquinolin-2(1H)-one (55 mg, 0.086 mmol, 34.6 % yield) as a white fluffy solid: ^{1}H NMR (500 MHz, DMSO-d_6) δ 10.08 (s, 1H), 8.15 (d, *J*=8.2 Hz, 1H), 8.02 - 7.97 (m, 2H), 7.89 - 7.78 (m, 1H), 7.76 - 7.69 (m, 2H), 7.45 (br d, *J*=8.6 Hz, 1H), 7.10 (s, 1H), 7.01 (d, *J*=8.2 Hz, 1H), 4.64 (br d, *J*=7.0 Hz, 2H), 3.99 (s, 3H), 3.74 (br s, 1H), 3.63 - 3.48 (m, 1H), 3.35 - 3.27 (m, 1H), 3.17 - 3.04 (m, 1H), 3.01 (br t, *J*=7.5 Hz, 2H), 2.56 - 2.52 (m, 3H), 2.23 (br s, 1H), 2.06 - 1.91 (m, 2H), 1.72 (br t, *J*=9.3 Hz, 1H), 1.49 - 1.39 (m, 1H), 1.23 (br d, *J*=8.4 Hz, 1H), 0.32 (br d, *J*=7.8 Hz, 2H), 0.23 (br s, 2H) LCMS = (M+H)+ = 616.3; retention time = 0.7 min (Method 3).

Example 8

((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(oxetan-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone.






Example 8

[00175] The tert-butyl ((1R,4R,7R)-2-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-yl)carbamate (30 mg, 0.050 mmol) was dissolved in dioxane (0.5 mL) prior to the addition of 3-bromooxetane (6.79 mg, 0.050 mmol), (Ir[DF(CF3)PPY]2(DTBPY))PF6 (1.112 mg, 0.992 μmol), sodium carbonate (0.011 mL, 0.198 mmol), 4,4'-di-tert-butyl-2,2'-bipyridine (0.798 mg, 2.97 μmol), tris(trimethylsilyl)silane (0.023 mL, 0.074 mmol), nickel (II) chloride ethylene glycol dimethyl ether complex (0.545 mg, 2.479 μmol) and a nitrogen purge followed. This was stirred overnight in front of two Kessil lamps with fan cooling of the reaction vial. After cooling EtOAc was added and this was filtered and concentrated. The resulting residue was dissolved in DCM (1 mL) prior to the addition of T-FA (2 mL). After 30 min, the mixture was concentrated. The resulting residue was purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5-μm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: a 0-minute hold at 10% B, 10-50% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 C. Fraction collection was triggered by MS and UV signals. Fractions containing the desired product were combined and dried via centrifugal evaporation. The purified material was then diluted with DMF, treated with Si-Pyridine and shaken for a minimum of 2 h. The resulting mixture was filtered and dried via centrifugal evaporation to give ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(oxetan-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone (5.8 mg, 0.01 mmol, 22.2%): ^{1}H NMR (500 MHz, DMSO-d_6, rotamers) δ 8.07 - 8.00 (m, 1H), 7.44 (m, 0.33H), 7.36 - 7.31 (m, 0.71H), 7.14 - 7.08 (m, 1H), 7.03 - 6.99 (m, 1H), 6.95 - 6.85 (m, 1H), 4.94 - 4.89 (m, 2H), 4.88 - 4.83 (m, 2H), 4.52 - 4.42 (m, 3H), 4.14 (m, 0.25H), 4.07 (s, 3H), 3.94 (s, 3H), 3.79 - 3.72 (m, 0.53H), 3.52 - 3.38 (m, 1H), 3.18 - 3.11 (m, 0.49H), 3.07 - 2.95 (m, 1H), 2.22 (m, 0.76H), 2.14 (m, 0.41H), 1.99 - 1.78 (m, 2H), 1.77 - 1.62 (m, 1H), 1.48 - 1.30 (m,

1H), 1.13 - 1.01 (m, 1H), 0.32 - 0.20 (m, 2H), 0.17 - 0.06 (m, 2H); LCMS (M + H)+ = 527.4; Retention Time: 1.37 min (Method 1).

[00176] The Examples in the tables below were prepared in the same manner as that outlined for Examples 1-8 above.

Table 1

Cmpd #	Structure	Name	Obs. MS Ion	HPLC Method IDs	RT (min)
9.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(pyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	548	1	1.6
10.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-methoxypyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	578.3	1	1.76
11.		N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methanesulfonamide	640.2	2	1.41

12.		methyl N-[5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate	621.2	1	1.57
13.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	551	2	1.47
14.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-1,3-benzodiazol-2-one	603.1	1	1.31
15.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-methoxypyridin-4-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	577.2	2	1.4

16.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1-methyl-1,2-dihydropyridin-2-one	577.1	1	1.34
17.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(5-methoxypyridin-3-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	577.3	1	1.57
18.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-pyrazol-5-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	550.4	1	1.42
19.		methyl N-[5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyridin-2-yl]carbamate	620.2	2	1.26

20.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	565.4	2	1.46
21.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3-methyl-1H-pyrazol-4-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	550.4	1	1.32
22.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(pyridin-3-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	547.4	1	1.49
23.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-pyrazol-4-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	550.2	1	1.77

24.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-pyrazol-4-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	536.3	1	1.22
25.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(pyridin-3-yloxy)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	563	1	1.53
26.		2-methoxyethyl N-[5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyridin-2-yl]carbamate	664.4	1	1.59
27.		2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-(pyridin-4-yl)-1H-indol-6-amine	562.3	1	1.15

28.		3-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1H-pyrazol-1-yl]propanamide	607.1	1	1.18
29.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-pyrazol-3-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	536.3	1	1.39
30.		2-{[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]formamido}acetic acid	647.1	1	1.15
31.		3-{[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]formamido}propanoic acid	661.2	1	1.19

32.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-N-(pyridin-4-yl)benzamide	666	2	1.2
33.		2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-(pyrimidin-5-yl)-1H-indol-6-amine	563.3	2	1.07
34.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(pyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine		1	
35.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)benzamide	589.4	1	1.42

36.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3,5-dimethyl-1H-pyrazol-4-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	564.4	1	1.36
37.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3-methyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	551.3	1	1.32
38.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	566.3	1	1.62
39.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(5-methoxypyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	577.9	1	1.55

40.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methyl-1,2-dihydropyridin-2-one	578.1	2	1.16
41.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3,5-dimethyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	565.2	1	1.38
42.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-pyrrol-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	536.1	2	1.25
43.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyrimidine-2-carbonitrile	573.4	1	1.64




44.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyrimidine-2-carbonitrile	574.1	1	1.61
45.		5-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)amino]pyrimidine-2-carbonitrile	588.4	2	1.36

Table 2

Cmpd #	Structure	Name	Obs. MS Ion	HPLC Method IDs	RT (min)
46.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydropyrimidine-2,4-dione	581.4	1	1.12

47.		N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]but-2-ynamide	627.2	1	1.66
48.		N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]prop-2-enamide	615.2	2	1.44
49.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(2,6-dimethylpyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	591.4	1	1.2
50.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-methylpyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	562.2	1	1.53

51.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(6-methoxypyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	578	1	1.96
52.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(2-methylpyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	577	1	1.4
53.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzamide	590.3	2	1.2
54.		(1R,4R,7R)-2-{2-[6-(6-aminopyridin-3-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	563.4	2	1.01

55.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[2-(methylamino)pyrimidin-5-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	578.3	1	1.48
56.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-2-carboxamide	591.1	1	1.41
57.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-fluoro-3-methylpyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	580.4	2	1.56
58.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorobenzamide	624.3	1	1.42

59.		(1R,4R,7R)-2-(2-{6-[(3-chloropyridin-4-yl)amino]-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl}-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-amine	597.3	1	1.67
60.		2-{3-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-1H-pyrazol-1-yl}ethan-1-ol	596.2	1	1.22
61.		methyl 4-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyridine-3-carboxylate	621.4	2	1.15
62.		4-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]benzonitrile	587.4	1	1.75

63.		(1R,4R,7R)-2-(2-{6-[(3-chloro-2-methylpyridin-4-yl)amino]-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl}-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-amine	611.1	1	1.76
64.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(3,5-dimethylpyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	591.1	2	0.99
65.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(2,3-dimethylpyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	591.5	2	1.1
66.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(3-methylpyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	577.2	1	1.25

67.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(3-fluoropyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	581.3	2	0.97
68.		N-(2-{5-[(3R)-3-aminopiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylpyridin-4-amine	565.2	2	1.1
69.		N-(2-{5-[(3R)-3-aminopiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dimethylpyridin-4-amine	579.2	2	1.14
70.		N-(2-{5-[(3R)-3-aminopiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-4-amine	551.1	1	1.13

71.		N-(2-{5-[(3R)-3-aminopiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylpyridin-4-amine	565.4	2	0.96
72.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(6-methylpyridin-3-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	577.4	1	1.54
73.		4-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyridine-2-carbonitrile	588.2	1	1.54
74.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[methyl(pyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	577.4	2	1

75.		{4-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyridin-3-yl}methanol	593.2	2	1.21
76.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(2-methoxypyrimidin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	594.2	1	1.6
77.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-{[2-(propan-2-yl)pyrimidin-4-yl]amino}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	606.2	1	1.84
78.		N4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyrimidine-4,6-diamine	579.5	1	1.2

79.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(2-methylpyrimidin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	578.2	1	1.54
80.		6-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyrimidin-4-ol	580.1	1	1.29
81.		5-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyridine-2-carbonitrile	588.2	2	1.46
82.		N5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-2,5-diamine	578.4	1	1.22

83.		N1-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzene-1,4-diamine	577.4	2	0.93
84.		N1-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzene-1,3-diamine	577.3	1	1.44
85.		4-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]benzamide	605.4	1	1.34
86.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1,2,3,6-tetrahydropyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	566.6	1	1.17

87.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[4-(5-methyl-1,3,4-oxadiazol-2-yl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	629.2	2	1.55
88.		(1R,4R,7R)-2-(2-{6-[4-(5-amino-1,3,4-thiadiazol-2-yl)phenyl]-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl}-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-amine	646.2	1	1.72
89.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenol	563.4	1	1.56
90.		3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenol	563.2	2	1.46

91.		[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methanol	576.9	2	1.42
92.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-2-carbonitrile	573.2	2	1.52
93.		[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methanol	577.5	2	1.35
94.		methyl 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-2-carboxylate	606.2	1	1.65

95.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2,5-dihydro-1H-pyrrol-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	538.4	1	1.03
96.		N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]ethene-1-sulfonamide	652.5	2	1.57
97.		3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-[2-(dimethylamino)ethyl]benzamide	661.5	1	1.28
98.		4-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyridin-2-ol	579.4	1	1.15

99.		3-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]phenol	578.4	2	1.26
100.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(2,5-dimethylpyridin-4-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	591.5	1	1.26
101.		3-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)amino]phenol	577.4	1	1.53
102.		2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-(2,5-dimethylpyridin-4-yl)-1H-indol-6-amine	590.5	1	1.17




103.		(1R,4R,7R)-2-{2-[6-(3-aminophenyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	562.4	2	1.07

Table 3

Cmpd #	Structure	Name	Obs. MS Ion	HPLC Method IDs	RT (min)
104.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-(2-hydroxyethyl)benzamide	634.1	1	1.46
105.		{4-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyridin-2-yl}methanol	593.2	2	1.13

106.		[5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]methanol	578.5	1	1.35
107.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenol	581.4	2	1.4
108.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	577.2	1	1.96

109.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N,N-dimethylbenzamide	618.5	2	1.38
110.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenol	593.4	2	1.39
111.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenol	597.4	2	1.49

112.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[1-(propan-2-yl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	579.4	1	1.65
113.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[1-(2-methylpropyl)-1H-pyrazol-3-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	593.5	1	1.83
114.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N,N-dimethylpyridine-2-carboxamide	619.2	1	1.39

115.		methyl 5-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyridine-2-carboxylate	621.2	2	1.26
116.		1-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-3-methylidenepyrrolidin-2-one	642.2	2	1.54
117.		N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenyl]-N-methylprop-2-enamide	644.2	1	1.93

118.		N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenyl]-3-methylbut-2-enamide	658.2	2	1.53
119.		N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]prop-2-enamide	615.2	1	1.9
120.		N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]-N-methylethene-1-sulfonamide	683.9	1	2.01

121.		1-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]-3-methylidenepyrrolidin-2-one	641.2	1	1.97
122.		N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]-N-methylprop-2-enamide	629.2	1	1.9
123.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3-dihydro-1H-isoindol-1-one	601.1	1	1.53

124.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[6-(methylsulfanyl)pyridin-3-yl]-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	593.3	2	1.62
125.		3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)benzoic acid	590.2	2	1.5
126.		ethyl 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-indole-2-carboxylate	329.7	2	1.81

127.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(6-methanesulfonylpyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	626.4	1	1.61
128.		2-methoxyethyl N-[5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate	333.2	1	1.75
129.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one	602.2	2	1.41

130.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1,3,5-trimethyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	579.4	1	1.75
131.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1,3-dimethyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	565.4	1	1.52
132.		(1R,4R,7R)-2-{2-[6-(1-cyclopropyl-1H-pyrazol-4-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	577.4	2	1.51

133.		(1R,4R,7R)-2-(2-{6-[4-(aminomethyl)phenyl]-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl}-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-amine	576.5	1	1.27
134.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1,2,3,4-tetrahydroquinolin-7-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	602.2	1	2.13
135.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-{1H-pyrrolo[2,3-b]pyridin-5-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	587.2, 587.2	1	

136.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-indol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	600.4	2	1.7
137.		N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-2-methylprop-2-enamide	630.5	1	1.8
138.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-indazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	587.4	1	1.58

139.		5-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyrimidine-2-carboxamide	607.1	1	1.34
140.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyrimidine-2-carboxamide	591.1	1	1.38
141.		{5-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-1-methyl-1H-1,3-benzodiazol-2-yl}methanol	646.5	2	1.08

142.		6-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-2,3-dihydro-1,3-benzoxazol-2-one	619.4	2	1.24
143.		5-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-2,3-dihydro-1H-isoindol-1-one	617.5	1	1.51
144.		6-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-2-methyl-2,3-dihydro-1H-isoindol-1-one	631.5	1	1.52

145.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroisoquinolin-1-one	616.5	2	1.33
146.		(1R,4R,7R)-2-{2-[6-(1-benzofuran-5-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	587.4	1	2.1
147.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one	602.4	2	1.29

148.		1-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]ethan-1-ol	591.5	2	1.46
149.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2,3-dihydro-1-benzofuran-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	589.4	1	2.02
150.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,3-dihydro-2-benzofuran-1-one	603.4	1	1.61




151.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methyl-2,3-dihydro-1H-isoindol-1-one	616.5	1	1.57
152.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one	602.4	1	1.48

Table 4

Cmpd #	Structure	Name	Obs. MS Ion	HPLC Method IDs	RT (min)
153.		cyclopropylmethyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]carbamate	660.5	1	2.03

154.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2,3-dihydro-1,4-benzodioxin-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	605.4	2	1.68
155.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[4-(ethanesulfonyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	639.4	2	1.52
156.		5-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]imidazolidine-2,4-dione	645.4	2	1.19

157.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one	602.4	1	1.51
158.		methyl 5-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyrimidine-2-carboxylate	622.5	1	1.36
159.		1-{6-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-2,3-dihydro-1H-indol-1-yl}ethan-1-one	645.5	2	1.32

160.		1-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)piperazin-2-one	568.5	1	1.11
161.		methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylphenyl]carbamate	634.3	2	1.5
162.		[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]urea	605.2	1	1.37

163.		3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzamide	590	1	1.57
164.		3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-methylbenzamide	604.4	1	1.5
165.		3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N,N-dimethylbenzamide	618.3	2	1.39

166.		[2-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-methoxyphenyl]methanol	607	1	1.65
167.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-difluorophenol	598.9	1	1.78
168.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,6-difluorophenol	598.4	2	1.49

169.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-chlorophenol	596.4	2	1.52
170.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenol	603.4	2	1.55
171.		6-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-1,2,3,4-tetrahydroquinolin-2-one	631.2	2	1.32

172.		[2-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-methoxyphenyl]methanol	607.5	2	1.52
173.		(1R,4R,7R)-2-{2-[6-(4-amino-3-fluorophenyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	580.2	2	1.41
174.		(1R,4R,7R)-2-{2-[6-(4-amino-3-fluorophenyl)-1-(cyclopropylmethyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	579.5	1	1.74

175.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorophenol	580.4	1	1.66
176.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenol	587.4	2	1.47
177.		methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]carbamate	620.5	1	1.73

178.		methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]carbamate	619.2	2	1.66
179.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-3-chlorophenol	596	1	1.86
180.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-3,5-difluorophenol	598.4	1	1.65

181.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,5-difluorophenol	597.9	1	1.85
182.		[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,6-difluorophenyl]methanol	611.9	2	1.5
183.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-chlorophenol	597.3	2	1.46

184.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,5-difluorophenol	599	1	1.76
185.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,5-difluorophenol	599.2	2	1.48
186.		[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-difluorophenyl]methanol	613.2	1	1.82

187.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydroquinolin-2-one	615.5	2	1.34
188.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinolin-2-one	622	1	1.66
189.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,3-dihydro-2-benzofuran-1-one	602.5	2	1.48

190.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1H,2H,3H-imidazo[4,5-b]pyridin-2-one	603	2	1.23
191.		2'-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1'-(cyclopropylmethyl)-1-methyl-2,3-dihydro-1H,1'H-[5,6'-biindole]-2-one	615.4	1	1.77
192.		methyl N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate	626.9	2	1.48

193.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one	602.5	2	1.33
194.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methyl-1,2-dihydroquinolin-2-one	628.5	1	1.51
195.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-methoxypyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	579.3	1	1.55

196.		7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinolin-2-one	616.4	1	1.55
197.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methyl-1,2,3,4-tetrahydroquinazolin-2-one	631.3	2	1.33
198.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinolin-2-one	616.5	1	1.5




199.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-2-one	644.4	1	1.73
200.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione	631.4	2	1.19

Table 5

Cmpd #	Structure	Name	Obs. MS Ion	HPLC Method IDs	RT (min)
201.		2-amino-3-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]propanoic acid	634.5	2	1.12

202.		N-{[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methyl}acetamide	618.5	1	1.29
203.		N-{[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methyl}methanesulfonamide	654.2	2	1.52
204.		methyl 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-oxo-1,2-dihydroquinoline-4-carboxylate	672.1	2	1.7

205.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxy-3-methyl-1,2-dihydroquinolin-2-one	644.4	1	1.21
206.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydroquinolin-2-one	614.3	2	1.45
207.		N-{[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]methyl}acetamide	617.1	1	1.48

208.		N-{[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]methyl}methanesulfonamide	653.2	2	1.83
209.		methyl 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-oxo-1,2-dihydroquinoline-4-carboxylate	671.3	2	1.72
210.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-hydroxy-3-methyl-1,2-dihydroquinolin-2-one	643.2	1	1.21

211.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2-dihydroquinolin-2-one	613.1	1	1.45
212.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,3-dihydro-2-benzofuran-1-one	603.4	2	1.78
213.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methyl-2,3-dihydro-1H-indol-2-one	616.5	1	1.42

214.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-one	617.2	2	1.64
215.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H,2H,3H-pyrrolo[2,3-b]pyridin-2-one	603.4	2	1.32
216.		7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydroquinolin-2-one	614.1	1	1.53

217.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydroisoquinolin-1-one	614.1	2	1.6
218.		2-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]acetic acid	605.3	1	1.57
219.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)benzene-1,3-diol	578	1	1.28

220.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2-dihydroisoquinolin-1-one	613.4	2	1.5
221.		7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2-dihydroquinolin-2-one	613.4	1	1.35
222.		2'-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1'-(cyclopropylmethyl)-2,3-dihydro-1H,1'H-[6,6'-biindole]-2-one	601.5	1	1.33

223.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-3-methyl-1,2,3,4-tetrahydroquinazolin-2-one	630.5	2	1.52
224.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydroquinolin-2-one	615.5	1	1.36
225.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4,4-dimethyl-1,2,3,4-tetrahydroquinolin-2-one	643.2	1	1.61

226.		2-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]acetamide	604.2	2	1.51
227.		2-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-N-methylacetamide	618.2	1	1.38
228.		2-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-N-(2-hydroxyethyl)acetamide	648.2	1	1.31

229.		2-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-N-(2-methanesulfonylethyl)acetamide	710.3	1	1.38
230.		7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione	629.9	2	1.54
231.		7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione	631.2	2	1.5

232.		N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]acetamide	604.1	1	1.42
233.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-(hydroxymethyl)-1,2-dihydroquinolin-2-one	644.4	1	1.29
234.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluoro-8-methyl-1,2-dihydroquinolin-2-one	646.2	1	1.42

235.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydropyridin-2-one	564.6	2	1.24
236.		N-[5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]acetamide	605.1	1	1.28
237.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2-dihydropyridin-2-one	563.1	2	1.41

238.		N-[5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyridin-2-yl]acetamide	604.2	1	1.13	
239.		N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]acetamide	603.1	1	1.43	
240.		N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]methanesulfonamide	639.3	1	1.37	

241.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-methyl-1,2-dihydroquinolin-2-one	627.2	1	1.31
242.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3-dihydro-1H-isoindol-1-one	601.6	2	1.49
243.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-(hydroxymethyl)-1,2-dihydroquinolin-2-one	643.2	2	1.44

244.		7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydroquinolin-2-one	615.1	1	1.51
245.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione	630.2	2	2.12
246.		7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one	617.9	2	1.71







247.		methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]carbamate	638.5	1	1.62
248.		N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenyl]methanesulfonamide	674.1	2	1.86

Table 6

Cmpd #	Structure	Name	Obs. MS Ion	HPLC Method IDs	RT (min)
249.		methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-difluorophenyl]carbamate	656.1	1	1.84

250.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione	631.5	2	1.22
251.		7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one	617.2	1	1.73
252.		methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorophenyl]carbamate	637.5	2	1.61

253.		N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-chlorophenyl]methanesulfonamide	673.2	1	1.88
254.		methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3-difluorophenyl]carbamate	655.2	1	1.91
255.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione	630.5	2	1.26

256.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,5-difluorophenol	605.1	2	1.58
257.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-chlorophenol	603.3	2	1.58
258.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxy-3-methyl-1,2-dihydroquinolin-2-one	650.1	2	1.41

259.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione	637.1	2	1.35
260.		2-amino-4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenol	578.4	1	1.34
261.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(isoquinolin-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	598.2	2	1.26

262.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl acetate	605.2	1	1.94
263.		(1R,4R,7R)-2-{2-[6-(3-chloro-4-methoxyphenyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	611.4	1	2.05
264.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-fluoro-4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	595.3	1	2.01

265.		(1R,4R,7R)-2-{2-[6-(3-chloro-4-fluorophenyl)-1-(cyclopropylmethyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	598.1	1	1.97
266.		(1R,4R,7R)-2-{2-[6-(3-chloro-4,5-difluorophenyl)-1-(cyclopropylmethyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	616.4	1	2.38
267.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-fluoro-4-methoxyphenyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	594.1	1	2.02




268.		(1R,4R,7R)-2-{2-[6-(1,3-benzothiazol-5-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	604.5	1	1.87
269.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1,3-thiazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	554.4	1	1.59
270.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3-fluoro-4-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	595.5	2	1.74

271.		(1R,4R,7R)-2-{2-[6-(2-chloro-4-methoxyphenyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	611.1	2	1.88
272.		(1R,4R,7R)-2-{2-[6-(1,3-benzothiazol-5-yl)-1-(cyclopropylmethyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	603.2	1	2.03
273.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1,3-thiazol-5-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	553.5	1	1.61

274.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3-fluoro-4-methoxyphenyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	594.2	2	1.64
275.		(1R,4R,7R)-2-{2-[6-(2-chloro-4-methoxyphenyl)-1-(cyclopropylmethyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	610.4	1	2.15
276.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3,5-difluoro-4-methoxyphenyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	612.5	1	2.14

277.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3,4,5-trifluorophenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	601.4	1	2.23
278.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(4-fluorophenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	565.1	1	2.12
279.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(4-fluoro-3-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	595.4	1	2.15

280.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(3,4,5-trifluorophenyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	600.4	2	1.84
281.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(4-fluorophenyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	564.1	2	1.83
282.		(1R,4R,7R)-2-{2-[6-(4-chloro-3-fluorophenyl)-1-(cyclopropylmethyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	598.4	1	2.29

283.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(4-fluoro-3-methoxyphenyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	594.3	2	1.58
284.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzoic acid	609	1	1.14
285.		3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-difluorobenzoic acid	627.1	1	1.22

286.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorobenzoic acid	608.2	1	1.41
287.		3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,6-difluorobenzoic acid	626	2	1.48
288.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-chlorobenzoic acid	624.3	2	1.57

289.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one	608.5	1	1.34
290.		2'-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1'-(cyclopropylmethyl)-2,3-dihydro-1H,1'H-[5,6'-biindole]-2-one	601.5	2	1.25
291.		[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]methanol	576	1	1.81

292.		[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-fluorophenyl]methanol	594.5	1	1.59
293.		[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorophenyl]methanol	594.6	2	1.49
294.		[5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-methoxyphenyl]methanol	606.6	2	1.52

295.		N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]acetamide	603.3	1	1.78
296.		[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-fluorophenyl]methanol	595.4	1	1.57
297.		[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]methanol	595.3	2	1.35




298.		[5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenyl]methanol	607.1	2	1.39




Table 7

Cmpd#	Structure	Name	Obs. MS Ion	HPLC Method IDs	RT (min)
299.		N-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]acetamide	604.1	1	1.34
300.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-acetamidobenzoic acid	648.2	1	1.34

301.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-acetamidobenzoic acid	647.5	2	1.24
302.		methyl N-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]carbamate	626.2	2	1.64
303.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenol	581.1	2	1.76

304.		methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate	621.4	2	1.62
305.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-difluorophenol	599.3	1	1.62
306.		3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-fluorophenol	581.1	1	1.56




307.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorophenol	580.4	2	1.73
308.		methyl N-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyridin-2-yl]carbamate	620.5	1	1.15
309.		3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-fluorophenol	580.5	1	1.47

310.		N-{[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]methyl}acetamide	617.5	2	1.58
311.		3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorophenol	580.4	2	1.7
312.		3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-5-fluorophenol	580.2	2	1.86

313.		2-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-6-fluorophenol	580.2	2	1.88
314.		N-{[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methyl}acetamide	617.9	2	1.74
315.		3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenol	581.3	2	1.72

316.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2,3-difluoropyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	584.4	1	1.63
317.		N-{[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methyl}methanesulfonamide	654.1	2	1.79
318.		methyl 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-indole-2-carboxylate	644	1	1.73

319.		ethyl 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-1,3-benzodiazole-2-carboxylate	659.4	1	1.42
320.		7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroisoquinolin-1-one	616.2	1	1.45
321.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7-fluoro-2,3-dihydro-1H-indol-2-one	620	2	1.69

322.		ethyl 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1H-1,3-benzodiazole-2-carboxylate	658	2	1.77
323.		7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydroisoquinolin-1-one	615	1	1.48
324.		2'-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1'-(cyclopropylmethyl)-7-fluoro-2,3-dihydro-1H,1'H-[5,6'-biindole]-2-one	618.9	1	1.44

325.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxy-1,2-dihydroquinolin-2-one	630	2	1.48
326.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinolin-4-ol	613.92, 613.96	2	
327.		methyl 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxyquinoline-2-carboxylate	672.2	2	1.58

328.		methyl 5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-benzothiophene-2-carboxylate	661	1	2.02
329.		7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one	602.2	1	1.61
330.		7-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)naphthalen-2-ol	613.3	2	1.87

331.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-hydroxy-1,2-dihydroquinolin-2-one	629.2	1	1.22
332.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinolin-4-ol	613.2	2	1.56
333.		methyl 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxynaphthalene-2-carboxylate	671.1	2	1.49

334.		2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-2',3'-dihydro-1H,1'H-[6,7'-biindole]-2'-one	601	1	1.48
335.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzamide	608.3	2	1.5
336.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzene-1-sulfonamide	626.2	1	1.37

337.		2-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzamide	590.3	2	1.4
338.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(quinolin-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	598.1	2	1.68
339.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorobenzamide	607.2	2	1.49

340.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-chlorobenzamide	623.3	2	1.48
341.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)benzene-1-sulfonamide	625.2	2	1.42
342.		2-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)benzamide	589.2	1	1.25

343.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(quinolin-6-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	597.3	1	1.13
344.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one	572.1	2	1.28
345.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one	571.9	2	1.39

346.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinolin-2-one	592.1	1	1.32
347.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one	578.1	2	1.42

Table 8

Cmpd #	Structure	Name	Obs. MS Ion	HPLC Method IDs	RT (min)
348.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one	578.1	1	1.43

349.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzamide	560.2	2	1.2
350.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzamide	566.2	1	1.28
351.		methyl N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate	597.3	1	1.43

352.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-difluorophenol	569.2	2	1.46
353.		methyl N-[5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate	591.3	1	1.47
354.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-methoxyphenyl acetate	634.3	2	1.69

355.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenyl acetate	635	1	2.04
356.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluorobenzamide	608.2	1	1.4
357.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-3-fluorobenzamide	607.4	1	1.42

358.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyridine-2-carboxamide	589.9	2	1.36
359.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(quinolin-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	598.2	1	1.7
360.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-methylquinolin-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	612	2	1.31

361.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[4-(1H-1,2,3,4-tetrazol-5-yl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	615	1	1.36
362.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(quinolin-5-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	597.2	2	1.32
363.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-methylquinolin-5-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	611.3	2	1.23

364.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methoxybenzamide	310.6	2	1.34
365.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinolin-1-ium-1-olate	614.1	1	1.56
366.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxyquinoline-3-carboxylic acid	658.3, 658.17, 658.31	1	

367.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-8-fluoro-1,2,3,4-tetrahydroquinolin-2-one	634.2	1	1.68
368.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-3-methoxybenzamide	619.4	1	1.54
369.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinolin-1-ium-1-olate	613.2	1	1.57

370.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-hydroxyquinoline-3-carboxylic acid	657.3	2	1.41
371.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-8-fluoro-1,2,3,4-tetrahydroquinolin-2-one	633.4	2	1.39
372.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinoline-2-carbonitrile	622.3	2	1.79

373.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-hydroxybenzamide	605.3	2	1.43
374.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinoline-2-carbonitrile	623.4	1	1.99
375.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-hydroxybenzamide	606.3	2	1.34

376.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-6-methoxyphenol	627.3	1	1.83
377.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluorophenol	581.4	1	1.55
378.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-methylbenzene-1-sulfonamide	640.4	1	1.71

379.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(quinoxalin-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	598.9	2	1.55
380.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-cyclopropylbenzene-1-sulfonamide	666.2	1	1.89
381.		methyl N-[5-(2-{5-[(2S,5R)-5-amino-2-methylpiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate	623	1	1.59

382.		4-(2-{5-[(2S,5R)-5-amino-2-methylpiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzamide	610.3	2	1.36
383.		4-(2-{5-[(2S,5R)-5-amino-2-methylpiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorobenzamide	626.2	2	1.36
384.		6-(2-{5-[(2S,5R)-5-amino-2-methylpiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydroisoquinolin-1-one	616.2	1	1.51

385.		5-(2-{5-[(2S,5R)-5-amino-2-methylpiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one	604.4	1	1.49
386.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-difluorobenzamide	626.4	1	1.49
387.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinazolin-4-ol	615.3	2	1.3

388.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinoxalin-2-ol	615.3	2	1.24
389.		methyl 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinoline-2-carboxylate	656.37, 656.37	1	
390.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinoxalin-2-ol	614.2	1	1.49

391.		5-(2-(5-(((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-indol-6-yl)benzo[d]isothiazol-3(2H)-one 1,1-dioxide	651.3	2	1.26
392.		methyl 6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinoline-2-carboxylate	655.4	2	1.57
393.		4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,6-difluorobenzamide	625.3	1	1.55

394.		2'-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1'-(cyclopropylmethyl)-3,3-difluoro-2,3-dihydro-1H,1'H-[5,6'-biindole]-2-one	637.3	2	1.56
395.		6-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)cinnolin-4-ol	613.9	2	1.35
396.		2'-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-4-chloro-1'-(cyclopropylmethyl)-2,3-dihydro-1H,1'H-[5,6'-biindole]-2-one	635.2	2	1.37

Table 9

Cmpd #	Structure	Name	Obs. MS Ion	HPLC Method IDs	RT (min)
397.		2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-[(oxolan-3-yl)methyl]-1H-indole-6-carboxamide	597.2	1	1.28
398.		2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-[(1,1-dioxidotetrahydrothiophen-3-yl)methyl]-1H-indole-6-carboxamide	645.1	1	1.21
399.		2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-[(pyridin-4-yl)methyl]-1H-indol-6-amine	576.3	1	1.3

400.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(pyridin-4-yloxy)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	564.3	2	1
401.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(2,6-dimethylpyridin-4-yl)oxy]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	592.3	1	1.75
402.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(pyridin-3-yl)amino]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	563.2	1	1.48

403.		N-{5-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]pyridin-2-yl}acetamide	620.2	1	1.43
404.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(pyridine-4-sulfonyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	611.4	1	1.45
405.		(1R,4R,7R)-2-{2-[6-(azetidin-3-yl)-1-(cyclopropylmethyl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	525.2	1	1.04






406.		1-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)azetidin-1-yl]ethan-1-one	567.4	1	1.33

Table 10

Cmpd #	Structure	Name	Obs. MS Ion	HPLC Method IDs	RT (min)
407.		(1R,4R,7R)-2-[2-(6-{[4-(aminomethyl)phenyl]amino}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-amine	591.4	1	1.18

408.		3-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]benzamide	605.4	1	1.34
409.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-{[(pyridin-4-yl)methyl]amino}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	577.4	1	1.42
410.		N-(3-{[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]methyl}phenyl)acetamide	633.5	2	1.17

411.		(1R,4R,7R)-2-[2-(6-{[3-(aminomethyl)phenyl]amino}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl]-2-azabicyclo[2.2.1]heptan-7-amine	591.2	2	1.11
412.		4-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]piperidin-2-one isomer 1	583.4	1	1.01
413.		4-[(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]piperidin-2-one isomer 2	583	1	1.3

414.		(1R,4R,7R)-2-{2-[6-cyclohexyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	553.4	1	2.33
415.		(1R,4R,7R)-2-{2-[6-cyclopropyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	511.2	2	1.4
416.		(1R,4R,7R)-2-{2-[6-cyclopentyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	539.4	1	2.25

417.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-ethoxypyrimidin-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	593.4	1	1.74
418.	mixture of isomers	(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(oxolan-3-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	555.5	1	1.6
419.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(oxetan-3-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	526.1	2	1.36

420.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(piperidin-4-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	553.5	2	0.95
421.	mixture of isomers	(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(pyrrolidin-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	539.9	2	1.08
422.	mixture of isomers	(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(pyrrolidin-3-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	539.2	1	1.31

423.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-[(piperidin-4-yl)methyl]-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	567.6	2	1.05
424.		1-[4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)piperidin-1-yl]ethan-1-one	595.5	1	1.53
425.		3-[2-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)ethyl]-1,3-oxazolidin-2-one	583.4	1	1.45

426.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(piperidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	554.3	1	1.26
427.	mixture of isomers	benzyl 3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyrrolidine-1-carboxylate	674.15, 674.08	2	1.67, 1.72
428.	mixture of isomers	benzyl 3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyrrolidine-1-carboxylate	673.24, 673.26	1	1.86

429.	mixture of isomers	1-[3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyrrolidin-1-yl]ethan-1-one	581.6	2	1.2
430.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-1,2,3-benzotriazol-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	602.4	2	1.37
431.		(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-1,2,3-benzotriazol-6-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	601.2	2	1.6

432.		5-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3-dihydro-1,3-benzoxazol-2-one	603.1	1	1.61
433.	isomer 1	3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)cyclobutan-1-ol	540.1	2	1.19
434.	isomer 2	3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)cyclobutan-1-ol	540.4	2	1.29

435.	isomer 1	(1r,3r)-3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)cyclobutan-1-ol	541.0	3	0.66
436.	isomer 2	(1s,3s)-3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)cyclobutan-1-ol	541.0	3	0.65
437.	isomer 1	(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-{[(2R)-oxan-2-yl]methyl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	569.3	1	1.68

438.	isomer 2	(1R,4R,7R)-2-{2-[1-(cyclopropylmethyl)-6-{[(2R)-oxan-2-yl]methyl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	569.2	1	1.77
439.	isomer 1	methyl 3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)cyclobutane-1-carboxylate	583.4	2	1.49
440.	isomer 1	4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)cyclohexan-1-ol	569.3	2	1.26


441.	isomer 2	methyl (1s,3s)-3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)cyclobutane-1-carboxylate	583.4	2	1.51
442.	mixture of isomers	3-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methylcyclobutan-1-ol	555.2	2	1.23
443.		1-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-methylpropan-2-ol	542.4	1	1.48

444.	isomer 2	4-(2-{5-[(1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)cyclohexan-1-ol	568.2	2	1.4

Other examples with experimental details are shown below for Examples 445-448.


Example 445

((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone



Example 445

Step A: methyl 2-(6-acetyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate




Example 445A

A mixture of methyl 2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate (890 mg, 2.095 mmol) [for this starting material see: WO 2017/0100594)], 1-ethoxyvinyltri-n-butyltin (0.856 mL, 2.51 mmol), xantphos (364 mg, 0.628 mmol) and $Pd_2(dba)_3$ (192 mg, 0.209 mmol) in degassed dioxane (10 mL) under nitrogen was stirred at 100 °C for 18 hours. The mixture cooled to rt. A solution of 1.0 M aqueous HCl (2.095 mL, 2.095 mmol) was added and the mixture was stirred at RT for 1 hours. The mixture was diluted with EtOAc (15 mL) and was washed with a solution of aqueous saturated sodium bicarbonate (2 x 15 mL). The organic layer was dried over sodium sulfate and concentrated. The resulting residue was subjected to ISCO flash chromatography (silica gel/hexane-EtOAc 100:0 to 0:100 gradient) to yield methyl 2-(6-acetyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate

445A (850 mg, 1.769 mmol, 84 % yield) as light brown solid: LCMS (M+H) = 433.4, retention time = 1.06 min (Method 3).


Step B: methyl (E)-2-(1-(cyclopropylmethyl)-6-(1-(hydroxyimino)ethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate



Example 445B

A mixture of methyl 2-(6-acetyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate 445A (400 mg, 0.925 mmol), hydroxylamine hydrochloride (70.7 mg, 1.017 mmol) in MeOH (12 mL) was stirred at 60 °C for 3 hours (J. Med. Chem. 2012, 55, 3364). The mixture was concentrated. The mixture was diluted with EtOAc (15 mL) and was washed with a solution of aqueous saturated sodium bicarbonate (2 x 15 mL). The organic layer was dried over sodium sulfate and concentrated to give crude methyl (E)-2-(1-(cyclopropylmethyl)-6-(1-(hydroxyimino)ethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate 445B as off-white solid: LCMS (M+H) = 448.5, retention time = 0.95 min (Method 3), which was taken to next step.

Step C: methyl 2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate




Example 445C

To a solution of methyl (E)-2-(1-(cyclopropylmethyl)-6-(1-(hydroxyimino)ethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate 445B from above in DCM (5.0 mL) in a capped syringe tube at -78 °C under nitrogen was added 70% HF-pyridine (1310 mg, 9.25 mmol), the mixture was stirred at -78 °C for 15 min. A solution of tert-butyl nitrite (286 mg, 2.77 mmol) in DCM (5.0 mL) was added

dropwise to the mixture, the reaction was stirred at -78 °C for 30 min. and rt for 1 hour. The mixture was then added to sulfuric acid (1.0 mL) and ice water (200 g) and the mixture was stirred at rt for 30 min. The organic layer was collected and was washed with a solution of aqueous saturated sodium bicarbonate (35 mL). The organic layer was dried over sodium sulfate and concentrated. The resulting residue was subjected to ISCO flash chromatography (silica gel/hexane-EtOAc 100:0 to 50:50 gradient) to give methyl 2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate (92 mg, 0.192 mmol, 20.79 % yield) 445C as white solid: ^{1}H NMR (499 MHz, chloroform-d) δ 8.23 (d, *J*=1.2 Hz, 1H), 8.09 (d, *J*=8.1 Hz, 1H), 7.56 (d, *J*=8.1 Hz, 1H), 7.52 - 7.47 (m, 1H), 6.84 (s, 1H), 4.55 (d, *J*=7.2 Hz, 2H), 4.18 (s, 3H), 4.09 - 4.06 (m, 3H), 3.99 (s, 3H), 2.16 (t, *J*=18.5 Hz, 3H), 1.22 - 1.12 (m, 1H), 0.39 - 0.31 (m, 2H), 0.23 - 0.17 (m, 2H); LCMS (M+H) = 455.4, retention time = 1.09 min (Method 3).


Step D: 2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid



Example 445D

A mixture of methyl 2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylate 445C (102 mg, 0.224 mmol) and 2.0 M aqueous lithium hydroxide (561 µl, 1.122 mmol) in THF (5.0 mL) was stirred at 50 °C for 18 hours. A solution of 1.0 M aqueous HCl (1.20 mL) was added and the mixture was concentrated. The mixture was extracted with EtOAc (2 x 15 mL) and the ethyl acetate layer was dried over sodium sulfate and concentrated to give crude 2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid 445D (101 mg, 0.218 mmol, 97 % yield) as white solid: LCMS (M+H) = 441.4, retention time = 0.96 min (Method 3).

Example 445: ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone



Example 445


A mixture of 2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carboxylic acid 445D (20 mg, 0.045 mmol), tert-butyl ((3R,5R)-5-fluoropiperidin-3-yl)carbamate (9.91 mg, 0.045 mmol), BOP (22.09 mg, 0.050 mmol) and TEA (31.6 µl, 0.227 mmol) in DMF (1.0 mL) was stirred at rt for 2 hours. The mixture was diluted with EtOAc (5 mL) and was washed with a solution of aqueous saturated sodium bicarbonate (2 x 5 mL). The organic layer was dried over sodium sulfate and concentrated to give crude tert-butyl ((3R,5R)-1-(2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate: LCMS (M+H) = 641.6, retention time = 1.00 min (Method 3), which was taken to next step.

A mixture of tert-butyl ((3R,5R)-1-(2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate in DCM (1.0 mL) and TFA (1.0 mL) was stirred at rt for 30 min. The mixture was concentrated. The resulting residue was purified by prep-HPLC (Phenomenex, Luna 5 micron 30 x 250 mm, flow rate = 30 ml/min., gradient = 20% A to 100%B in 30 min., A =H2O/ ACN/TFA(90:10:0.1), B = H2O/ ACN/TFA(10:90:0.1)). The pure product fraction was loaded onto Strata-X-C 33 um cation mixed-mode polymer cartridge (0.30 g), the cartridge was washed with methanol (20 ml) and the product was eluted with 0.5 N NH_3 in methanol (5.0 mL). The NH_3 eluent was concentrated and the pure product was lyophilized with ACN/H2O (1:1, 10 mL) to yield ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone 445 (16.90 mg, 0.031 mmol, 67.5 % yield) as white powder: ^{1}H NMR (499 MHz, METHANOL-d_4) δ 8.22 (d, *J*=8.1 Hz, 1H), 7.55 (d, *J*=8.2

Hz, 1H), 7.44 (s, 1H), 7.05 (s, 1H), 7.02 - 6.95 (m, 1H), 4.82 - 4.64 (m, 1H), 4.48 (d, *J*=7.2 Hz, 2H), 4.06 (s, 7H), 3.43 - 3.35 (m, 2H), 3.26 - 3.06 (m, 1H), 3.01 - 2.53 (m, 1H), 2.45 - 2.28 (m, 1H), 2.12 (t, *J*=18.5 Hz, 3H), 1.72 - 1.50 (m, 1H), 1.05 - 0.97 (m, 1H), 0.38 - 0.30 (m, 2H), 0.14 - 0.04 (m, 2H); LCMS (M+H) = 541.5, retention time = 0.83 min (Method 3).


Example 446

((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(6-(1-cyclobutyl-1-hydroxyethyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone



Example 446

Step A: tert-butyl ((3R,5R)-1-(2-(6-acetyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate




Example 446A

tert-butyl ((3R,5R)-1-(2-(6-acetyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate was prepared using the procedure of example 445, step A, but starting with tert-butyl ((3R,5R)-1-(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate to give tert-butyl ((3R,5R)-1-(2-(6-acetyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-

fluoropiperidin-3-yl)carbamate 446A: LCMS (M+H) = 619.4, retention time = 0.89 min (Method 3).

Example 446: ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(6-(1-cyclobutyl-1-hydroxyethyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone



Example 446


To a solution of tert-butyl ((3R,5R)-1-(2-(6-acetyl-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate 446A (20 mg, 0.032 mmol) in THF (1.0 mL) was added a solution of 0.5 M cyclobutylmagnesium bromide in 2-methyltetrahydrofuran (194 µl, 0.097 mmol), the mixture was stirred at rt for 60 min. The mixture was added to a solution of 10% aqueous ammonium chloride solution (10 mL). The mixture was extracted with EtOAc (15 mL). The organic layer was dried over sodium sulfate and concentrated to give crude tert-butyl ((3R,5R)-1-(2-(6-(1-cyclobutyl-1-hydroxyethyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate: LCMS (M+H) = 675.4, retention time = 0.94 min (Method 3), which was taken to next step.

A mixture of tert-butyl ((3R,5R)-1-(2-(6-(1-cyclobutyl-1-hydroxyethyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate in DCM (1.0 mL) and TFA (0.40 mL) was stirred at rt for 30 min. The mixture was concentrated. The resulting residue was purified by prep-HPLC (Phenomenex, Luna 5 micron 30 x 250 mm, flow rate = 30 ml/min., gradient = 20% A to 100%B in 30 min., A =H2O/ ACN/TFA(90:10:0.1), B = H2O/ ACN/TFA(10:90:0.1)). The pure product fraction was loaded onto Strata-X-C 33 um cation mixed-mode polymer cartridge (0.30 g), the cartridge was washed with methanol (20 ml) and the product was then eluted with 0.5 N NH_3 in methanol (5.0 mL). The NH_3 eluent was concentrated and the product was lyophilized with ACN/H2O (1:1, 5

mL) to give ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(6-(1-cyclobutyl-1-hydroxyethyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone 446 (8.19 mg, 0.014 mmol, 41.9 % yield) as white powder: ^{1}H NMR (499 MHz, methanol-d$_4$) δ 8.08 (d, *J*=8.2 Hz, 1H), 7.41 (d, *J*=8.3 Hz, 2H), 6.99 - 6.95 (m, 2H), 4.83 - 4.63 (m, 1H), 4.48 (br s, 2H), 4.26 - 3.96 (m, 7H), 3.47 - 3.35 (m, 1H), 3.24 - 3.15 (m, 1H), 3.03 - 2.92 (m, 1H), 2.79 - 2.53 (m, 1H), 2.46 - 2.14 (m, 2H), 2.05 - 1.93 (m, 2H), 1.88 - 1.75 (m, 1H), 1.74 - 1.46 (m, 7H), 1.03 - 0.91 (m, 1H), 0.33 (br d, *J*=8.1 Hz, 2H), 0.07 (br d, *J*=4.1 Hz, 2H); LCMS (M+H) = 575.4, retention time = 0.91 min (Method 3).


Example 447

((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(1,3-difluoro-2-hydroxypropan-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone



Example 447

Step A: tert-butyl ((3R,5R)-1-(2-(1-(cyclopropylmethyl)-6-(1,3-difluoro-2-hydroxypropan-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate




Example 447A

To a solution of tert-butyl ((3R,5R)-1-(2-(6-bromo-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate (85 mg, 0.130 mmol) [made in a similar fashion to Intermediate 2 but starting with ethyl 6-bromo-1H-pyrrolo[2,3-b]pyridine-2-carboxylate]

in anhydrous ethyl ether (10 mL) and anhydrous THF (3.0 mL) under nitrogen at -78 °C was added a solution of 1.60 M n-butyllithium in hexane (203 µl, 0.324 mmol), the mixture was stirred at -78 °C for 30 min. 1,3-difluoropropan-2-one (14.63 mg, 0.156 mmol) was then added to the mixture at -78 °C, the mixture was stirred at -78 °C for 10 min and rt for 1 hours. The mixture was diluted with EtOAc (15 mL) and was washed with a solution of aqueous saturated sodium bicarbonate (2 x 15 mL). The organic layer was dried over sodium sulfate and concentrated. The resulting residue was subjected to ISCO flash chromatography (silica gel/hexane-5% MeOH/EtOAc 100:0 to 0:100 gradient) to give tert-butyl ((3R,5R)-1-(2-(1-(cyclopropylmethyl)-6-(1,3-difluoro-2-hydroxypropan-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate 447A (35 mg, 0.052 mmol, 40.2 % yield): LCMS (M+H) = 671.5, retention time = 0.86 min (Method 3).

Example 447: ((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(1,3-difluoro-2-hydroxypropan-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone




Example 447

A mixture of tert-butyl ((3R,5R)-1-(2-(1-(cyclopropylmethyl)-6-(1,3-difluoro-2-hydroxypropan-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazole-5-carbonyl)-5-fluoropiperidin-3-yl)carbamate 447A (35 mg, 0.052 mmol, 40.2 % yield) in DCM (1.0 mL) and TFA (1.0 mL) was stirred at rt for 30 min. The solution was concentrated and the resulting residue was purified by prep-HPLC (Phenomenex, Luna 5 micron 30 x 250 mm, flow rate = 30 ml/min., gradient = 20% A to 100%B in 30 min., A =H2O/ ACN/TFA(90:10:0.1), B = H2O/ ACN/TFA(10:90:0.1)). The pure product fraction was loaded onto Strata-X-C 33 um cation mixed-mode polymer cartridge (0.30 g), the cartridge was washed with methanol (20 ml) and then the product was eluted with 0.5 N NH_3 in methanol (5.0 mL). The product NH_3 eluent was concentrated and the product was lyophilized with ACN/H2O (1:1, 5 mL) to give

((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(1,3-difluoro-2-hydroxypropan-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone 447 (16.30 mg, 0.029 mmol, 22.03 % yield): ^{1}H NMR (500 MHz, DMSO-d_6) δ 7.97 (d, *J*=8.2 Hz, 1H), 7.36 (d, *J*=8.2 Hz, 1H), 7.13 (s, 1H), 6.87 (s, 1H), 6.66 (s, 1H), 4.92 - 4.48 (m, 6H), 4.44 - 4.17 (m, 3H), 4.01 - 3.62 (m, 6H), 2.79 - 2.43 (m, 2H), 2.04 - 1.88 (m, 1H), 1.47 - 1.16 (m, 1H), 1.08 - 0.87 (m, 2H), 0.19 - -0.10 (m, 4H); LCMS (M+H) = 571.3, retention time = 1.39 min (Method 2).

Example 448

2-(4-(2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenoxy)acetamide



Example 448

A mixture of of ((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(6-chloro-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone (1.5 g, 2.495 mmol), 4,4,4',4',5,5,5',5'-octamethyl-2,2'-bi(1,3,2-dioxaborolane) (0.760 g, 2.99 mmol), and potassium acetate (0.612 g, 6.24 mmol) in dioxane (12 ml) in a 2dr vial was sonicated and treated with 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (0.102 g, 0.125 mmol) and the vial was capped. This reaction mixture was made anaerobic by a pump / backfill with nitrogen cycle (5X). It was set to stir at 90 °C for 5 h and the starting material was found to be consumed. The reaction mixture was evaporated and dried in vacuo. The resulting brown solid was used or the next step. A portion of this material (45 mg, 0.047 mmol), 2-(4-bromophenoxy)acetamide (13.08 mg, 0.057 mmol), sodium carbonate, 2N in water (0.071 mL, 0.142 mmol) and 1,1'-bis(diphenylphosphino)ferrocene-palladium(II)dichloride dichloromethane complex (3.87 mg, 4.74 µmol) in DMF (1 mL). The vial was capped and the reaction mixture was made anaerobic by a pump / backfill with nitrogen cycle (5X). The reaction was stirred at 70

°C for overnight. After cooling to rt, the solution was diluted with DMF, filtered and purified via preparative LC/MS with the following conditions: Column: XBridge C18, 200 mm x 19 mm, 5-µm particles; Mobile Phase A: 5:95 acetonitrile: water with 0.1% trifluoroacetic acid; Mobile Phase B: 95:5 acetonitrile: water with 0.1% trifluoroacetic acid; Gradient: a 0-minute hold at 11% B, 11-51% B over 20 minutes, then a 4-minute hold at 100% B; Flow Rate: 20 mL/min; Column Temperature: 25 C. Fraction collection was triggered by product MS signals. Fractions containing the desired product were combined and dried via centrifugal evaporation. The purified product was then diluted with DMF, treated with Si-Pyridine resin and shaken for a minimum of 2 h. The resulting mixture was filtered and dried via centrifugal evaporation to give 2-(4-(2-(5-((1R,4R,7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenoxy)acetamide 448 (20.6 mg): ^{1}H NMR (500 MHz, DMSO-d_6) δ 8.17 - 8.13 (m, 3H), 7.95 - 7.92 (m, 1H), 7.78 - 7.74 (m, 1H), 7.62 - 7.53 (m, 2H), 7.44 - 7.40 (m, 1H), 7.11 - 7.08 (m, 2H), 7.08 - 7.06 (m, 1H), 7.02 - 6.94 (m, 1H), 4.57 - 4.52 (m, 2H), 4.52 - 4.50 (m, 2H), 4.18 - 4.12 (m, 3H), 4.03 - 3.95 (m, 3H), 3.83 - 3.71 (m, 1H), 3.66 - 3.54 (m, 1H), 3.53 - 3.44 (m, 1H), 3.22 - 3.15 (m, 1H), 2.69 - 2.57 (m, 1H), 2.02 - 1.85 (m, 3H), 1.74 - 1.59 (m, 1H), 1.28 - 1.11 (m, 2H), 0.35 - 0.29 (m, 2H), 0.20 (br s, 2H); LCMS (M+H) = 620.0, retention time = 1.58 min (Method 1).

From the methods above, the following compounds were synthesized.

#	Structure	Name	Obs. MS Ion	HPLC Method ID	RT
449.		2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)propan-2-ol	528.1	2	1.31
450.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinazolin-4-ol	614.2	2	1.2

451.		methyl 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1H-pyrrolo[2,3-b]pyridine-3-carboxylate	644.2	1	1.62
452.		6-(2-(5-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-indol-6-yl)-1-methyl-1H-benzo[c][1,2]thiazin-4(3H)-one 2,2-dioxide	679	1	1.76

453.		7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)isoquinolin-2-ium-2-olate	613.1	1	1.43
454.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,3-difluoro-2,3-dihydro-1H-indol-2-one	638.3	2	1.51

455.		6-(2-(5-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methyl-1H-benzo[c][1,2]thiazin-4(3H)-one 2,2-dioxide	680.4	1	1.79
456.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)cinnolin-4-ol	615.1	1	1.41

457.		7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoquinolin-2-ium-2-olate	614.4	2	1.21
458.		S-[3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-2-hydroxyethane-1-sulfonamido	670.1	2	1.39

459.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorobenzamide	624.3	2	1.33
460.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzamide	608.2	2	1.29

461.		4-[(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-2-methoxyphenol	608.1	2	1.21
462.		7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinazolin-4-ol	615	2	1.29

463.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7-methoxy-1,2,3,4-tetrahydroquinolin-2-one	646.4	1	1.53
464.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7-hydroxy-1,2,3,4-tetrahydroquinolin-2-one	632.4	2	1.37

465.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydroquinolin-2-one	614	1	1.56
466.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzene-1-sulfonamide	626.4	1	1.49

467.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3-dihydro-1H-isoindol-1-one	606.9	1	1.62
468.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3-dihydro-1H-isoindol-1-one	601.5	2	1.3

469.		6-(2-{5-[(2S,5R)-5-amino-2-methylpiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one	604.4	1	1.44
470.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-fluoro-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one	590.4	2	1.33

471.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one	608.2	2	1.43
472.		ethyl 7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-hydroxyquinoline-3-carboxylate	685.2	2	1.45

473.		7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinolin-4-ol	613.3	1	1.4
474.		7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinolin-4-ol	614.1	1	1.35

475.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,8-naphthyridin-2-ol	614.3	2	1.3
476.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,8-naphthyridin-2-ol	615.4	2	1.19

477.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinoline-2-carboxamide	641.5	2	1.43
478.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-hydroxyquinoline-2-carboxylic acid	657.2	1	1.14

479.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxyquinoline-2-carboxylic acid	658.4	2	1.14
480.		((7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-hydroxyquinolin-7-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-(methyl-d3)-1H-benzo[d]imidazol-5-yl)methanone	617.4	2	1.15

481.		5-(2-(5-(((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-(methyl-d3)-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)indolin-2-one	605.2	2	1.24
482.		6-(2-(5-(((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-(methyl-d3)-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoindolin-1-one	605.4	2	1.24

483.		5-(2-(5-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-(methyl-d3)-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinolin-2(1H)-one	617.4	1	1.55
484.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-5H,6H,7H-pyrrolo[3,4-b]pyridin-5-one	602.3	2	1.11

485.		methyl (5-(2-(5-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-(methyl-d3)-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl)carbamate	624.1	1	1.72
486.		methyl (4-(2-(5-((7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl)-7-methoxy-1-(methyl-d3)-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl)carbamate	623.4	1	1.81

487.		methyl 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-pyrrole-2-carboxylate	594.2	2	1.67
488.		methyl N-[6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-3-yl]carbamate	621.4	1	1.55

489.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-hydroxy-3-methyl-2,3-dihydro-1H-indol-2-one	632.4	2	1.2
490.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxyquinoline-3-carbonitrile	639.2	1	1.48

491.		ethyl 6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-hydroxyquinoline-3-carboxylate	685.4	2	1.3
492.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-hydroxyquinoline-3-carbonitrile	638.2	1	1.54

493.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoquinolin-1-ol	614.2	1	1.57
494.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-(2-hydroxy-2-methylpropyl)-1,2-dihydroquinolin-2-one	686.3	2	1.43

495.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)isoquinolin-1-ol	613.3	1	1.65
496.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1-(2-hydroxy-2-methylpropyl)-1,2-dihydroquinolin-2-one	685.2	1	1.75

497.		1-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-fluoro-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)ethan-1-ol (mixture of diastereomers)	503.3	1	1.44
498.		2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluorobenzamide	608.4	1	1.33

499.		2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluorobenzamide	608.4	1	1.43
500.		2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-fluoro-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)butan-2-ol (mixture of diastereomers)	531.4	1	1.55

501.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenol	587.4	1	1.64
502.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroisoquinolin-1-one	622.3	1	1.66

503.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5H,6H,7H-pyrrolo[3,4-b]pyridin-7-one	603.4	2	1.1
504.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H,2H,3H-pyrrolo[3,2-b]pyridin-2-one	603.1	1	1.45

505.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7-fluoro-2,3-dihydro-1H-isoindol-1-one	620.2	1	1.57
506.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-5H,6H,7H-pyrrolo[3,4-b]pyridin-7-one	602.2	1	1.41

507.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-7-fluoro-2,3-dihydro-1H-isoindol-1-one	619.4	2	1.28
508.		1-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-fluoro-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-cyclopropylethan-1-ol (mixture of diastereomers)	543.4	2	1.55

509.		1-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-fluoro-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-phenylethan-1-ol (mixture of diastereomers)	579.4	2	1.62
510.		7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroisoquinolin-3-one	616.2	1	1.56

511.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinazolin-2-one	616.9	1	1.5
512.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7-fluoro-1,2,3,4-tetrahydroquinolin-2-one	634.2	2	1.47

513.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydroquinazolin-2-one	616.2	1	1.67
514.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-7-fluoro-1,2,3,4-tetrahydroquinolin-2-one	633.2	2	1.44

515.		methyl 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzoate	623.4	2	1.78
516.		methyl 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-difluorobenzoate	640.9	1	2.12

517.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-7-methoxy-1,2,3,4-tetrahydroquinolin-2-one	645	2	1.42
518.		2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-6-fluorobenzamide	607.3	1	1.41

519.		2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-5-fluorobenzamide	607	1	1.61
520.		methyl 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorobenzoate	622.2	2	1.79

521.		methyl 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,6-difluorobenzoate	640.4	2	1.75
522.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluoro-2,3-dihydro-1H-indol-2-one	620.1	1	1.74

523.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-dihydro-1H-3,1-benzoxazin-2-one	618.4	2	1.31
524.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-difluorobenzene-1-sulfonamide	662.2	1	1.68

525.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-difluorophenol	599.2	2	1.54
526.		2'-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1'-(cyclopropylmethyl)-6-fluoro-2,3-dihydro-1H,1'H-[5,6'-biindole]-2-one	619.2	2	1.38

527.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,4-dihydro-1H-3,1-benzoxazin-2-one	617.3	1	1.75
528.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,4-difluorobenzene-1-sulfonamide	661.1	1	1.79

529.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,6-difluorophenol	598.2	1	1.82
530.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methoxyphenol	611.2	2	1.45

531.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-5-fluoro-2-methoxyphenol	610.2	2	1.42
532.		1-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-[(1-methyl-1H-pyrazol-4-yl)methyl]-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)ethan-1-ol (mixture of diastereomers)	594.2	1	1.38

533.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-ethyl-1H-indol-2-yl]-7-methoxy-1-[(1-methyl-1H-pyrazol-4-yl)methyl]-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	578.1	2	1.63
534.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-(2-hydroxyethyl)benzamide	640.4	2	1.25

535.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzamide	596.4	1	1.58
536.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-methylbenzene-1-sulfonamide	646.4	2	1.48

537.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methyl-1,2-dihydroquinolin-2-one	634.4	2	1.37
538.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,3-dihydro-2-benzofuran-1-one	609.3	1	1.83

539.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-fluoro-2,3-dihydro-1H-indol-2-one	620.1	1	1.61
540.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-fluoro-2,3-dihydro-1H-indol-2-one	626.4	2	1.39

541.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluoro-2,3-dihydro-1H-indol-2-one	626.4	2	1.39
542.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H,2H,3H-pyrrolo[2,3-b]pyridin-2-one	609.4	2	1.29

543.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-dihydro-1H-3,1-benzoxazin-2-one	624.4	1	1.66
544.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5H,6H,7H-pyrrolo[3,4-b]pyridin-5-one	609.4	1	1.45

545.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-difluorobenzene-1-sulfonamide	668.2	1	1.75
546.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7-hydroxy-1,2,3,4-tetrahydroquinolin-2-one	638.5	2	1.4

547.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,5-difluorophenol	605.3	1	1.88
548.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methoxyethyl)-1H-indol-2-yl]-7-methoxy-1-[(1-methyl-1H-pyrazol-4-yl)methyl]-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (mixture of diastereomers)	608.4	2	1.4

549.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-hydroxybenzamide	612.2	1	1.67
550.		7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinolin-4-ol	620	2	1.18

551.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydroquinazolin-2-one	621.4	2	1.4
552.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,8-naphthyridin-2-ol	621.2	2	1.22

553.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinolin-2-ol	620.1	1	1.65
554.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinoline-2,4-diol	636.4	1	1.45

555.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylquinolin-4-ol	634.2	1	1.55
556.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoquinolin-1-ol	620.3	1	1.62

557.		methyl 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-hydroxybenzoate	627	1	2.17
558.		methyl 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-hydroxybenzoate	621.2	1	2.19

559.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylquinolin-4-ol	628.2	1	1.53
560.		5-(2-{5-[(3S,4R)-3-amino-4-hydroxypiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one	606.2	2	1.35

561.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinolin-1-ium-1-olate	620.4	1	1.39
562.		7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoquinolin-2-ium-2-olate	620.1	1	1.57

563.		7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinazolin-4-ol	621.2	2	1.22
564.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinoxalin-2-ol	621.4	2	1.26

565.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydroisoquinolin-1-one	620.2	2	1.47
566.		methyl 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-methyl-1H-pyrazole-3-carboxylate	609.1	2	1.14

567.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzamide	614.4	1	1.44
568.		methyl 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzoate	629.1	2	1.83

569.		ethyl 2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenoxy]acetate	655.2	2	1.68
570.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H,2H,3H-imidazo[4,5-b]pyridin-2-one	610.3	1	1.21

571.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-8-fluoro-1,2-dihydroquinolin-2-one	638.1	1	1.58
572.		7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione	637.1	1	1.49

573.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7-methoxy-1,2,3,4-tetrahydroquinolin-2-one	652.2	1	1.54
574.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxybenzamide	626.5	1	1.37

575.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroisoquinolin-1-one	622.2	1	1.56
576.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7-fluoro-2,3-dihydro-1H-indol-2-one	626.4	2	1.38

577.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinazoline-2,4-dione	637.5	1	1.29
578.		methyl 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-methyl-1H-pyrazole-3-carboxylate	615.1	2	1.3

579.		methyl 2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-6-carboxylate	535.4	2	1.4
580.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)cyclobutan-1-ol (mixture of diastereomers)	547.4	2	1.2

581.		(3R,5R)-1-{2-[6-(azetidin-3-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	532.5	1	1.02
582.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{2H,3H,4H-pyrido[3,2-b][1,4]oxazin-7-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	611.4	1	1.5

583.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-{2H,3H,4H-pyrido[3,2-b][1,4]oxazin-7-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	605.5	1	1.52
584.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyrimidine-2-carbonitrile	580.4	2	1.56

585.		N-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylpyridin-4-amine	583.4	1	1.21
586.		6-[(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)amino]-2,3-dihydro-1H-isoindol-1-one	623.4	1	1.35

587.		6-amino-2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one	623.5	1	1.5
588.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenol	599.3	1	1.65

589.		7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-fluoro-2,3-dihydro-1H-indol-2-one	620.4	2	1.62
590.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-(trifluoromethyl)-2,3-dihydro-1H-1,3-benzodiazol-2-one	677.1	1	2.03

591.		8-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluoro-3-methyl-1,2-dihydroquinoxalin-2-one	653.2	1	1.87
592.		1-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenoxy]-2-methylpropan-2-ol	653.5	2	1.61

593.		2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-N-(4-carbamoyl-3-fluorophenyl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide	657.4	1	1.52
594.		2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-(2,6-dioxopiperidin-3-yl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide	631.4	1	1.27

595.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-{4-[(pyridin-4-yl)methoxy]phenyl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	654.4	1	1.94
596.		2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenoxy]ethan-1-ol	607.5	1	1.64

597.		N-[2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methanesulfonamide	640	1	1.91
598.		2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenoxy]ethan-1-ol	613.4	2	1.47

599.		N-[2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]formamide	596.2	2	1.62
600.		2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-(4-sulfamoylphenyl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide	675	1	1.57

601.		2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-(4-hydroxy-3-methoxyphenyl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide	642.5	1	1.52
602.		2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-[3-(hydroxymethyl)pyridin-4-yl]-1H-pyrrolo[2,3-b]pyridine-6-carboxamide	627.4	1	1.46

603.		2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-(3-sulfamoylphenyl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide	675.2	1	1.5
604.		2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-(2-methylpyridin-4-yl)-1H-pyrrolo[2,3-b]pyridine-6-carboxamide	611.4	1	1.58

605.		7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluoro-2,3-dihydro-1H-indol-2-one	620.5	1	1.83
606.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzene-1-sulfonamide	644.4	1	1.58

607.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluorobenzene-1-sulfonamide	644.4	2	1.41
608.		7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluoro-2,3-dihydro-1H-indol-2-one	626.2	2	1.57

609.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzene-1-sulfonamide	650.4	1	1.56
610.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluorobenzene-1-sulfonamide	650.4	2	1.41

611.		2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N-[3-(hydroxymethyl)pyridin-4-yl]-1H-pyrrolo[2,3-b]pyridine-6-carboxamide	627.2	2	0.98
612.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-(1,2-oxazol-5-yl)phenol	630.4	1	1.43

613.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-methylpyridin-3-ol	578.1	1	1.57
614.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-(1,2-oxazol-5-yl)phenol	636.2	1	1.44

615.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-methylpyridin-3-ol	584	2	1.19
616.		3-[2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)ethyl]-1,3-oxazolidin-2-one	590	2	1.26

617.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[(oxan-2-yl)methyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	575.02	2
618.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[2-(piperidin-4-yl)ethyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	588.5	1

619.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)cyclohexan-1-ol (mixture of diastereomers)	575.46	1
620.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-8-fluoro-1,2,3,4-tetrahydroquinolin-2-one	640.2	1

621.		2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenoxy]acetamide	626.2	1	1.53
622.		methyl 2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methoxyphenoxy]acetate	689.2	1	1.97

623.	2-[6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-3-yl]acetamide	611.3	1	1.37
624.	2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]-2-hydroxyacetamide (mixture of diastereomers)	644.2	2	1.12

625.		2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]acetamide	628.2	2	1.37
626.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,5-difluorobenzamide	632.1	1	1.7

627.		2-[6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-3-yl]acetamide	605.2	1	1.38
628.		2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]-2-hydroxyacetamide (mixture of diastereomers)	638.3	2	1.1

629.		2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]acetamide	622.2	1	1.6
630.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,5-difluorobenzamide	626.4	2	1.3

631.		7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroisoquinolin-1-one	621.9	1	1.68
632.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(3,5-dimethyl-1,2-oxazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	572.2	1	1.72

633.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{4-[(5-methyl-1,3,4-oxadiazol-2-yl)methoxy]phenyl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	665.1	1	1.68
634.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-{4-[(5-methyl-1,3,4-oxadiazol-2-yl)methoxy]phenyl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	659.2	2	1.48

635.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-one	623.3	3	0.68
636.		7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-3-one	625.2	2	1.4

637.		7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one	625.1	2	1.35
638.		7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one	624.2	1	1.58

639.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one	624.1	2	1.45
640.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(6-methanesulfonylpyridin-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	632.2	2	1.35

641.		7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-3-one	619.2	1	1.58
642.		7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H,2H,3H-pyrido[2,3-b][1,4]oxazin-2-one	619.3	1	1.37

643.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one	618.2	1	1.64
644.		4-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]azetidin-2-one	622.2	1	1.76

645.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluoropyridine-2-carboxamide	615.1	1	1.46
646.		[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1-benzofuran-2-yl]methanol	625.2	2	1.53

647.		3-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-4,5-dihydro-1,2,4-oxadiazol-5-one	637.1	2	1.59
648.		4-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]azetidin-2-one	616	2	1.45

649.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluoropyridine-2-carboxamide	609.2	2	1.34
650.		[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1-benzofuran-2-yl]methanol	619.2	2	1.5

651.		3-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-4,5-dihydro-1,2,4-oxadiazol-5-one	631.4	2	3.43
652.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-{4-[(1,3-oxazol-2-yl)methoxy]phenyl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	1287.4	1	1.93

653.		methyl 2-{2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenoxy]acetamido}acetate	692.2	2	1.52
654.		methyl (2E)-3-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]prop-2-enoate	637.2	1	2

655.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{4-[(1,3-oxazol-2-yl)methoxy]phenyl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	650.1	1	1.9
656.		N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]acetamide	306	2	1.32

657.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(2,3-dihydro-1-benzofuran-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	595.2	1	2.05
658.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-2-carboxamide	596.9	2	1.32

659.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,3-dihydro-2-benzofuran-1-one	608.9	2	1.52
660.		2-methoxyethyl N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]carbamate	336.3	1	1.71

661.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(2,3-dihydro-1-benzofuran-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	595.2	1	1.97
662.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(2,3-dihydro-1,4-benzodioxin-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	611.2	2	1.68

663.		3-[3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]propanoic acid	619.2	1	1.44
664.		ethyl 2-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]acetate	640.2	2	1.42

665.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-3-ol	570.1	1	1.42
666.		[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]methanol	584.2	1	1.41

667.		[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methoxyphenyl]methanol	631.2	2	1.6
668.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1-benzofuran-3-one	603.2	1	1.85

669.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoropyridin-3-ol	582.2	2	1.43
670.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoropyridin-3-ol	582.2	2	1.49

671.		1-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]pyrrolidin-2-one	316	2	1.48
672.		[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methoxyphenyl]methanol	625.2	2	1.56

673.		[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,5-difluorophenyl]methanol	613.2	1	1.6
674.		[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]methanol	595.2	2	1.52

675.		[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,5-difluorophenyl]methanol	619.2	1	1.65
676.		[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]methanol	601.2	1	1.69

677.		2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenoxy]-N-(cyanomethyl)acetamide	665.2	2	1.51
678.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N,N-dimethylpyridine-2-carboxamide	625.2	2	1.27

679.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2H,3H-[1,3]oxazolo[4,5-b]pyridin-2-one	611.2	1	1.43
680.		[2-amino-5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-3-yl]methanol	599.2	1	1.24

681.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxypyridin-3-ol	600.1	2	1.35
682.		[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methanesulfonamide	646.1	2	1.42

683.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{2H,3H,4H-pyrido[3,2-b][1,4]oxazin-6-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	611.2	2	1.34
684.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluoropyridin-3-ol	588.1	1	1.6

685.		[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluoropyridin-2-yl]methanol	602.1	2	1.24
686.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2H,3H-[1,3]oxazolo[4,5-b]pyridin-2-one	605.2	1	1.45

687.		[2-amino-5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-3-yl]methanol	593.3	1	1.27
688.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxypyridin-3-ol	594.2	1	1.55

689.		[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methanesulfonamide	640.1	2	1.26
690.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluoropyridin-3-ol	582	1	1.51

691.		[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluoropyridin-2-yl]methanol	596.2	1	1.59
692.		1-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-methoxypyridin-2-yl]pyrrolidin-2-one	667.1	1	1.93

693.		1-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]-3-hydroxypyrrolidin-2-one (mixture of diastereomers)	653.3	1	1.42
694.		1-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylpyridin-2-yl]-3-hydroxypyrrolidin-2-one (mixture of diastereomers)	667.1	1	1.35

695.		1-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-3-hydroxypiperidin-2-one (mixture of diastereomers)	666	2	1.51
696.		1-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]imidazolidin-2-one	637.3	2	1.36

697.		1-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]pyrrolidin-2-one	636	2	1.64
698.		1-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-methoxypyridin-2-yl]pyrrolidin-2-one	661.1	2	1.68

699.		1-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]-3-hydroxypyrrolidin-2-one (mixture of diastereomers)	647.1	1	1.45
700.		1-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylpyridin-2-yl]-3-hydroxypyrrolidin-2-one (mixture of diastereomers)	661.2	2	1.2

701.		1-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-3-hydroxypiperidin-2-one (mixture of diastereomers)	660.4	1	1.48
702.		1-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]imidazolidin-2-one	631.2	2	1.33

703.		1-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]pyrrolidin-2-one	630.2	2	1.6
704.		2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-hydroxybenzonitrile	594.2	2	1.5

705.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxybenzonitrile	594.3	1	1.79
706.		2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-hydroxybenzonitrile	588.3	1	1.55

707.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-hydroxybenzonitrile	588.1	2	1.7
708.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenol	599.3	1	1.62

709.		2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzonitrile	578.1	2	1.72
710.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzonitrile	596	1	1.86

711.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-fluorophenol	587.1	2	1.5
712.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-methylpyridine-2-carboxamide	611.1	1	1.49

713.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-difluorophenol	605.2	1	1.74
714.		1-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]-3-hydroxypiperidin-2-one (mixture of diastereomers)	684.3	2	1.41

715.		4-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-2,3-dihydro-1H-imidazol-2-one	635.4	2	1.22
716.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzonitrile	572.2	1	2.04

717.		2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzonitrile	572.4	1	1.9
718.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenol	593.2	1	1.76

719.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzonitrile	590.2	1	1.9
720.		2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluoropyridin-4-ol	582.1	1	1.11

721.		1-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]-3-hydroxypiperidin-2-one (mixture of diastereomers)	678.3	2	1.49
722.		(7R)-2-{2-[6-(6-amino-5-methoxypyridin-3-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	593.3	1	1.58

723.		4-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-2,3-dihydro-1H-imidazol-2-one	629.2	2	1.21
724.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-fluorophenol	293.9	2	1.53

725.		((3R,5R)-3-amino-5-fluoropiperidin-1-yl)(2-(1-(cyclopropylmethyl)-6-(4-(1,1-dioxidoisothiazolidin-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone	672.3	1	1.56
726.		5-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-5-methylimidazolidine-2,4-dione	665	2	1.38

727.		7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2,5-dione	651.1	2	1.18
728.		((7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(4-(1,1-dioxidoisothiazolidin-2-yl)phenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone	666.2	1	1.67

729.		5-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-5-methylimidazolidine-2,4-dione (mixture of diastereomers)	659	1	1.53
730.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methoxy-1,2-dihydropyridin-2-one	594.2	2	1.2

731.		7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2,5-dione	645.2	2	1.24
732.		7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)quinolin-2-ol	620.18	2	1.34

733.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[4-(methanesulfonylmethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	645.2	2	1.52
734.		2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-4-ol	570.2	2	1.09

735.		N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]-2,2-dimethylpropanamide	653.4	1	1.86
736.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydropyridin-2-one	570.1	2	1.18

737.		N-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]cyclopropanesulfonamide	672.2	2	1.58
738.		N-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-2,2-dimethylpropanamide	646	2	1.69

739.		N-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]-2,2-dimethylpropanamide	647	1	2.02
740.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydropyridin-2-one	564.2	1	1.21

741.		N-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]cyclopropanesulfonamide	666	1	1.82
742.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)isoquinolin-3-ol	614.2	1	1.47

743.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[4-(methanesulfonylmethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	639.2	2	1.45
744.		2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-4-ol	564	1	1.27

745.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2-dihydropyridin-2-one	564.2	1	1.44
746.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorophenol	586.4	2	1.58

747.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-fluorophenol	586.2	2	1.47
748.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-methoxyphenol	598	1	1.65

749.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,5-difluorophenol	604.2	1	1.75
750.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-N-(2-hydroxyethyl)benzamide	639.2	1	1.45

751.		N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)pyridin-2-yl]acetamide	610.2	1	1.56
752.		2'-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1'-(cyclopropylmethyl)-2,3-dihydro-1H,1'H-[5,6'-biindole]-2-one	607	2	1.38

753.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1H,2H,3H-pyrrolo[2,3-b]pyridin-2-one	608.1	1	1.53
754.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1-methyl-1,2-dihydropyridin-2-one	582.9	1	1.41

755.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methyl-1,2-dihydropyridin-2-one	584.2	2	1.31
756.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenol	603.2	1	1.7

757.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenol	583	1	1.7
758.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenol	599.2	1	1.68

759.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,4-dimethyl-1,2-dihydropyridin-2-one	597.9	2	1.32
760.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenol	597.4	1	1.72

761.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenol	593.2	1	1.6
762.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,4-dimethyl-1,2-dihydropyridin-2-one	592	1	1.33

763.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzene-1,3-diol	578.9	1	1.47
764.		1-[6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylpyridin-3-yl]-3-hydroxypyrrolidin-2-one	661.3	1	1.51

765.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)benzene-1,3-diol	585.2	1	1.42
766.		1-[6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylpyridin-3-yl]-3-hydroxypyrrolidin-2-one	667.2	1	1.37

767.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{2H,3H,4H-pyrido[3,2-b][1,4]oxazin-7-yl}-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	610	2	1.23
768.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-5H,6H,7H-pyrrolo[3,4-b]pyridin-5-one	608.1	1	1.47

769.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1H,2H,3H-imidazo[4,5-b]pyridin-2-one	608.9	2	1.19
770.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinolin-1-ium-1-olate	619.2	1	1.49

771.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2,3,4-tetrahydro-1,8-naphthyridin-2-one	622.2	2	1.35
772.		7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)isoquinolin-2-ium-2-olate	619.2	1	1.47

773.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)cinnolin-4-ol	620	1	1.38
774.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-4-hydroxyquinoline-3-carboxylic acid	663.2	2	1.41

775.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinolin-2-ol	619.2	1	1.55
776.		7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2H,3H,4H-pyrido[3,2-b][1,4]oxazin-3-one	624	2	1.41

777.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(1-methanesulfonylpiperidin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	638.2	2	1.53
778.		7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3,4,5-tetrahydro-1H-1,4-benzodiazepine-2,5-dione	649.9	1	1.38

779.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-hydroxybenzamide	611.2	1	1.45
780.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(6-methanesulfonylpyridin-3-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	631.2	1	1.6

781.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,4-difluorobenzene-1-sulfonamide	667.2	1	1.66
782.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-8-fluoro-4-hydroxyquinoline-3-carboxylic acid	680.92	2	1.47

783.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,2-dihydropyridin-2-one	569.2	2	1.2
784.		N-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)phenyl]methanesulfonamide	645.2	1	1.65

785.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-N,N-dimethylpyridine-2-carboxamide	624.2	2	1.3
786.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-N-methylpyridine-2-carboxamide	610.2	1	1.61

787.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-3-carbonitrile	573	2	1.53
788.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-2-carbonitrile	573.2	1	1.79

789.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[4-(morpholine-4-sulfonyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	696.2	1	1.82
790.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-(hydroxymethyl)benzonitrile	608.2	2	1.54

791.		N-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methoxyphenyl]methanesulfonamide	676.4	2	1.46
792.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-8-fluoro-4-hydroxyquinoline-3-carboxylic acid	676.2	2	1.48

793.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-(hydroxymethyl)benzonitrile	601.9	1	1.67
794.		N-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methoxyphenyl]methanesulfonamide	670.2	2	1.44

795.		2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluoro-1,2,3,4-tetrahydroisoquinolin-1-one	640	2	1.73
796.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-fluoro-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)quinazoline-2,4-diol	625.4	2	1.26

797.		6-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-fluoro-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3-dihydro-1H-isoindol-1-one	596.2	1	1.52
798.		methyl 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-cyclopropaneamidopyridine-4-carboxylate	689.2	1	1.64

799.		N-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-chloropyridin-2-yl]acetamide	639.1	1	1.73
800.		[2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-4-yl]methanol	578.2	1	1.52

801.	[6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-3-yl]methanol	578	2	1.08
802.	(7R)-2-{2-[1-(cyclopropylmethyl)-6-{[1,2,3,4]tetrazolo[1,5-a]pyridin-6-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	589.2	1	1.54

803.		methyl 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-cyclopropaneamidopyridine-4-carboxylate	695.2	1	1.71
804.		N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-chloropyridin-2-yl]acetamide	645.2	2	1.52

805.		[3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,5-difluorophenyl]methanol	619	1	1.61
806.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{[1,2,3,4]tetrazolo[1,5-a]pyridin-6-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	595	2	1.44

807.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-(2-methoxy-3-methylpyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	592.1	2	1.74
808.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-dimethylphenol	591.2	1	1.7

809.		[3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenyl]urea	619.1	2	1.38
810.		N-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-hydroxypyridin-2-yl]acetamide	621.2	1	1.58

811.		N-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-(hydroxymethyl)pyridin-2-yl]acetamide	635.2	1	1.6
812.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(2-methoxy-3-methylpyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	598.1	1	1.9

813.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-dimethylphenol	597.2	1	1.68
814.		[3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenyl]urea	625.2	1	1.43

815.		2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2H-indazol-5-ol	603.2	1	1.67
816.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-chloro-2-methylphenol	611.2	1	1.93

817.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-oxo-1,2-dihydropyridine-3-carbonitrile	589.2	1	1.45
818.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-{[1,2,3,4]tetrazolo[1,5-a]pyridin-7-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	588.9	1	1.63

819.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-chloro-2-methylphenol	616.9	1	1.9
820.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{[1,2,3,4]tetrazolo[1,5-a]pyridin-7-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	595.2	1	1.6

821.		5-(2-{5-[(6S,7R)-7-amino-6-hydroxy-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-indol-2-one	618.4	2	1.25
822.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-4-fluorophenol	615.2	1	1.64

823.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-4-fluorophenol	621.4	1	1.62
824.		1-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)azetidin-3-ol	542.1	1	1.34

825.		7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,7-diazaspiro[3.5]nonan-2-one	609.3	2	1
826.		2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]ethan-1-ol	591	1	1.68

827.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-(2,3-dimethoxypyridin-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	608	2	1.64
828.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-(3-fluoro-4-methanesulfonylphenyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	643.1	2	1.45

829.		7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,7-diazaspiro[3.5]nonan-1-one	609.2	1	1.12
830.		((7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-(1,1-dioxidothiomorpholino)azetidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone	659.4	1	1.58

831.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-(3-methoxyazetidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	556.2	2	1.37
832.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-{2-oxa-6-azaspiro[3.3]heptan-6-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	568.1	1	1.51

833.		7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-hydroxy-4H-pyrido[1,2-a]pyrimidin-4-one	630.9	1	1.3
834.		8-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,4-dihydro-2H-1,4-benzoxazin-3-one	618	1	1.58

835.		8-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one	625.3	1	1.13
836.		1-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-(2-hydroxyethyl)piperidine-4-carboxamide	641	1	1.28

837.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-(4-methanesulfonylpiperidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	632.2	2	1.32
838.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-{[1,2,4]triazolo[1,5-a]pyridin-6-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	588	2	1.4

839.		1-[1-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl]pyrrolidin-2-one	319.1	2	1.4
840.		N-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-2-methoxyacetamide	640	1	1.71

841.		N-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-2-methoxyacetamide	634.3	1	1.64
842.		1-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroquinolin-1-yl]ethan-1-one	644.1	2	1.62

843.		(3R,5R)-1-{2-[6-(1,2,4-benzotriazin-6-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	606.3	1	1.66
844.		(3R,5R)-1-{2-[6-(1,3-benzoxazol-4-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	594.1	2	1.71

845.		(7R)-2-{2-[6-(1,2,4-benzotriazin-6-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	600.1	1	1.69
846.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylphenol	583.1	1	1.6

847.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylphenol	577.1	1	1.83
848.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenol	577	2	1.71

849.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-4-fluorophenol	620.9	1	1.99
850.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-4-fluorophenol	615.3	2	1.71

851.		[1-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyrrolidin-3-yl]methanol (mixture of diastereomers)	570.9	1	1.63
852.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-{4H,5H,6H,7H-pyrazolo[1,5-a]pyridin-3-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	591	2	1.39

853.		ethyl 2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-pyrazol-1-yl]acetate	623.1	1	1.69
854.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-chlorophenol	603.3	1	1.78

855.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-chlorophenol	603.1	2	1.65
856.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-chlorophenol	597.4	1	1.83

857.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-chloro-4-fluorophenol	620.4	1	1.77
858.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-{[1,2,4]triazolo[4,3-a]pyridin-7-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	588.4	2	1.19

859.		2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-hydroxybenzonitrile	594.1	1	1.56
860.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-6-methylphenol	611.1	2	1.73

861.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-ethylphenol	591	2	1.65
862.		ethyl 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,3-dimethyl-1H-pyrazole-5-carboxylate	637.1	2	1.61

863.		1-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H-pyrazol-1-yl]-2-methylpropan-2-ol	609.2	1	1.54
864.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[3-(methoxymethyl)azetidin-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2azabicyclo[2.2.1]heptan-7-amine	570.1	1	1.86

865.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[3-(pyridin-3-yl)azetidin-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	603.1	2	1.15
866.		1-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N,N-dimethylazetidine-3-carboxamide	597.2	1	1.59

867.		((7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(1,1-dioxido-1-thia-6-azaspiro[3.3]heptan-6-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone	616	2	1.35
868.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-(3-methanesulfonylazetidin-1-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	604.1	1	1.51

869.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-{6-oxa-2-azaspiro[3.4]octan-2-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	582	2	1.43
870.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-5-methylphenol	617	1	1.83

871.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylphenol	583.1	2	1.58
872.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-(trifluoromethyl)phenol	637.3	1	1.71

873.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-5-methylphenol	611.3	2	1.66
874.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylphenol	577.2	1	1.74

875.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-(trifluoromethyl)phenol	631.2	1	1.8
876.		3-{[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]formamido}propanamide	661.1	2	1.3

877.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-N-[(1-carbamoylcyclopropyl)methyl]benzamide	687.2	2	1.4
878.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-(5-methoxy-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	567.3	1	1.62

879.		ethyl 4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,5-dimethyl-1H-pyrazole-3-carboxylate	637.4	1	1.69
880.		methyl 3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methyl-1H-indazole-6-carboxylate	659.1	1	1.97

881.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-pyrazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	551	1	1.67
882.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-{pyrazolo[1,5-a]pyridin-3-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	587.1	2	1.62

883.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-(1H-indazol-3-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	587.3	1	1.75
884.		(7R)-2-{2-[6-(3-cyclopropyl-1H-pyrazol-4-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	577	2	1.28

885.		methyl 2-[1-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)piperidin-4-yl]acetate	626.2	1	1.98
886.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[(2R)-2-(methoxymethyl)azetidin-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	570.2	2	1.44

887.		1-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-phenylpyrrolidin-3-ol (mixture of diastereomers)	632.2	2	1.62
888.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[2-(1-methyl-1H-pyrazol-4-yl)pyrrolidin-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (mixture of diastereomers)	620.2	2	1.51

889.		(3S)-1-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyrrolidine-3-carbonitrile	565.1	1	1.62
890.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[2-(pyridin-3-yl)pyrrolidin-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (mixture of diastereomers)	617.2	2	1.27

891.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[(2R)-2-(methoxymethyl)azetidin-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	576.2	1	1.84
892.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methoxyphenol	599.1	1	1.63

893.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxy-6-methylphenol	607.3	2	1.66
894.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methoxyphenol	593	1	1.69

895.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[3-(pyridin-4-yl)pyrrolidin-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine (mixture of diastereomers)	617.2	2	1.07
896.		3-{[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]formamido}-2,2-dimethylpropanamide	695	1	1.49

897.		[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-5-fluorophenyl]methanol	635.1	2	1.61
898.		3-{[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]formamido}-2,2-dimethylpropanamide	689.2	1	1.61

899.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-7aH-pyrrolo[3,2-b]pyridine-3-carboxamide	629.9	1	1.41
900.		1-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-cyclopropylethan-1-ol (mixture of diastereomers)	561.2	2	1.67

901.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-(trifluoromethyl)phenol	636.3	1	1.79
902.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-methoxyphenol	598.1	2	1.6

903.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,4-dimethylphenol	596.1	1	1.87
904.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-methylphenol	582.1	2	1.59

905.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-chlorophenol	602.1	2	1.65
906.		1-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroisoquinolin-2-yl]ethan-1-one	650.2	1	1.76

907.		2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-hydroxyphenyl]acetamide	625.9	1	1.49
908.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H,2H,3H-pyrrolo[2,3-b]pyridin-2-one	609.1	1	1.49

909.		[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenyl]methanol	613.3	2	1.43
910.		1-[6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-8-fluoro-1,2,3,4-tetrahydroisoquinolin-2-yl]ethan-1-one	662.1	2	1.52

911.		1-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,2,3,4-tetrahydroisoquinolin-2-yl]ethan-1-one	644	1	1.73
912.		2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenyl]acetamide	633.9	1	1.6

913.		2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-difluorophenyl]acetamide	640.2	1	1.64
914.		2-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-fluorophenyl]acetamide	622.2	2	1.27

915.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1H,2H,3H-pyrrolo[2,3-b]pyridin-2-one	603.3	1	1.56
916.		[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenyl]methanol	1213.3	1	1.63

917.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-{2-oxa-6-azaspiro[3.3]heptan-6-yl}-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	567	2	1.15
918.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methoxyphenol	617.2	1	1.8

919.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-2-carboxamide	597.2	1	1.53
920.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3,5-dimethylphenol	591	1	1.72

921.		[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenyl]methanol	591.1	1	1.82
922.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[3-(methoxymethyl)azetidin-1-yl]-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	569.2	2	1.36

923.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-(3-methoxyazetidin-1-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	555.2	2	1.22
924.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[3-(pyridin-3-yl)azetidin-1-yl]-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	602.2	1	1.69

925.		2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-azaspiro[3.3]heptan-6-ol	582.1	1	1.63
926.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[3-(pyridin-2-yl)azetidin-1-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	603.1	2	1.2

927.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-{[1,2,4]triazolo[4,3-a]pyridin-3-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	588.3	1	1.49
928.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-{[1,5-a]pyridin-2-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	587.9	2	1.41

929.		ethyl 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,5-dimethyl-1H-pyrazole-3-carboxylate	643.2	1	1.44
930.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(1,3-dimethyl-1H-pyrazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	571.2	1	1.63

931.		ethyl 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,3-dimethyl-1H-pyrazole-5-carboxylate	643.2	1	1.69
932.		methyl 4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methyl-1H-pyrazole-5-carboxylate	615.4	2	1.53

933.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-pyrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	557.2	1	1.69
934.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,5-dimethylphenol	597.2	1	1.62

935.		2-[3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]acetamide	610.4	2	1.41
936.		(2E)-3-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]prop-2-enamide	622.1	1	1.57

937.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-methylpyridine-2-carboxamide	611.2	1	1.55
938.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methoxypyridine-2-carboxamide	626.9	1	1.48

939.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylpyridine-2-carboxamide	611.3	1	1.4
940.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,5-dimethylphenol	591.3	1	1.75

941.		2-[3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]acetamide	604.2	1	1.41
942.		(2E)-3-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]prop-2-enamide	616.1	1	1.6

943.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-methylpyridine-2-carboxamide	605.3	1	1.58
944.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methoxypyridine-2-carboxamide	621.2	1	1.51

945.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylpyridine-2-carboxamide	605.2	1	1.43
946.		(2E)-3-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorophenyl]prop-2-enamide	634	1	1.69

947.		2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)butan-2-ol (mixture of diastereomers)	549	2	1.55
948.		((7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(3-(1,1-dioxidothiomorpholino)azetidin-1-yl)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone	658.1	1	1.44

949.		2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2-azaspiro[3.3]heptan-6-ol	581.2	2	1.15
950.		1-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-cyclopentylethan-1-ol (mixture of diastereomers)	589.4	3	0.78

951.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,3-dihydro-1H-isoindol-1-one	607.1	1	1.38
952.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-isoindol-1-one	608.1	1	1.56

953.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-inden-2-ol (mixture of diastereomers)	609.1	1	1.64
954.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-inden-2-ol (mixture of diastereomers)	603.2	2	1.59

955.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-1,2,3-triazol-4-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	558.3	1	1.45
956.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	625.3	2	1.55

957.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-difluorophenol	604.9	1	1.57
958.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,4-difluorophenol	599.5	1	1.54

959.		2-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenyl]propan-1-ol (mixture of diastereomers)	645.5	1	1.88
960.		1-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]ethan-1-ol (mixture of diastereomers)	597.5	2	1.46

961.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[1-methyl-3-(trifluoromethyl)-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	618.9	2	1.67
962.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[5-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	645.3	2	1.68

963.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[3-(4-fluorophenyl)-1-methyl-1H-pyrazol-4-yl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	645	1	1.8
964.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-{[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	589.1	2	1.32

965.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoro-5-methylbenzamide	628.1	2	1.33
966.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methoxybenzamide	644	1	1.52

967.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoro-5-methylbenzamide	622.1	2	1.31
968.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methoxybenzamide	638.2	2	1.36

969.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{[1,2,4]triazolo[1,5-a]pyrimidin-2-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	595.5	1	1.26
970.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-(1-methyl-1H-1,2,3,4-tetrazol-5-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	553.3	1	1.44

971.		2-[1-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)azetidin-3-yl]propan-2-ol	584.2	1	1.75
972.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylpyridine-2-carbonitrile	587.1	1	1.89

973.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyrimidine-2-carboxamide	598.1	2	1.09
974.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyrimidine-2-carboxamide	592.2	1	1.22

975.		[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyrimidin-2-yl]methanol	579.1	1	1.26
976.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoro-6-methoxyphenol	611	2	1.42

977.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylpyridine-2-carbonitrile	587.2	1	1.65
978.		2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,1,1-trifluoropropan-2-ol (first isomer off preparative HPLC)	582.1	1	1.84

979.		2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,1,1-trifluoropropan-2-ol (second isomer off preparative HPLC)	582.3	2	1.5
980.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dimethylphenol	597.2	1	1.9

981.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-difluorophenol	604.9	2	1.51
982.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-dichloro-3-methylphenol	651.1	1	1.89

983.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dimethylphenol	591.1	2	1.58
984.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-difluorophenol	599.3	2	1.48

985.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,6-dichloro-3-methylphenol	645.3	1	2.07
986.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-hydroxy-2-methylbenzoic acid	621	1	1.29

987.		2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,3-difluoropropan-2-ol	564.4	1	1.68
988.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-(hydroxymethyl)phenol	598.9	1	1.36

989.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-chlorobenzamide	630.3	1	1.31
990.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoro-3-methylbenzamide	628	1	1.32

991.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-(hydroxymethyl)phenol	593.1	2	1.36
992.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-chlorobenzamide	624.4	1	1.29

993.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluoro-3-methylbenzamide	622.2	2	1.48
994.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-inden-1-ol (mixture of diastereomers)	603.2	1	1.69

995.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-5-fluorobenzamide	648.1	1	1.7
996.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chloro-5-fluorobenzamide	642.2	1	1.74

997.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[4-(methanesulfonylmethyl)phenyl]-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	644	1	1.65
998.		2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,1,1-trifluoropropan-2-ol (mixture of diastereomers)	588	2	1.51

999.		2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-fluoropropan-2-ol (mixture of diastereomers)	553.4	1	1.56
1000.		2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,1,1-trifluoropropan-2-ol (first isomer off preparative HPLC)	588.2	1	1.71

1001.		2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1,1,1-trifluoropropan-2-ol (second isomer off preparative HPLC)	588.3	2	1.51
1002.		2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,1-difluoropropan-2-ol (mixture of diastereomers)	571.3	1	1.63

1003.		N-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]acetamide	610.2	2	1.53
1004.		N-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylphenyl]acetamide	624.4	2	1.48

1005.		N-[4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-ethylphenyl]acetamide	638.2	1	1.74
1006.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[2-fluoro-4-(methanesulfonylmethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	663.2	1	1.66

1007.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[4-(methanesulfonylmethyl)-2-methylphenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	659.1	1	1.73
1008.		(3R,5R)-1-(2-{6-[2-chloro-4-(methanesulfonylmethyl)phenyl]-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl}-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl)-5-fluoropiperidin-3-amine	679.1	2	1.55

1009.		N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-inden-2-yl]acetamide (mixture of diastereomers)	650.1	2	1.5
1010.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-hydroxy-2-methylbenzamide	626.2	1	1.37

1011.		N-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylphenyl]acetamide	618.2	2	1.46
1012.		N-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-ethylphenyl]acetamide	632.2	1	1.75

1013.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[2-fluoro-4-(methanesulfonylmethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	657.2	1	1.63
1014.		(7R)-2-(2-{6-[2-chloro-4-(methanesulfonylmethyl)phenyl]-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl}-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl)-2-azabicyclo[2.2.1]heptan-7-amine	673.1	1	1.65

1015.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[4-(methanesulfonylmethyl)-2-methylphenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	653.5	3	0.74
1016.		N-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,3-dihydro-1H-inden-2-yl]acetamide (mixture of diastereomers)	644	2	1.49

1017.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-hydroxy-2-methylbenzamide	620	1	1.37
1018.		2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methoxypropan-2-ol (mixture of diastereomers)	565	2	1.39

1019.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-fluorobenzamide	614.4	1	1.5
1020.		N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylpyridin-2-yl]acetamide	625.2	2	1.3

1021.		(2E)-N-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylphenyl]-3-ethoxyprop-2-enamide	672	1	1.87
1022.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-fluorobenzamide	608.4	1	1.4

1023.		N-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylpyridin-2-yl]acetamide	618.9	2	1.37
1024.		1-[4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]ethane-1,2-diol (mixture of diastereomers)	607	1	1.49

1025.		2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,1,1-trifluoropropan-2-ol (first isomer off preparative HPLC)	589.2	1	1.82
1026.		2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,1,1-trifluoropropan-2-ol (second isomer off preparative HPLC)	589.3	1	1.82

1027.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)thietan-3-ol	565.3	1	1.65
1028.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylbenzamide	604.2	1	1.5

1029.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[3-fluoro-4-(methanesulfonylmethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	656.9	1	1.7
1030.		8-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one	624.2	1	1.23

1031.		8-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one	630	1	1.28
1032.		8-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-oxa-3,8-diazaspiro[4.5]decan-2-one	631.2	2	1.06

1033.		7-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,7-diazaspiro[3.5]nonan-1-one	608	1	1.28
1034.		7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,7-diazaspiro[3.5]nonan-1-one	614.2	1	1.24

1035.		7-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2,7-diazaspiro[3.5]nonan-1-one	615	1	1.25
1036.		3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylbenzamide	306	2	1.34

1037.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-ethylbenzamide	624.2	1	1.55
1038.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-methylbenzamide	604.2	1	1.34

1039.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-ethylbenzamide	618.1	2	1.42
1040.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorobenzamide	630.2	1	1.47

1041.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-(trifluoromethyl)benzamide	664.4	1	1.66
1042.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-[2,5-difluoro-4-(methanesulfonylmethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	681.1	1	1.79

1043.		methyl N-[3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenyl]carbamate	640.3	2	1.77
1044.		methyl N-[3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenyl]carbamate	656.1	1	1.86

1045.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-(trifluoromethyl)benzamide	657.9	1	1.64
1046.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-(trifluoromethyl)benzamide	658.4	1	1.61

1047.		3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylbenzoic acid	605.1	1	1.32
1048.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[2,5-difluoro-4-(methanesulfonylmethyl)phenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	675.3	2	1.53

1049.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[4-(methanesulfonylmethyl)-3-methylphenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	653.1	1	1.72
1050.		methyl N-[3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methylphenyl]carbamate	634.2	1	1.78

1051.		methyl N-[3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-methoxyphenyl]carbamate	650.4	2	1.65
1052.		2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,1-difluoropropan-2-ol (first isomer off preparartive HPLC)	571.5	3	0.75

1053.		2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1,1-difluoropropan-2-ol (second isomer off preparative HPLC)	571.5	3	0.76
1054.		2-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluorobenzoic acid	615.1	2	1.57

1055.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(5-methanesulfonylpyridin-2-yl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	632.3	2	1.55
1056.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	608.4	1	1.42

1057.		2-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-6-fluorobenzoic acid	609.4	1	1.27
1058.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-{3-methyl-[1,2,4]triazolo[4,3-a]pyridin-7-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	602.4	1	1.45

1059.		8-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one	638.2	1	1.59
1060.		8-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one	639.2	2	1.38

1061.		8-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-3-methyl-1-oxa-3,8-diazaspiro[4.5]decan-2-one	644.1	1	1.56
1062.		2-[1-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)azetidin-3-yl]propan-2-ol	583.2	1	1.7

1063.		8-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,8-diazaspiro[4.5]decan-1-one	622.1	1	1.29
1064.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-(4-methanesulfonylpiperidin-1-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	631.1	1	1.52

1065.		1-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)piperidine-4-carbonitrile	578.2	1	1.73
1066.		2-[1-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)piperidin-4-yl]propan-2-ol	611.2	2	1.18

1067.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-(4-methoxypiperidin-1-yl)-1H-indol-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	583.2	1	1.8
1068.		8-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,8-diazaspiro[4.5]decan-3-one	622.2	1	1.21

1069.		((7R)-7-amino-2-azabicyclo[2.2.1]heptan-2-yl)(2-(1-(cyclopropylmethyl)-6-(1,1-dioxido-1-thia-6-azaspiro[3.3]heptan-6-yl)-1H-indol-2-yl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-5-yl)methanone	615.3	1	1.59
1070.		N-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-ethylpyridin-2-yl]acetamide	639.3	1	1.7

1071.		5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylpyridine-2-carboxamide	611.1	1	1.53
1072.		2-[5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]acetamide	611.4	1	1.16

1073.		methyl N-[3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenyl]carbamate	660.4	1	1.94
1074.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methylbenzamide	628.2	1	1.59

1075.		N-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-ethylpyridin-2-yl]acetamide	633.2	2	1.4
1076.		5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-3-methylpyridine-2-carboxamide	605.1	1	1.56

1077.		2-[5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridin-2-yl]acetamide	605.2	1	1.42
1078.		methyl N-[3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-2-chlorophenyl]carbamate	654.1	1	1.97

1079.		4-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-5-fluoro-2-methylbenzamide	622.1	1	1.56
1080.		methyl 5-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methyl-1H-pyrazole-3-carboxylate	308.4	1	1.46

1081.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)pyridine-3-carboxamide	591.5	1	1.08
1082.		[3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]methanesulfonamide	640.5	1	1.34

1083.		6-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-4-chloropyridine-3-carboxamide	625	1	1.5
1084.		methyl 5-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)-1-methyl-1H-pyrazole-3-carboxylate	609.6	1	1.42

1085.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{3-fluoro-2-methylpyrazolo[1,5-a]pyridin-5-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	625.2	1	2.02
1086.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-{2-methylpyrazolo[1,5-a]pyrimidin-5-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	608.2	1	1.85

1087.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-{3-fluoro-2-methylpyrazolo[1,5-a]pyridin-5-yl}-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	619.2	1	2.06
1088.		1-[3-(2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl]-3,3-dimethylurea	633.3	1	1.49

1089.		1-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-indol-6-yl)-2,2-difluoroethan-1-ol (mixture of diastereomers)	556.3	3	0.74
1090.		methyl 3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)azetidine-1-carboxylate	590.2	1	1.62

1091.		1-[3-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)azetidin-1-yl]ethan-1-one	574.2	1	1.4
1092.		2-{5-[(7R)-7-amino-2-azabicyclo[2.2.1]heptane-2-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-N,N-dimethyl-1H-indol-6-amine	513.3	3	0.57

1093.		4-(2-{5-[(3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl]-7-methoxy-1-methyl-1H-1,3-benzodiazol-2-yl}-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)piperidin-2-one (mixture of diastereomers)	574.3	1	1.4
1094.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-[3-(difluoromethyl)-2-fluorophenyl]-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-methoxy-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	615.2	1	2.17

1095.		(7R)-2-{2-[1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-fluoro-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-2-azabicyclo[2.2.1]heptan-7-amine	523.5	3	0.85
1096.		(3R,5R)-1-{2-[1-(cyclopropylmethyl)-6-(1,1-difluoroethyl)-1H-pyrrolo[2,3-b]pyridin-2-yl]-7-fluoro-1-methyl-1H-1,3-benzodiazole-5-carbonyl}-5-fluoropiperidin-3-amine	529.5	3	0.86
1097.		(R)-3-(4-(2-(5-((3R,5R)-3-amino-5-fluoropiperidine-1-carbonyl)-7-methoxy-1-methyl-1H-benzo[d]imidazol-2-yl)-1-(cyclopropylmethyl)-1H-pyrrolo[2,3-b]pyridin-6-yl)phenyl)-5-(hydroxymethyl)oxazolidin-2-one	668.2	2	1.45

Biological Assays

[00177] Compounds of the present invention were assayed as inhibitors of PAD4 using the assay protocol described below.

RFMS human PAD4 Functional Assay:

[00178] Compounds were solubilized in 100% DMSO to achieve a10 mM compound concentration. Compound stock solutions were stored at RT. A series of dilutions were prepared in DMSO and mixed 8 times with 20 µL mixing volume. Final top concentration of compound in the assay is 50 µM. Final assay conditions were as follows:

Reaction volume: 26 µl

Assay buffer: 25 mM hepes, pH 7.5, 5 mM NaCl, 1 mM DTT, 0.2 mg/ml BSA, 0.01% CHAPS, 50 µM Calcium, and 5 µM TPEN

Final concentrations: 5 nM hPAD4 enzyme, 250 µM BAEE, and 0.5% DMSO

Total incubation time: 30 mins compound and enzyme preincubation at 37 °C, 90 min enzyme/substrate reaction, 30 min reaction with phenyl glyoxal at 37 °C

Stop solution: 40 µl 5% TCA in ACN

[00179] 0.13 µL of compound solution was added to 13 µL of 10 nM PAD4 in assay buffer. After 30 min 13 µl of 500 µM of BAEE was added in 25 mM hepes, pH 7.5, 5 mM NaCl, 1 mM DTT, 0.2 mg/ml BSA, 0.01% CHAPS, 50 µM Calcium, 5 µM TPEN was added and the reaction incubated for 90 min at 37 °C. The enzymatic reaction was quenched by addition of 15 µl of 6.1N TCA, 100% Final Concentration is 20%, 35 µl of 8.5 mM phenyl glyoxal (final concentration 4 mM) is then added and the reaction is incubated for 30 min at 37°C.

[00180] After 30 minutes the plates are spun down to remove all precipitate. The enzyme reaction was quenched with an equal volume of methanol containing internal standard (modified citrulline). Samples were loaded onto the Rapid Fire RF300 system (Agilent) wherein they were first sipped for 1000 ms and then directly loaded to a C18 separations cartridge using a mixture of acetonitrile containing 0.01% formic acid for 3000 ms desalting. The flow rate of the mobile phase was 1.5 ml/min. Once the samples were eluted from the cartridge, a mobile phase of acetonitrile containing 0.01% formic acid was used to move the samples into the mass spectrometer for 4000 ms at a flow rate

of 1.25 ml/min/ Sciex API5500 triple quadrupole mass spectrometer (Applied Biosystems) equipped with ESI was used to analyze the peptidyl citrulline and internal standard ions.

[00181] MRM transition of product and internal standard were monitored at m/z 424.5 to 350.4 and m/z 293 to 247 respectively. The dwell time for each transition was set at 200 ms, and the ESI voltage was used at 5500 with a source temperature of 400°C. Extracted ion peaks for each transition were integrated using the Rapid Fire Integrator software. Peak area of analyte was normalized with internal standard.).

[00182] For a given compound example, the Table below shows the human PAD4 (hPAD4) IC_{50} in the rapid-fire mass spectrum (RFMS) assay.

Table 11. PAD4 Activity

Cmpd #	hPAD4 RFMS IC_{50} (μM)
1.	0.022
2.	0.198
3.	0.065
4.	0.252
5.	0.086
6.	0.090
7.	0.026
8.	0.053
9.	0.152
10.	0.089
11.	0.162
12.	0.136
13.	0.103
14.	0.123
15.	0.092
16.	0.071
17.	0.106
18.	0.097
19.	0.141
20.	0.091
21.	0.103
22.	0.159
23.	0.175
24.	0.176
25.	0.119
26.	0.161
27.	0.036

28.	0.116
29.	0.134
30.	0.113
31.	0.097
32.	0.170
33.	0.106
34.	0.035
35.	0.064
36.	0.082
37.	0.080
38.	0.101
39.	0.162
40.	0.129
41.	0.055
42.	0.160
43.	0.099
44.	0.109
45.	0.112
46.	0.051
47.	0.076
48.	0.160
49.	0.090
50.	0.163
51.	0.168
52.	0.018
53.	0.045
54.	0.065
55.	0.071
56.	0.046
57.	0.077
58.	0.077
59.	0.169
60.	0.148
61.	0.077
62.	0.199
63.	0.059
64.	0.056
65.	0.020
66.	0.020
67.	0.054
68.	0.077
69.	0.091
70.	0.032
71.	0.125
72.	0.102
73.	0.107
74.	0.051

75.	0.050
76.	0.143
77.	0.141
78.	0.125
79.	0.122
80.	0.055
81.	0.137
82.	0.091
83.	0.099
84.	0.123
85.	0.097
86.	0.178
87.	0.049
88.	0.030
89.	0.019
90.	0.128
91.	0.109
92.	0.099
93.	0.112
94.	0.075
95.	0.116
96.	0.010
97.	0.049
98.	0.035
99.	0.112
100.	0.053
101.	0.110
102.	0.120
103.	0.106
104.	0.064
105.	0.015
106.	0.055
107.	0.042
108.	0.067
109.	0.039
110.	0.034
111.	0.028
112.	0.058
113.	0.083
114.	0.030
115.	0.053
116.	0.058
117.	0.074
118.	0.041
119.	0.033
120.	0.080
121.	0.110

122.	0.077
123.	0.018
124.	0.041
125.	0.102
126.	0.148
127.	0.046
128.	0.050
129.	0.016
130.	0.035
131.	0.093
132.	0.113
133.	0.032
134.	0.143
135.	0.161
136.	0.066
137.	0.188
138.	0.073
139.	0.044
140.	0.027
141.	0.136
142.	0.044
143.	0.024
144.	0.069
145.	0.023
146.	0.148
147.	0.022
148.	0.149
149.	0.097
150.	0.028
151.	0.058
152.	0.013
153.	0.191
154.	0.069
155.	0.068
156.	0.154
157.	0.139
158.	0.143
159.	0.181
160.	0.163
161.	0.025
162.	0.056
163.	0.146
164.	0.092
165.	0.112
166.	0.060
167.	0.039
168.	0.025

169.	0.081
170.	0.155
171.	0.181
172.	0.063
173.	0.142
174.	0.148
175.	0.076
176.	0.088
177.	0.039
178.	0.094
179.	0.066
180.	0.092
181.	0.065
182.	0.060
183.	0.048
184.	0.037
185.	0.058
186.	0.083
187.	0.047
188.	0.060
189.	0.084
190.	0.017
191.	0.064
192.	0.083
193.	0.027
194.	0.032
195.	0.174
196.	0.094
197.	0.047
198.	0.039
199.	0.092
200.	0.012
201.	0.037
202.	0.053
203.	0.077
204.	0.095
205.	0.058
206.	0.015
207.	0.122
208.	0.062
209.	0.052
210.	0.032
211.	0.017
212.	0.060
213.	0.040
214.	0.036
215.	0.016

216.	0.047
217.	0.018
218.	0.113
219.	0.086
220.	0.021
221.	0.036
222.	0.022
223.	0.030
224.	0.058
225.	0.086
226.	0.060
227.	0.181
228.	0.121
229.	0.155
230.	0.026
231.	0.025
232.	0.072
233.	0.078
234.	0.146
235.	0.046
236.	0.051
237.	0.054
238.	0.058
239.	0.145
240.	0.068
241.	0.083
242.	0.026
243.	0.022
244.	0.132
245.	0.030
246.	0.050
247.	0.130
248.	0.118
249.	0.137
250.	0.030
251.	0.048
252.	0.139
253.	0.186
254.	0.116
255.	0.057
256.	0.119
257.	0.110
258.	0.125
259.	0.034
260.	0.107
261.	0.046
262.	0.070

263.	0.095
264.	0.034
265.	0.059
266.	0.165
267.	0.042
268.	0.059
269.	0.151
270.	0.151
271.	0.037
272.	0.095
273.	0.051
274.	0.070
275.	0.112
276.	0.036
277.	0.186
278.	0.032
279.	0.098
280.	0.053
281.	0.131
282.	0.156
283.	0.077
284.	0.110
285.	0.186
286.	0.161
287.	0.063
288.	0.150
289.	0.048
290.	0.028
291.	0.123
292.	0.049
293.	0.051
294.	0.166
295.	0.045
296.	0.039
297.	0.034
298.	0.085
299.	0.061
300.	0.157
301.	0.097
302.	0.095
303.	0.110
304.	0.167
305.	0.060
306.	0.033
307.	0.096
308.	0.162
309.	0.115

310.	0.099
311.	0.112
312.	0.188
313.	0.122
314.	0.107
315.	0.065
316.	0.103
317.	0.113
318.	0.107
319.	0.123
320.	0.042
321.	0.029
322.	0.188
323.	0.066
324.	0.040
325.	0.091
326.	0.042
327.	0.022
328.	0.127
329.	0.037
330.	0.039
331.	0.062
332.	0.030
333.	0.046
334.	0.057
335.	0.017
336.	0.064
337.	0.062
338.	0.038
339.	0.031
340.	0.042
341.	0.033
342.	0.035
343.	0.061
344.	0.040
345.	0.024
346.	0.087
347.	0.124
348.	0.141
349.	0.059
350.	0.092
351.	0.179
352.	0.028
353.	0.029
354.	0.192
355.	0.073
356.	0.023

357.	0.019
358.	0.019
359.	0.023
360.	0.016
361.	0.079
362.	0.052
363.	0.104
364.	0.013
365.	0.034
366.	0.027
367.	0.013
368.	0.038
369.	0.021
370.	0.146
371.	0.034
372.	0.136
373.	0.073
374.	0.062
375.	0.013
376.	0.066
377.	0.069
378.	0.059
379.	0.027
380.	0.107
381.	0.148
382.	0.176
383.	0.199
384.	0.128
385.	0.189
386.	0.052
387.	0.011
388.	0.013
389.	0.101
390.	0.024
391.	0.144
392.	0.009
393.	0.011
394.	0.052
395.	0.012
396.	0.025
397.	0.278
398.	0.236
399.	0.771
400.	0.209
401.	0.331
402.	0.638
403.	0.335

404.	0.252
405.	0.209
406.	0.222
407.	0.088
408.	0.079
409.	0.151
410.	0.161
411.	0.083
412.	0.155
413.	0.095
414.	0.122
415.	0.050
416.	0.168
417.	0.034
418.	0.165
419.	0.042
420.	0.045
421.	0.023
422.	0.105
423.	0.089
424.	0.070
425.	0.069
426.	0.051
427.	0.089
428.	0.143
429.	0.079
430.	0.090
431.	0.037
432.	0.047
433.	0.052
434.	0.043
435.	0.041
436.	0.049
437.	0.098
438.	0.153
439.	0.141
440.	0.095
441.	0.099
442.	0.086
443.	0.110
444.	0.281
445.	0.034
446.	0.039
447.	0.027
448.	0.075
449.	0.116
450.	0.021

451.	0.145
452.	0.157
453.	0.051
454.	0.102
455.	0.135
456.	0.061
457.	0.060
458.	0.113
459.	0.030
460.	0.038
461.	0.139
462.	0.031
463.	0.076
464.	0.057
465.	0.016
466.	0.028
467.	0.061
468.	0.028
469.	0.123
470.	0.012
471.	0.031
472.	0.072
473.	0.005
474.	0.023
475.	0.018
476.	0.013
477.	0.034
478.	0.022
479.	0.116
480.	0.014
481.	0.043
482.	0.020
483.	0.028
484.	0.025
485.	0.101
486.	0.031
487.	0.184
488.	0.082
489.	0.058
490.	0.038
491.	0.156
492.	0.048
493.	0.016
494.	0.050
495.	0.030
496.	0.044
497.	0.033

498.	0.046
499.	0.046
500.	0.032
501.	0.066
502.	0.058
503.	0.026
504.	0.174
505.	0.019
506.	0.032
507.	0.032
508.	0.049
509.	0.073
510.	0.044
511.	0.042
512.	0.045
513.	0.026
514.	0.041
515.	0.047
516.	0.199
517.	0.042
518.	0.115
519.	0.063
520.	0.103
521.	0.112
522.	0.029
523.	0.071
524.	0.027
525.	0.063
526.	0.047
527.	0.118
528.	0.052
529.	0.054
530.	4.075
531.	0.102
532.	0.048
533.	0.034
534.	0.194
535.	0.107
536.	0.168
537.	0.076
538.	0.191
539.	0.043
540.	0.054
541.	0.055
542.	0.049
543.	0.072
544.	0.087

545.	0.045
546.	0.064
547.	0.154
548.	0.107
549.	0.057
550.	0.052
551.	0.031
552.	0.025
553.	0.051
554.	0.150
555.	0.132
556.	0.029
557.	1.270
558.	0.112
559.	0.065
560.	0.192
561.	0.097
562.	0.074
563.	0.026
564.	0.021
565.	0.049
566.	0.051
567.	0.081
568.	0.138
569.	0.157
570.	0.018
571.	0.058
572.	0.070
573.	0.074
574.	0.180
575.	0.055
576.	0.064
577.	0.024
578.	0.083
579.	0.175
580.	0.053
581.	0.167
582.	0.046
583.	0.137
584.	0.094
585.	0.061
586.	0.184
587.	0.169
588.	0.243
589.	0.181
590.	0.101
591.	0.192

592.	0.140
593.	0.113
594.	0.137
595.	0.189
596.	0.025
597.	0.175
598.	0.107
599.	0.059
600.	0.124
601.	0.172
602.	0.020
603.	0.055
604.	0.081
605.	0.018
606.	0.026
607.	0.021
608.	0.045
609.	0.054
610.	0.033
611.	0.050
612.	0.062
613.	0.028
614.	0.104
615.	0.054
616.	0.089
617.	0.132
618.	0.029
619.	0.072
620.	0.048
621.	0.105
622.	0.138
623.	0.142
624.	0.082
625.	0.059
626.	0.037
627.	0.176
628.	0.059
629.	0.075
630.	0.031
631.	0.087
632.	0.115
633.	0.073
634.	0.063
635.	0.035
636.	0.021
637.	0.162
638.	0.020

639.	0.192
640.	0.129
641.	0.022
642.	0.033
643.	0.081
644.	0.083
645.	0.063
646.	0.123
647.	0.157
648.	0.040
649.	0.075
650.	0.049
651.	0.088
652.	0.124
653.	0.162
654.	0.177
655.	0.158
656.	0.043
657.	0.132
658.	0.047
659.	0.039
660.	0.036
661.	0.195
662.	0.118
663.	0.167
664.	0.489
665.	0.151
666.	0.162
667.	0.149
668.	0.141
669.	0.165
670.	0.147
671.	0.159
672.	0.086
673.	0.039
674.	0.140
675.	0.028
676.	0.330
677.	0.108
678.	0.147
679.	0.102
680.	0.164
681.	0.075
682.	0.068
683.	0.173
684.	0.070
685.	0.132

686.	0.071
687.	0.041
688.	0.044
689.	0.044
690.	0.048
691.	0.039
692.	0.137
693.	0.027
694.	0.144
695.	0.031
696.	0.023
697.	0.153
698.	0.094
699.	0.015
700.	0.143
701.	0.025
702.	0.037
703.	0.034
704.	0.056
705.	0.129
706.	0.035
707.	0.022
708.	0.108
709.	0.154
710.	0.113
711.	0.068
712.	0.045
713.	0.147
714.	0.050
715.	0.037
716.	0.074
717.	0.041
718.	0.024
719.	0.033
720.	0.092
721.	0.035
722.	0.163
723.	0.019
724.	0.777
725.	0.070
726.	0.149
727.	0.032
728.	0.035
729.	0.126
730.	0.185
731.	0.006
732.	0.031

733.	0.294
734.	0.134
735.	0.124
736.	0.079
737.	0.108
738.	0.043
739.	0.136
740.	0.040
741.	0.056
742.	0.108
743.	0.052
744.	0.153
745.	0.019
746.	0.175
747.	0.067
748.	1.443
749.	0.076
750.	0.045
751.	0.036
752.	0.063
753.	0.026
754.	0.038
755.	0.143
756.	0.033
757.	0.043
758.	0.036
759.	0.106
760.	0.040
761.	0.096
762.	0.048
763.	0.054
764.	0.108
765.	0.173
766.	0.175
767.	0.032
768.	0.019
769.	0.036
770.	0.068
771.	0.060
772.	0.096
773.	0.051
774.	0.103
775.	0.046
776.	0.016
777.	0.071
778.	0.023
779.	0.072

780.	0.089
781.	0.083
782.	0.180
783.	0.118
784.	0.111
785.	0.088
786.	0.032
787.	0.080
788.	0.078
789.	0.148
790.	0.112
791.	0.086
792.	0.115
793.	0.037
794.	0.064
795.	0.105
796.	2.444
797.	0.114
798.	0.117
799.	0.076
800.	0.188
801.	0.083
802.	0.092
803.	0.159
804.	0.188
805.	0.452
806.	0.109
807.	0.120
808.	0.105
809.	0.050
810.	0.050
811.	0.138
812.	0.280
813.	0.101
814.	0.064
815.	0.090
816.	0.422
817.	0.081
818.	0.062
819.	0.272
820.	0.107
821.	0.753
822.	0.093
823.	0.038
824.	0.393
825.	0.060
826.	0.480

827.	0.445
828.	0.155
829.	0.164
830.	3.551
831.	0.647
832.	0.241
833.	0.184
834.	0.060
835.	0.103
836.	0.132
837.	0.685
838.	0.024
839.	0.652
840.	1.549
841.	0.943
842.	0.037
843.	0.036
844.	1.821
845.	0.054
846.	0.653
847.	0.130
848.	2.061
849.	0.564
850.	2.222
851.	0.038
852.	0.518
853.	0.009
854.	0.074
855.	0.195
856.	0.309
857.	0.096
858.	0.149
859.	0.017
860.	0.467
861.	4.562
862.	0.451
863.	3.849
864.	1.441
865.	0.564
866.	1.622
867.	1.347
868.	1.401
869.	1.032
870.	0.238
871.	0.206
872.	0.162
873.	0.262

874.	0.478
875.	0.239
876.	0.658
877.	0.564
878.	0.141
879.	0.357
880.	1.000
881.	0.539
882.	0.064
883.	0.049
884.	0.587
885.	0.110
886.	0.264
887.	0.197
888.	0.085
889.	0.130
890.	0.113
891.	0.272
892.	0.635
893.	0.258
894.	0.047
895.	0.034
896.	0.151
897.	0.317
898.	0.447
899.	0.729
900.	2.367
901.	1.208
902.	0.281
903.	0.917
904.	0.824
905.	0.659
906.	0.045
907.	0.124
908.	0.024
909.	0.244
910.	0.080
911.	0.633
912.	1.363
913.	0.256
914.	0.130
915.	0.039
916.	0.441
917.	3.020
918.	1.145
919.	0.085
920.	0.330

921.	0.086
922.	0.126
923.	0.265
924.	1.784
925.	0.677
926.	0.059
927.	0.019
928.	0.116
929.	0.036
930.	0.162
931.	0.069
932.	0.113
933.	0.043
934.	0.064
935.	0.144
936.	0.069
937.	0.046
938.	0.040
939.	0.074
940.	0.053
941.	0.035
942.	0.038
943.	0.012
944.	0.054
945.	0.054
946.	0.076
947.	0.033
948.	0.178
949.	0.443
950.	0.025
951.	0.047
952.	0.054
953.	0.242
954.	0.194
955.	0.134
956.	0.134
957.	0.201
958.	0.221
959.	0.168
960.	0.298
961.	0.040
962.	0.180
963.	0.092
964.	0.091
965.	0.084
966.	0.182
967.	0.104


968.	0.199
969.	0.130
970.	0.198
971.	0.398
972.	0.127
973.	0.184
974.	0.043
975.	0.239
976.	0.333
977.	0.106
978.	0.007
979.	0.045
980.	0.024
981.	0.063
982.	0.170
983.	0.040
984.	0.063
985.	0.133
986.	0.043
987.	0.034
988.	0.113
989.	0.044
990.	0.057
991.	0.084
992.	0.069
993.	0.147
994.	0.199
995.	0.102
996.	0.031
997.	0.132
998.	0.042
999.	0.194
1000.	0.035
1001.	0.042
1002.	0.043
1003.	0.036
1004.	0.042
1005.	0.194
1006.	0.083
1007.	0.066
1008.	0.055
1009.	0.182
1010.	0.084
1011.	0.052
1012.	0.238
1013.	0.061
1014.	0.029

1015.	0.025
1016.	0.111
1017.	0.036
1018.	0.110
1019.	0.037
1020.	0.593
1021.	0.158
1022.	0.024
1023.	0.362
1024.	1.133
1025.	0.149
1026.	0.302
1027.	0.228
1028.	0.066
1029.	0.741
1030.	0.047
1031.	0.062
1032.	0.034
1033.	0.086
1034.	0.141
1035.	0.086
1036.	0.066
1037.	0.031
1038.	0.035
1039.	0.148
1040.	0.065
1041.	0.045
1042.	0.207
1043.	0.076
1044.	0.109
1045.	0.135
1046.	0.038
1047.	0.102
1048.	0.110
1049.	0.111
1050.	0.043
1051.	0.093
1052.	0.062
1053.	0.015
1054.	0.117
1055.	0.070
1056.	0.038
1057.	0.133
1058.	0.047
1059.	0.068
1060.	0.059
1061.	0.124

1062.	0.538
1063.	0.077
1064.	0.045
1065.	0.015
1066.	0.058
1067.	0.051
1068.	0.093
1069.	0.006
1070.	0.072
1071.	0.162
1072.	0.128
1073.	0.073
1074.	0.052
1075.	0.043
1076.	0.052
1077.	0.146
1078.	0.058
1079.	0.021
1080.	0.102
1081.	0.104
1082.	0.113
1083.	0.199
1084.	0.064
1085.	0.043
1086.	0.102
1087.	0.061
1088.	0.151
1089.	0.057
1090.	0.032
1091.	0.136
1092.	0.195
1093.	0.111
1094.	0.148
1095.	0.024
1096.	0.066
1097.	0.020

What is claimed is:

1. A compound of Formula (I):



(I)

or a pharmaceutically acceptable salt thereof, wherein:

Q is selected from N and CH;

Ring A is 4- to 15-membered heterocyclyl substituted with 1-4 R_7;

R_1 is selected from CH_3, CD_3, and $–CH_2$-5 membered heterocyclyl compring carbon atoms and 1-3 heteroatoms selected from N, NC_{1-4}alkyl, O, and S;

R_2 is selected from H, C_{1-3} alkyl substituted with 0-5 R_e, and $-(CH_2)_r-C_{3-6}$ cycloalkyl substituted with 0-5 R_e;

R_3 is selected from H, F, Cl, Br, $–OR_b$, and C_{1-3} alkyl substituted with 0-5 R_e;

L is absent or selected from $-NR_d-$, -O-, $-C(=O)NR_d-$, and $-S(O)_p-$;

R_4 is selected from $-(CH_2)_r$-aryl substituted with 1-7 R_5, $-(CH_2)_r-C_{3-12}$ cycloalkyl (substituted with 1-2 OR_b, $C(=O)OR_b$, $-C(=O)NR_aR_a$, $-NR_aC(=O)R_b$), $-(CH_2)_r$-heterocyclyl comprising carbon atoms and 1-3 heteroatoms selected from N, NR_6, O, and S and substituted with 1-7 R_5;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, =O, nitro, C_{1-4}alkyl substituted with 0-5 R_e, C_{2-4}alkenyl substituted with 0-5 R_e, C_{2-4}alkynyl substituted with 0-5 R_e, $-(CHR_d)_rOR_b$, $-(CHR_d)_rS(O)_pR_c$, $-(CHR_d)_rS(O)_pNR_aR_a$, $-(CHR_d)_rNR_aS(O)_pR_c$, $-(CHR_d)_rNR_aR_a$, $-(CHR_d)_rNR_aC(=O)R_b$, $-(CHR_d)_rNR_aC(=O)OR_b$, $-(CHR_d)_rNR_aC(=O)NR_aR_a$, $-(CHR_d)_rC(=O)R_b$, $-(CHR_d)_rC(=O)OR_b$, $-(CHR_d)_rC(=O)NR_aR_a$, $-(CHR_d)_rOC(=O)R_b$, $-(CHR_d)_rOC(=O)OR_b$, $-(CHR_d)_rO(CH_2)_rC(=O)NR_aR_a$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_6 is selected from H, C_{1-3}alkyl substituted with 0-4 R_e, -$S(O)_pR_c$, -$(CH_2)_rC(=O)R_b$, -$(CH_2)_r C(=O)OR_b$, -$(CH_2)_rC(=O)(CH_2)_rNR_aR_a$, -$C(=O)(CH_2)_rNR_aC(=O)R_b$,

-$S(O)_pNR_aR_a$, -$(CH_2)_r$-C_{3-6}cycloalkyl substituted with 0-4 R_e, -$(CH_2)_r$-aryl substituted with 0-4 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-4 R_e;

R_7 is selected from H, F, Cl, CN, C_{1-3} alkyl, =N-OR_b, -$(CH_2)_rOR_b$, -$(CH_2)_rNR_aR_a$, -$NR_aC(=NH)C_{1-3}$alkyl, -$NR_aC(=O)OR_b$, carbocyclyle, and heterocyclyle; alternatively, two R_7 groups are taken together to form carbocyclyl or heterocyclyl;

R_8, at each occurrence, is independently selected from H, F, Cl, Br, and C_{1-4}alkyl substituted with 0-5 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-6} carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_d, at each occurrence, is independently selected from H,C_{1-6} alkyl substituted with 0-5 R_e, and OH,

R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, -$(CH_2)_r$-C_{3-6} cycloalkyl, -$(CH_2)_r$-aryl, -$(CH_2)_r$-heterocyclyl, $Si(C_{1-4}alkyl)_3$, F, Cl, Br, CN, NO_2, =O, CO_2H, -$(CH_2)_rOR_f$, $S(O)_pR_f$, $C(=O)NR_fR_f$, $S(O)_pNR_fR_f$, and -$(CH_2)_rNR_fR_f$;




R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{2-5} alkenyl, C_{2-5} alkynyl, C_{3-6} cycloalkyl, and



phenyl, or R_f and R_f together with the nitrogen atom to which they are both attached form a heterocyclic ring optionally substituted with C_{1-4}alkyl;

p, at each occurrence, is independently selected from zero, 1, and 2;

r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4;






provided:

(1) when L is absent, R_4 is not  ,  , and  ;

(2) when L is $-NR_d-$, R_4 is not  , and  ; and

(3) when L is –O-, R_4 is not C_{3-6} cycloalkyl.

2. The compound according to claim 1 or a pharmaceutically acceptable salt thereof, wherein:

 is selected from  ,  ,  ,  ,  , and ;






R_1 is selected from CH_3 and CD_3;


R_2 is selected from methyl, ethyl and $-CH_2$-cyclopropyl substituted with 0-3 R_e;


R_3 is selected from H, F, Cl, Br, and $-OC_{1-4}$ alkyl;


L is absent or selected from $-NR_d-$, -O-, -C(=O)NH-, -S-, and $-S(O)_2-$;


R_4 is selected from

 ,  ,  ,  ,  ,









;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, =O, C_{1-4}alkyl substituted with 0-5 R_e, C_{2-4}alkenyl, C_{2-4}alkynyl, -$(CHR_d)_rOR_b$, -$(CH_2)_rS(O)_pR_c$, -$(CH_2)_rS(O)_pNR_aR_a$, -$(CH_2)_rNR_aS(O)_pR_c$, -$(CH_2)_rNR_aR_a$, -$(CH_2)_rNR_aC(=O)R_b$, -$(CH_2)_rNR_aC(=O)OR_b$, -$(CH_2)_rNR_aC(=O)NR_aR_a$, -$(CH_2)_rC(=O)R_b$, -$(CH_2)_rC(=O)OR_b$, -$(CHR_d)_rC(=O)NR_aR_a$, -$(CH_2)_rOC(=O)R_b$, -$(CH_2)_rOC(=O)OR_b$, -$(CH_2)_r$ $O(CH_2)_rC(=O)NR_aR_a$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_6, at each occurrence, is independently selected from H, C_{1-3}alkyl substituted with 0-4 R_e, $-S(O)_pR_c$, $-C(=O)R_b$, $-(CH_2)_rC(=O)OR_b$, $-(CH_2)_rC(=O)(CH_2)_rNR_aR_a$, $-C(=O)(CH_2)_rNR_aC(=O)R_b$, $-S(O)_pNR_aR_a$, $-(CH_2)_r$-aryl substituted with 0-4 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-4 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r$-C_{3-6} carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_d, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, and OH;


R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, $-(CH_2)_r$-C_{3-6} cycloalkyl, $-(CH_2)_r$-aryl, $-(CH_2)_r$-heterocyclyl, F, Cl, Br, CN, NO_2, =O, $-NH_2$, $-NHC_{1-4}$alkyl, $-N(C_{1-4}alkyl)_2$, $-C(=O)OH$, $-C(=O)OC_{1-4}$alkyl, $-(CH_2)_rOH$, and $-(CH_2)_rOC_{1-4}$alkyl;

R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;

p, at each occurrence, is independently selected from zero, 1, and 2; and


r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

3. The compound according to claim 2 of Formula (II):



(II)


or a pharmaceutically acceptable salt thereof, wherein:




is selected from


R_2 is selected from CH_3, CH_2CH_3 and –CH_2-cyclopropyl substituted with 0-2 F, Cl, and CH_3;


R_3 is selected from H, F, and –OC_{1-4} alkyl;



R_4 is selected from







R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, =O, C_{1-4}alkyl substituted with 0-4 R_e, $-(CHR_d)_rOR_b$, $-(CH_2)_r S(O)_pR_c$, $-S(O)_pNR_aR_a$, $-(CH_2)_rNR_aS(O)_pR_c$, $-(CH_2)_rNR_aR_a$, $-(CH_2)_rNR_aC(=O)R_b$, $-NR_aC(=O)OR_b$, $-NR_aC(=O)NR_aR_a$, $-(CH_2)_rC(=O)R_b$, $-(CH_2)_rC(=O)OR_b$, $-(CHR_d)_rC(=O)NR_aR_a$, $-(CH_2)_rOC(=O)R_b$, $-(CH_2)_rOC(=O)OR_b$, $-(CH_2)_r O(CH_2)_rC(=O)NR_aR_a$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_6, at each occurrence, is independently selected from H, C_{1-3}alkyl substituted with 0-4 R_e, $-S(O)_pR_c$, $-C(=O)R_b$, $-(CH_2)_rC(=O)OR_b$, $-(CH_2)_rC(=O)NR_aR_a$, -

$C(=O)(CH_2)_rNR_aC(=O)R_b$, $-S(O)_pNR_aR_a$, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, $-(CH_2)_r-C_{2-6}$ alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-6}$ carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_d, at each occurrence, is independently selected from H and C_{1-6} alkyl substituted with 0-5 R_e;


R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, $-(CH_2)_r-C_{3-6}$ cycloalkyl, $-(CH_2)_r$-aryl, $-(CH_2)_r$-heterocyclyl, F, Cl, Br, CN, NO_2, =O, $-NH_2$, $-NHC_{1-4}$alkyl, $-N(C_{1-4}alkyl)_2$, $-C(=O)OH$, $-C(=O)OC_{1-4}$alkyl, $-(CH_2)_rOH$, and $-(CH_2)_rOC_{1-4}$alkyl;

R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;

p, at each occurrence, is independently selected from zero, 1, and 2; and




r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

4. The compound according to claim 3 of Formula (III):



(III)

or a pharmaceutically acceptable salt thereof, wherein:

 is selected from  and  ,

R_2 is -CH_2-cyclopropyl;

R_3 is –OC_{1-4} alkyl;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, C_{1-4}alkyl substituted with 0-4 R_e, -$(CHR_d)_rOR_b$, -$(CH_2)_rS(O)_pR_c$, -$S(O)_pNR_aR_a$, -$(CH_2)_rNHS(O)_pR_c$, -$(CH_2)_rNR_aR_a$, -$(CH_2)_rNHC(=O)R_b$, -$NHC(=O)OR_b$, -$(CHR_d)_rC(=O)NR_aR_a$, -$(CH_2)_rC(=O)OR_b$, -$OC(=O)OR_b$, -$O(CH_2)_{0-1}C(=O)NR_aR_a$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-

C_{3-6} carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_d, at each occurrence, is independently selected from H, C_{1-4} alkyl, and OH;

R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, -$(CH_2)_r$-C_{3-6} cycloalkyl, -$(CH_2)_r$-aryl, -$(CH_2)_r$-heterocyclyl, F, Cl, Br, CN, NO_2, =O, -NH_2, -NHC_{1-4}alkyl, -$N(C_{1-4}alkyl)_2$, -C(=O)OH, -$C(=O)OC_{1-4}$alkyl, -$(CH_2)_rOH$, -$(CH_2)_rOC_{1-4}$alkyl, and SO_2C_{1-4}alkyl;






R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;

p, at each occurrence, is independently selected from zero, 1, and 2; and

r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

5. The compound according to claim 4, or a pharmaceutically acceptable salt thereof, wherein:

R_3 is –OCH_3;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, C_{1-4}alkyl, -$(CH_2)_{0-1}OR_b$, -$S(O)_2NH_2$, -$NHS(O)_2C_{1-3}$ alkyl,-$NHS(O)_2C_{2-4}$alkenyl, -$NHC(=O)R_b$, -$C(=O)NH_2$ and heterocyclyl selected from  ,  ,  ,  , and  ;

R_b, at each occurrence, is independently selected from H and C_{1-6} alkyl substituted with 0-5 R_e,


R_e, at each occurrence, is independently selected from C_{1-6} alkyl, F, Cl, Br, CN, NO_2, =O, -NH_2, -NHC_{1-4}alkyl, -$N(C_{1-4}alkyl)_2$, -C(=O)OH, -$C(=O)OC_{1-4}$alkyl, -$(CH_2)_rOH$, -$(CH_2)_rOC_{1-4}$alkyl, and SO_2C_{1-4}alkyl; and


r, at each occurrence, is independently selected from zero and 1.

.

6. The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein:




is selected from 


and 


;


R_2 is -CH_2-cyclopropyl;

R_3 is –OC_{1-4} alkyl;

R_4 is selected from 

, 

, 

, and 

;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, C_{1-4}alkyl substituted with 0-4 R_e, -$(CH_2)_rOR_b$, -$S(O)_pR_c$, -$S(O)_pNR_aR_a$, -$(CH_2)_rNR_aS(O)_pR_c$, -$(CH_2)_rNR_aR_a$, -$(CH_2)_rNR_aC(=O)R_b$, -$NR_aC(=O)OR_b$, -$NR_aC(=O)NR_aR_a$, -$(CH_2)_rC(=O)R_b$, -$(CH_2)_rC(=O)OR_b$, -$(CH_2)_rC(=O)NR_aR_a$, -$(CH_2)_rOC(=O)R_b$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-10}carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, -$(CH_2)_r$-C_{3-6} carbocyclyl substituted with 0-5 R_e, and -$(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, -$(CH_2)_r$-C_{3-6} cycloalkyl, -$(CH_2)_r$-aryl, F, Cl, Br, CN,

NO_2, =O, $-NH_2$, $-NHC_{1-4}$alkyl, $-N(C_{1-4}alkyl)_2$, $-C(=O)OH$, $-C(=O)OC_{1-4}$alkyl, $-(CH_2)_rOH$, and $-(CH_2)_rOC_{1-4}$alkyl;



R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;

p, at each occurrence, is independently selected from zero, 1, and 2; and

r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.




7. The compound according to claim 6, or a pharmaceutically acceptable salt thereof, wherein:

R_3 is $-OCH_3$;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, C_{1-4}alkyl, -OH, $-OC_{1-3}$alkyl, $-NHS(O)_2C_{2-4}$alkenyl, $NHC(=O)OC_{1-4}$ alkyl, $C(=O)NH_2$, $C(=O)NHC_{1-4}$alkyl, and heterocyclyl selected from  and  ; and


















R_e, at each occurrence, is independently selected from C_{1-6} alkyl, F, Cl, Br, CN, NO_2, =O, $-NH_2$, $-NHC_{1-4}$alkyl, $-N(C_{1-4}alkyl)_2$, $-C(=O)OH$, $-C(=O)OC_{1-4}$alkyl, $-(CH_2)_rOH$, $-(CH_2)_rOC_{1-4}$alkyl, and SO_2C_{1-4}alkyl.






8. The compound according to claim 3 or a pharmaceutically acceptable salt thereof, wherein:

 is selected from  and  ;

R_2 is $-CH_2$-cyclopropyl;

R_3 is $-OC_{1-4}$ alkyl;

R_4 is selected from  ,  ,  ,  ,  ,  ,  ,  ,  , , , , , , , , ,  ,  ,  ,  ,  ,  ,  ,  .





, and

:

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN C_{1-4}alkyl, $-OR_b$, $-S(O)_pR_c$ $-(CH_2)_rNR_aS(O)_pR_c$, $-(CH_2)_rNR_aR_a$, $-(CH_2)_rNR_aC(=O)R_b$, $-NR_aC(=O)OR_b$, $-C(=O)OR_b$, $C(=O)NR_aR_a$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_6, at each occurrence, is independently selected from H, C_{1-3}alkyl substituted with 0-4 R_e, $-S(O)_pR_c$, $-C(=O)R_b$, $-C(=O)OR_b$, $-(CH_2)_r-C(=O)NR_aR_a$, $-C(=O)(CH_2)_rNR_aC(=O)R_b$, $-S(O)_pNR_aR_a$, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e; or R_a and R_a together with the nitrogen atom to which they are both attached form a heterocyclic ring substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, $-(CH_2)_r-C_{2-6}$ alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-6}$ carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;













R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, $-(CH_2)_r-C_{3-6}$ cycloalkyl, $-(CH_2)_r$-aryl, F, Cl, Br, CN, NO_2, =O, $-NH_2$, $-NHC_{1-4}$alkyl, $-N(C_{1-4}alkyl)_2$, $-C(=O)OH$, $-C(=O)OC_{1-4}$alkyl, $-(CH_2)_rOH$, and $-(CH_2)_rOC_{1-4}$alkyl;

R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;

p, at each occurrence, is independently selected from zero, 1, and 2; and


r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

9. The compound according to claim 8, or a pharmaceutically acceptable salt thereof, wherein:

R_4 is selected from  ,  ,  ,  ,  ,  ,  ,  ,  ,  ,  , and  ; and




R_5, at each occurrence, is independently selected from H, F, Cl, Br, C_{1-4}alkyl, OH, and –C(=O)OH.

10. The compound according to claim 2 of Formula (IV):






(IV)






or a pharmaceutically acceptable salt thereof, wherein:


 is selected from  and  ;

R_2 is selected from CH_3 and -CH_2-cyclopropyl;

R_3 is selected from H, F, and –OC_{1-4} alkyl;

R_4 is selected from  ,  ,  ,

 ,  ,  ,  ,  , and

 ;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, CN, C_{1-4}alkyl, -$(CH_2)_rOR_b$, -$NR_aS(O)_pR_c$, -NR_aR_a, -$NR_aC(=O)R_b$, -$NR_aC(=O)OR_b$, - $C(=O)OR_b$, -$C(=O)NR_aR_a$, -$NR_aC(=O)NR_aR_a$, C_{3-6}cycloalkyl substituted with 0-4 R_e, aryl substituted with 0-4 R_e, and heterocyclyl substituted with 0-4 R_e;

R_6, at each occurrence, is independently selected from H and C_{1-3}alkyl;

R_a, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H, C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6} alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-10}$carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_c, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_e, C_{2-6}alkenyl substituted with 0-5 R_e, C_{2-6} alkynyl substituted with 0-5 R_e, $-(CH_2)_r-C_{3-6}$ carbocyclyl substituted with 0-5 R_e, and $-(CH_2)_r$-heterocyclyl substituted with 0-5 R_e;

R_d, at each occurrence, is independently selected from H and C_{1-3} alkyl;

R_e, at each occurrence, is independently selected from C_{1-6} alkyl substituted with 0-5 R_f, C_{2-6} alkenyl, C_{2-6} alkynyl, $-(CH_2)_r-C_{3-6}$ cycloalkyl, $-(CH_2)_r$-aryl, F, Cl, Br, CN, NO_2, =O, $N(C_{1-4}alkyl)_2$, -C(=O)OH, $-C(=O)OC_{1-4}$alkyl, $-(CH_2)_rOH$, and $-(CH_2)_rOC_{1-4}$alkyl;

R_f, at each occurrence, is independently selected from H, F, Cl, Br, CN, OH, C_{1-5} alkyl optionally substituted with OH, C_{3-6} cycloalkyl, and phenyl;


p, at each occurrence, is independently selected from zero, 1, and 2; and

r, at each occurrence, is independently selected from zero, 1, 2, 3, and 4.

11. The compound according to claim 10, or a pharmaceutically acceptable salt thereof, wherein:

R_2 is CH_2-cyclopropyl;

R_3 is $-OCH_3$;

R_4 is 

;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, C_{1-4}alkyl, and $-(CH_2)_{0-1}OH$; and



R_d is H.

12. The compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein:

L is -C(=O)NH-;

R_2 is -CH_2-cyclopropyl;

R_3 is –OC_{1-4} alkyl;

R_4 is selected from  ,  , and ;

R_5, at each occurrence, is independently selected from H, F, Cl, Br, C_{1-4}alkyl, -OH, and -CN; and




R_6, at each occurrence, is independently selected from H and C_{1-3}alkyl.

13. The compound according to claim 2 or a pharmaceutically acceptable salt thereof, wherein:

L is -O-;


R_2 is -CH_2-cyclopropyl;

R_3 is –OC_{1-4} alkyl;

R_4 is selected from  ,  , and  ; and





R_5, at each occurrence, is independently selected from H, F, Cl, Br, C_{1-4}alkyl, -OH, and –CN.

14. A compound of Formula (V):






(V)

or a pharmaceutically acceptable salt thereof, wherein:


 is selected from  ,  , and  ;

R_2 is -CH_2-cyclopropyl;

R_3 is –OCH_3; and





R_4 is selected from  ,  , and  .

15. The compound according to claim 2 of Formula (VI):




(VI)

or a pharmaceutically acceptable salt thereof, wherein:

 is selected from  ,  , and  ;


R_2 is -CH_2-cyclopropyl;

R_4 is selected from 

; and


R_5 is selected from H, OH, CH_2OH, and $-C(CH_3)_2OH$.

16. The compound according to claim 2 of Formula (VII):




(VII)

or a pharmaceutically acceptable salt thereof, wherein:



is selected from and ;

R_2 is $-CH_2$-cyclopropyl;

R_4 is selected from 

R_5, at each occurrence, is independently selected from F, Cl, C_{1-4}alkyl, $-(CH_2)_tOR_b$, $-S(O)_2NR_aR_a$, $-NR_aS(O)_2R_c$, and $-C(=O)NR_aR_a$;

R_6, at each occurrence, is independently selected from H and C_{1-3}alkyl;

R_a, at each occurrence, is independently selected from H and C_{1-4} alkyl substituted with 0-5 R_e;

R_b, at each occurrence, is independently selected from H and C_{1-4} alkyl substituted with 0-5 R_e,

R_c, at each occurrence, is independently C_{1-4} alkyl substituted with 0-5 R_e;

R_e, at each occurrence, is independently selected from F, Cl, Br, -OH, and -OC_{1-4}alkyl;
r, at each occurrence, is independently selected from zero, 1, and 2.

17. A pharmaceutically acceptable composition comprising the compound according to claim 1, and a pharmaceutically acceptable carrier, adjuvant, or vehicle.

18. The composition according to claim 17, in combination with an additional therapeutic agent.

19. A method of inhibiting PAD4 in a subject or in a biological sample comprising the step of contacting the PAD4 with a compound according to claim 1.

20. A method of treating a PAD4-mediated disease, disorder, or condition selected from the group consisting of acute lymphocytic leukemia, ankylosing spondylitis, cancer, chronic lymphocytic leukemia, colitis, lupus, rheumatoid arthritis, multiple sclerosis, and ulcerative colitis, in a subject having a PAD4-mediated disease, disorder, or condition, comprising the step of administering to said subject the composition according to claim 17.

21. The method according to claim 20, wherein the PAD4-mediated disease, disorder, or condition is selected from rheumatoid arthritis, systemic lupus erythematosus, cutaneous lupus erythematosus, ulcerative colitis, and cancer.

22. The compounds according to any one of claims 1 to 16 or composition according to claim 17 for use in therapy.